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SUMMARY OF THE THESIS 
 
In Australia, thousands of koalas are presented to wildlife rehabilitation facilities 
annually for medical treatment. Most admissions are due to trauma (dog attacks and 
motor vehicle strikes) and disease. The most common infectious disease treated in koala 
rehabilitation facilities is chlamydiosis, caused by the intracellular bacteria, Chlamydia 
pecorum and Chlamydia pneumoniae. Although less common, the fungal disease 
cryptococcosis, caused by Cryptococcus gattii, also occurs and is often fatal. Despite 
the large number of koalas administered therapeutic drugs in Australia annually, there is 
a paucity of information regarding the pharmacokinetics and pharmacodynamics of 
commonly used therapeutic drugs in this species. The information available indicates 
koalas may have highly developed barriers to oral absorption of therapeutic drugs, and 
an ability to rapidly metabolise and eliminate therapeutic drugs following 
administration; these mechanisms are likely to have evolved due to the highly toxic 
Eucalyptus spp. diet that these specialist folivores ingest. This thesis aims to describe 
the pharmacokinetics of three drugs commonly administered to koalas, 
chloramphenicol, enrofloxacin and fluconazole, and to use 
pharmacokinetic/pharmacodynamic (PK/PD) principles to draw conclusions regarding 
the theoretical efficacy of these drugs when administered at commonly used dosages. 
 
The literature review presented in Chapter 1 outlines the history and conservation status 
of the koala in Australia, and discusses the two most common infectious diseases of 
wild koalas, chlamydiosis and cryptococcosis. Literature regarding the medical 
management of these diseases is considered, current treatment recommendations 
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discussed, published case studies reviewed, and gaps in the current knowledge of drug 
pharmacokinetics in koalas identified.  
 
Pharmacokinetic studies of chloramphenicol and enrofloxacin, both commonly used to 
treat chlamydiosis in koalas, are presented in Chapters 2 and 3. The elimination rate of 
both drugs is found to be similar to other mammals, and consideration of the 
pharmacodynamics reveals that chloramphenicol is likely to be a suitable treatment 
option for koala chlamydiosis, although slight dosage adjustments may be necessary. 
Conversely, enrofloxacin is found to be unsuitable for treating chlamydiosis in koalas. 
Enrofloxacin may, however, show promise for treating infections caused by gram 
positive bacteria with low minimum inhibitory concentrations (MICs).  
 
Chapter 4 investigates the pharmacokinetics of fluconazole, commonly used to treat 
cryptococcosis. Pertinent findings include poor and variable oral absorption, rapid 
elimination, and absorption rate-limited disposition following oral administration; these 
findings are in stark contrast to the pharmacokinetics of fluconazole in other species that 
have been studied. Consideration of the pharmacodynamics indicates that fluconazole is 
not likely to be successful in treating cryptococcosis at currently used dosages when 
used alone. Interestingly, this study demonstrates that fluconazole is unsuitable for 
allometric scaling in koalas, despite demonstrating a strong allometric relationship in 
other mammalian species ranging in size from mice to whales. 
 
Chapter 5 was born out of a need to determine the in vitro susceptibility of koala 
isolates of Chlamydia pecorum to enrofloxacin and chloramphenicol, for use in PK/PD 
integration and modelling. A method to grow Chlamydia spp. in vitro is developed and 
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used to determine the susceptibility of recently collected, as well as stored, koala 
isolates of C. pecorum. In vitro susceptibilities of C. pecorum to enrofloxacin, 
chloramphenicol, and the chloramphenicol derivative, florfenicol, are found to be 
similar to the susceptibilities reported for other species of Chlamydia. The results of this 
study add further support to the findings presented in Chapters 2 and 3, as the assumed 
C. pecorum susceptibilities used for PK/PD integration and modelling in Chapters 2 and 
3 are in close alignment with those determined in this study.   
 
In Chapter 6, the major findings of these studies are highlighted and discussed within 
the context of what is known about the metabolism of chloramphenicol, enrofloxacin 
and fluconazole in other mammals. Hypotheses regarding the metabolism of these drugs 
in koalas are proposed, and recommendations for future studies are discussed.  
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CHAPTER 1. INTRODUCTION, LITERATURE REVIEW 
AND AIMS OF THE THESIS 
 
1.1  INTRODUCTION 
The koala (Phascolarctos cinereus) is an iconic Australian marsupial that has multiple 
rehabilitation centres and non-governmental organisations dedicated to its conservation 
and care (Griffith, 2010). Despite many wild koalas receiving medical treatment in 
rehabilitation facilities in eastern Australia every year, therapeutic drug dosages for 
koalas have been extrapolated from physiologically distinct species or formulated by 
trial and error, and no currently recommended drug dosages have been based on koala-
specific pharmacokinetic data. This project was undertaken to determine the 
pharmacokinetic profiles of three drugs commonly administered to koalas, and to use 
the pharmacokinetic profiles of each drug in combination with pharmacodynamic 
principles to assess the likely suitability of currently administered dosages. This general 
introduction and literature review commences by outlining the distribution and 
conservation status of the koala, as well as past and present threats to its survival. The 
aetiological agents, clinical signs, pathological changes and treatment of chlamydiosis 
and cryptococcosis, the two most prevalent infectious diseases of koalas, are then 
reviewed. This is followed by a summary of the few pharmacokinetic studies that have 
been undertaken in the koala to date, and a discussion of the basic principles of 
pharmacokinetics and pharmacodynamics. Finally, there is a brief discussion of factors 
that may influence pharmacokinetic profiles in koalas as well as background 
information on each of the drugs investigated, culminating in the introduction of the 
specific aims of the study. 
 2 
 
1.2 THE KOALA 
The koala is an Australian arboreal folivorous marsupial, and the last surviving member 
of the Family Phascolarctidae. Koalas hold great ecological importance by contributing 
to Australia’s biodiversity and dwelling in a habitat that is home to many other native 
species (Natural Resource Management Ministerial Council, 2009). With immense 
public appeal, both locally and internationally, the koala is the most popular Australian 
wildlife species among international tourists, with one study indicating that 75% of 
international visitors to Australia hoped to see a koala (Hundloe & Hamilton, 1997). As 
such, the koala contributes significantly to the Australian economy with a conservative 
estimate, made in 1997, being in the order of billions of dollars annually, in addition to 
the provision of thousands of jobs (Hundloe & Hamilton, 1997). Perhaps the clearest 
demonstration of the extent of public affection for the koala was the South Australian 
Government’s decision to implement an extensive sterilisation and translocation 
program to address the environmentally damaging problem of koala overpopulation on 
Kangaroo Island at the turn of the twenty-first century (St John, 1997; Martin & 
Handasyde, 1999). Culling of other native, over-abundant wildlife species, including the 
tammar wallaby, the western-grey kangaroo, and the Cape Barren goose, is a commonly 
employed environmental management strategy on Kangaroo Island (Duka & Masters, 
2005; Jackson, 2007), and many other native marsupial species are routinely culled in 
Australia to manage species overpopulation (Jackson, 2007). However, the national and 
international public outcry at the prospect of culling koalas on Kangaroo Island was so 
great that the state government instead opted for a sterilisation and translocation project, 
involving thousands of koalas and costing A$1.235 million (Duka & Masters, 2005; 
Jackson, 2007). 
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1.3 DISTRIBUTION AND CONSERVATION STATUS 
The current distribution of the koala is widespread, yet fragmented (Blanshard & 
Bodley, 2008), and both the distribution and abundance of koalas have changed since 
European settlement (Phillips, 1990; Natural Resource Management Ministerial 
Council, 2009). Prior to European settlement, koalas inhabited the sclerophyll forests of 
eastern Australia, extending from north-eastern Queensland to Victoria and across to 
south-eastern South Australia (Natural Resource Management Ministerial Council, 
2009). They are also thought to have inhabited six offshore islands at the time of 
settlement (Jackson, 2007). Initially, koala numbers were reported to have risen 
dramatically after European settlement; this has been attributed to a concurrent decline 
in the indigenous population, and a subsequent decrease in hunting pressure (Phillips, 
1990). The abundance of koalas during the mid-late nineteenth century was short-lived 
due to the fur trade, during which they were hunted in immense numbers for their 
valuable pelts (Lee & Martin, 1988; Martin & Handasyde, 1999). Government 
legislation to protect the koala from hunting was introduced in Victoria in 1898, and in 
New South Wales in 1909. The Queensland trade continued intermittently, with the 
interspersion of open and closed hunting seasons. Due to public protest, the final open 
season was held in Queensland in 1927 (Lee & Martin, 1988). By this time, koalas 
occupied less than 50% of their previous habitat, and they were considered extinct in 
South Australia. In Victoria, only a few animals were thought to remain, while the New 
South Wales koalas were thought to still exist in small remnant populations. In 
Queensland, the population was noted to have declined (Natural Resource Management 
Ministerial Council, 2009). Concerns about population crashes induced by the fur trade 
drove the opening of three koala sanctuaries in Australia in the 1920s and 1930s 
(Jackson, 2007).  
 4 
 
Since the cessation of the fur trade, parts of the koala’s former range in Victoria, South 
Australia, and the Australian Capital Territory have been recolonised with koalas from 
French Island and Phillip Island. In South Australia, some regions outside of the koala’s 
former range were also repopulated from these island populations (Natural Resource 
Management Ministerial Council, 2009). In some cases, the introduction of koalas onto 
islands or to areas outside of their natural range has resulted in overpopulation and 
overbrowsing, and there are concerns about low genetic diversity in populations that 
were founded from a few individuals (Houlden et al., 1996; Natural Resource 
Management Ministerial Council, 2009). Today, koalas still extend from north-eastern 
Queensland to the South Australian Eyre Peninsula, however, their distribution 
throughout this range is fragmented. They extend inland past the Great Dividing Range, 
towards the arid zone of Queensland and New South Wales (Natural Resource 
Management Ministerial Council, 2009), and into the Australian Capital Territory 
(Phillips, 1990) (Figure 1-1).  
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Figure 1-1. Geographical distribution of the koala (Adapted from Department of Sustainability, 
Environment, Water, Population and Communities, 2013). 
 
The conservation status of the koala varies across its range, with some listings differing 
between state and federal governments. Under Queensland state legislation, the koala is 
listed as least concern wildlife, except for the South East Queensland bioregion where it 
is listed as vulnerable (Natural Resource Management Ministerial Council, 2009; 
Threatened Species Scientific Committee, 2012). In New South Wales, there are two 
isolated populations listed as endangered, and koalas throughout the rest of the state are 
listed as vulnerable (Natural Resource Management Ministerial Council, 2009; 
Threatened Species Scientific Committee, 2012). In the states of Victoria and South 
Australia, the koala is not included on the threatened species list (Natural Resource 
Management Ministerial Council, 2009). In April 2012, the koala was listed as 
vulnerable throughout Queensland, New South Wales and the Australian Capital 
Territory under federal environment law. This listing was passed under the 
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Environmental Protection and Biodiversity Conservation Act 1999, due to a significant 
population decline throughout this region over three generations (Threatened Species 
Scientific Committee, 2012; Department of Sustainability, Environment, Water, 
Population and Communities, 2013).  
 
1.4 THREATS TO THE SPECIES 
Despite public awareness and interest in the koala, this iconic species faces a number of 
threats to its survival. Many of these threats have arisen since European settlement. 
Destruction, degradation and fragmentation of koala habitat are the result of land-
clearing for agriculture and urban development. These habitat threats have been 
identified as the major threats to the survival of the koala in New South Wales and 
Queensland, where koala populations are declining (Jackson, 2007, Natural Resource 
Management Ministerial Council, 2009). South East Queensland currently has one of 
the fastest growing human populations in Australia (Department of Environment and 
Resource Management, 2012), and it is little coincidence that koala populations in this 
region are in decline. Population monitoring in the Koala Coast region of South East 
Queensland, which is a 375 km
2
 area comprising parts of the Redland, Logan and 
Brisbane City councils 20 km south-east of Brisbane, has identified a startling 51% 
decline in koala abundance over the three years from 2005 to 2008 (Department of 
Environment and Resource Management, 2009), with an overall decline of 68% from 
1996 to 2010 (Department of Environment and Resource Management, 2012). Other 
threats directly related to human activity include motor vehicle strikes and dog attacks. 
Natural threats to the koala throughout its range include fires, droughts, the effects of 
climate change, and disease (Gordon et al., 1988; Lee & Martin, 1988; Phillips, 1990; 
Melzer et al., 2000; Jackson, 2007; Blanshard & Bodley, 2008; Natural Resource 
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Management Ministerial Council, 2009). Two of the most widely researched and 
frequently diagnosed infectious diseases to affect koalas are chlamydiosis and 
cryptococcosis. These diseases underlie the focus of this thesis.  
 
Chlamydiosis is the most common infectious disease of koalas, affecting up to 85% of 
koalas in some populations (Jackson et al., 1999). A common outcome of chlamydiosis 
is infertility (McColl et al., 1984; refer to section 1.6.2). Although infertility induced by 
chlamydiosis is considered unlikely to lead to the extinction of the koala when acting in 
isolation (Handasyde, 1986; Martin & Handasyde, 1990; Augustine, 1998), modelling 
suggests that host extinction may occur if chlamydial transmission rates increase in 
conjunction with pathogenicity, or if non-Chlamydia related birth rate decreases or 
mortality rate increases occur (Augustine, 1998). In support of this model, low 
fecundity levels in a population in Inverness, Queensland, had a significant effect on 
population density (Gordon et al., 1990). Additional findings in this population included 
a negative correlation between chlamydial cystitis and population density, and a 
reduced survival rate for koalas with cystitis. The authors of this study postulated that in 
the years of population decline due to reduced fecundity, an additional mortality factor 
might have had an extreme effect on population size. The historical ability of koala 
populations to recover from population declines has been attributed to their high 
reproductive rate (Martin, 1985); however, a decrease in fecundity due to Chlamydia-
induced infertility has been shown to increase population doubling time in Chlamydia-
infected koalas compared with their disease-free counterparts (12.2 years and 2.7 – 3.6 
years, respectively) (Martin & Handasyde, 1990), which may impact the koala’s ability 
to recover from population declines. Given that the fecundity of Chlamydia-infected 
populations is generally lower than that of disease-free populations, with fertility rates 
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of 0 – 56% and 59 – 78%, respectively, population declines tend to occur when 
mortality rates increase (Martin & Handasyde, 1990). Increased habitat destruction and 
fragmentation can lead to an increased number of animals exposed to edge effects, of 
which motor vehicle strikes and predation by dogs are likely to be the most important 
for koalas (Griffith et al., 2013). Thus, edge effects related to habitat loss have the 
potential to increase mortality rates in affected populations, and coupled with the 
prolonged population doubling time seen in Chlamydia-infected populations, may affect 
population sizes. 
   
Infectious disease expression in animals results from a complex and dynamic interaction 
between the host, pathogen and environment. Many koalas carry organisms responsible 
for disease, including Chlamydia spp. and Cryptococcus spp., without overt disease 
expression (Handasyde, 1986; Weigler et al., 1988; Canfield et al., 1991; Connolly et 
al., 1999; Jackson et al., 1999; Krockenberger et al., 2002b). Stress placed upon 
individual animals, such as that imposed by loss of habitat, overpopulation, poor 
nutrition or concurrent disease, can tip the balance in favour of the pathogen and allow 
clinical disease to ensue. Although cryptococcosis occurs much less frequently than 
chlamydiosis, clinical disease requires prolonged courses of treatment, and it is a 
disease that may be seen more frequently as the environmental stressors placed upon 
koalas, particularly habitat destruction and fragmentation, take their toll. 
 
1.5 THE CHLAMYDIALES 
The Chlamydiaceae are obligate intracellular bacteria of the Order Chlamydiales, and 
are recognised as important pathogens of humans and animals worldwide. These 
atypical bacteria have a unique biphasic growth-cycle involving replication inside 
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eukaryotic cells. The two distinct morphological forms of Chlamydiaceae are the 
infectious elementary body (EB), and the non-infectious reticulate body (RB). The 
metabolically inactive EB is approximately 0.2 – 0.4 µm (Jones et al., 1997) and is 
responsible for attaching to and invading target host cells, which are not usually active 
phagocytes (Moulder, 1991; AbdelRahman & Belland, 2005). Chlamydial EBs are 
dense units, and possess a rigid cell wall that provides protection from the extracellular 
environment during host cell lysis and transit between host cells (Beatty et al., 1994). 
Following host cell infection, the EB internalises itself in a membrane-bound vacuole 
within the host cell cytoplasm; this is known as the chlamydial inclusion (Moulder, 
1991; Hogan et al., 2004; AbdelRahman & Belland, 2005). Within the membrane-
bound inclusion, EBs differentiate into metabolically active RBs. These are larger and 
less dense than EBs, ranging in size from 0.6 to 1.5 µm (Jones et al., 1997). Using 
energy derived from the host cell in the form of adenosine triphosphate (ATP) (Beatty 
et al., 1994), RBs multiply by binary fission before reverting to EBs which are released 
from the host cell by cell lysis or exocytosis (Beatty et al., 1994). During the replicative 
phase, both EBs and RBs at different stages of replication can be present at any one 
time (Moulder, 1991). Once liberated from the inclusion, newly formed EBs are able to 
infect neighbouring cells (Beatty et al., 1994; AbdelRahman & Belland, 2005). In one 
growth-cycle, a single EB infecting a host cell can give rise to over 1000 new infectious 
EBs (Moulder, 1991).  
 
Deviations from the typical chlamydial growth-cycle have been observed in vitro in 
association with a number of factors: the presence of certain antibiotics, including 
penicillin, trimethoprim/sulfamethoxazole and fluoroquinolones (Matsumoto & Manire, 
1970; Hammerschlag, 1982; Dreses-Werringloer et al., 2000; Skilton et al., 2009); host 
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cytokines (Beatty et al., 1993) and other immune system-mediated factors such as 
monocytes and macrophages (Manor & Sarov, 1988); or changes in the concentrations 
of nutrients such as amino acids and vitamins (Coles et al., 1993; Raulston, 1997; 
Harper et al., 2000). This can result in persistent infection, whereby Chlamydiaceae can 
persist within the host cells without apparent growth or replication (Figure 1-2). Whilst 
in this persistent state, Chlamydiaceae are often refractory to antibiotic treatment 
(Hammerschlag, 2002). Although these aberrant chlamydial forms are viable, they 
remain culture-negative until the cause of growth suppression is removed (Beatty et al., 
1994; Rottenberg et al., 2002). Persistent chlamydial forms hold clinical relevance as 
the host immune response to recurrent or persistent infections can lead to severe 
scarring of the infected organs over time (Rottenberg et al., 2002; Stephens, 2003). 
Chlamydial persistence reflects the difficulties associated with successful elimination of 
this organism, either by host immune defences or exogenous antimicrobial therapy. 
 
 
Figure 1-2. The chlamydial life cycle (adapted from Rottenberg et al., 2002). EB: elementary body. 
RB: reticulate body. N: cell nucleus. 
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1.6 CHLAMYDIOSIS IN KOALAS 
1.6.1 History, taxonomy and epidemiology 
Clinical signs consistent with ocular chlamydiosis were first reported as early as 1887 
(Troughton, 1973), and reports of urogenital pathology followed (Pratt, 1937). In 1974, 
koala keratoconjunctivitis was attributed to Chlamydia spp. for the first time (Cockram 
& Jackson, 1974). It was another decade before the chlamydial links to urogenital 
disease and a rhinitis/pneumonia complex were made (Brown & Grice, 1984; McColl et 
al., 1984). Chlamydial organisms have been isolated from nasal swabs of koalas with 
pneumonia and rhinitis using molecular and culture techniques (Brown et al., 1984; 
Wardrop et al., 1999), yet the results of immunohistochemical staining of the lungs of 
koalas suffering pneumonitis were inconclusive (Higgins et al., 2005). Thus, the 
question still remains regarding respiratory tract colonisation versus contamination of 
nasal surfaces and discharges, either by transient macrophages and monocytes, or from 
drainage of ocular infections through the nasolacrimal duct (Higgins, 2005).  
  
Initially designated C. psittaci, (Cockram & Jackson, 1974; Brown & Grice, 1984; 
McColl et al., 1984; Girjes et al., 1988), the Chlamydiaceae implicated in koala disease 
have since been reclassified into two species, C. pecorum and C. pneumoniae (Glassick 
et al., 1996). A taxonomic revision of the Order Chlamydiales in 1999 resulted in a 
proposal for division into two genera, Chlamydia and Chlamydophila (Everett et al., 
1999), with C. pecorum and C. pneumoniae being included in the new genus, 
Chlamydophila. However, this proposal was not widely adopted. The commonly 
accepted taxonomy remains a single genus, Chlamydia (Kuo & Stephens, 2011), 
containing nine species (Kuo et al., 2011); this is the taxonomy that will be used 
throughout this thesis. In addition to C. pecorum and C. pneumoniae, genotypes of nine 
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novel Chlamydia-like bacteria have been identified in urogenital and ocular swabs taken 
from koalas. These have been designated the uncultured koala Chlamydiales (UKC), 
and tend to occur as co-infections with C. pecorum and C. pneumoniae; although their 
role in disease is unclear, there is speculation they may be implicated in ascending 
urinary tract infections (Devereaux et al., 2003). 
 
Chlamydiosis has been detected in koala populations throughout their range (McKenzie, 
1981; Obendorf, 1983; Weigler et al., 1988; Jackson et al., 1999; Wardrop et al., 1999; 
Griffith & Higgins, 2012), although not all infected koalas show clinical disease. C. 
pecorum appears to be more pathogenic than C. pneumoniae, causing infections of a 
higher severity and at a higher frequency than the latter (Jackson et al., 1999). Sole C. 
pneumoniae infections are frequently low-grade or asymptomatic (Jackson et al., 1999; 
Devereaux et al., 2003; Griffith, 2010). The mode of transmission has not been formally 
studied, although there is strong evidence for venereal transmission (Obendorf, 1983; 
Handasyde, 1986; Girjes et al., 1988). Faecal-oral transmission to dependent young 
during pap feeding and direct transfer of infected ocular and urogenital discharges 
between koalas have also been suggested (Blanshard & Bodley, 2008). 
 
 1.6.2 Clinical signs and pathological changes associated with chlamydiosis 
The range of body systems affected by chlamydiosis accounts for the variation in 
clinical signs and pathological changes associated with disease. Ocular infection may 
result in unilateral or bilateral disease, although chronic cases are usually bilateral. 
Clinical signs include excessive lacrimation, blepharospasm, a serous to mucopurulent 
ocular discharge, hyperaemia and proliferation of the conjunctiva and nictitating 
membrane, chemosis, keratitis, pannus formation, corneal oedema, and forced closure 
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of the eyelids due to excessive discharge (Cockram & Jackson, 1981; Brown & Grice, 
1986; Kempster et al., 1996). Secondary bacterial infections and trauma to the eyelids 
due to excessive rubbing may be seen (Obendorf, 1983). Koalas with urogenital 
chlamydiosis often show clinical signs of cystitis, including gross haematuria, 
pollakiuria, and dysuria; the latter may be identified by grunting or cloacal eversion 
during micturition. Urinary incontinence may be identified as a lack of posturing for 
micturition and by the greasy, brownish pelage staining of the rump, for which the 
condition is colloquially termed ‘wet bottom’ or ‘dirty tail’ (Figure 1-3). The skin may 
be inflamed and ulcerated as a result of urine scalding, and cutaneous myiasis may be 
present (Obendorf, 1983; Brown et al., 1987; Blanshard & Bodley, 2008). Affected 
koalas may be dehydrated, with muscle wasting and signs of depression (Canfield, 
1990). The sparse data regarding chlamydial respiratory disease in koalas describe a 
serous to purulent nasal discharge, sneezing, coughing, and dyspnoea as the clinical 
signs (Brown & Grice, 1986; Wardrop et al., 1999).   
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Figure 1-3. Rump pelage staining due to urinary incontinence associated with urogenital tract 
chlamydiosis  (Author’s own image). 
 
Histopathologically, transmigration of polymorphonuclear cells may be seen across 
capillary walls of the affected organs in the acute stage of chlamydiosis, with more 
chronic disease being characterised by a lymphocytic-plasmacytic infiltration 
(Kempster et al., 1996), sometimes with monocytes and neutrophils (McColl et al., 
1984; Obendorf & Handasyde, 1990; Hemsley & Canfield, 1997). The normal 
architecture of the affected tissue is eventually replaced with fibrous connective tissue 
(Obendorf & Handasyde, 1990), rendering affected organs dysfunctional and causing 
profound morbidity in some animals. Although affected females with reproductive tract 
disease may not show overt signs of disease, they are often infertile (Blanshard & 
Bodley, 2008). The ovaries tend to retain cyclical activity, containing follicles at various 
stages of development, corpora lutea, and degenerate remnants of corpora lutea 
(Obendorf, 1981). This suggests that infertility associated with chlamydiosis is due to 
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fibrosis of the reproductive tract rather than a lack of cyclic ovarian activity. In order to 
prevent the chronic changes associated with chlamydiosis, effective antimicrobial 
treatment is required early in the course of disease prior to the development of the 
irreversible fibrosis that occurs with chronic disease.  
 
1.6.3 Treatment of chlamydiosis 
 1.6.3.1  Topical therapy 
Topical therapy is usually administered when affected koalas are presented to wildlife 
rehabilitation facilities with conjunctivitis. Topical therapy often consists of commercial 
eye ointments containing antimicrobials with anti-chlamydial activity, including 
oxytetracycline, chloramphenicol and ofloxacin. A topical corticosteroid may also be 
applied, and the duration of therapy varies between rehabilitation facilities. Topical 
therapy may be accompanied by conjunctival ablation in eyes with severe conjunctival 
proliferation, or in cases that are refractory to treatment (Blanshard & Bodley, 2008).  
 
Topical therapy for chlamydial conjunctivitis is often accompanied by systemic 
antimicrobial therapy, typically enrofloxacin or chloramphenicol (Blanshard & Bodley, 
2008). In some cases of chlamydial keratoconjunctivitis, systemic antimicrobial therapy 
is not administered despite evidence that keratoconjunctivitis is often accompanied by 
clinical or subclinical urogenital disease (Griffith, 2010), and that topical treatment does 
not prevent chlamydial shedding from other infected sites (Markey et al., 2007). 
 
 1.6.3.2  Systemic therapy 
Systemic therapy is administered for the treatment of urogenital disease, and in some 
facilities it is used in conjunction with topical treatment for keratoconjunctivitis. The 
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systemic treatment of chlamydiosis is complicated by the koala’s intolerance of the first 
line anti-chlamydial drugs used in humans and other species, the macrolides (e.g. 
erythromycin, azithromycin) and tetracyclines. Oxytetracycline and erythromycin have 
been found to induce a syndrome of inappetence, wasting, and death following systemic 
administration to koalas (Brown et al., 1984; Osawa & Carrick, 1990). More recently, a 
clinical trial testing newer forms of the macrolides and tetracyclines, azithromycin and 
doxycycline, was undertaken in koalas suffering chlamydiosis. All koalas receiving 
azithromycin orally (p.o.; n = 3) and five of six koalas receiving doxycycline [either 
intramuscularly (i.m.) once weekly, or p.o. once daily (s.i.d.) or twice daily (b.i.d.)] 
displayed signs of depression, inappetence, weight loss, and decreased faecal output. 
There was no response to various rescue treatments (including gastrointestinal 
prokinetic agents, vitamin B injections, oral administration of fresh caecal contents or 
pulverised Eucalyptus spp. leaf, soya-based supplements, or parenteral fluid therapy) 
and all koalas were euthanased on welfare grounds, except for one that died prior to 
euthanasia (Griffith, 2010).  
 
The koala’s intolerance of these antimicrobials may be due to disruption of the tall, 
dense fringe of bacteria that is closely adhered to the caecal mucosal surface. This 
bacterial layer is arranged in long parallel chains, with an orientation perpendicular to 
the caecal wall (McKenzie, 1978). The bacterial fringe consists of numerous 
morphologically distinct bacteria, including gram positive cocci and bacilli, gram 
negative bacilli, both gram positive and gram negative fine branching filaments thought 
to be actinomycetes, and tannin-protein complex-degrading enterobacteria (T-PCDE) 
(McKenzie, 1978; Osawa, 1992; Osawa et al., 1993). The latter are involved in 
degradation of tannin-protein complexes that are abundant in the koala’s Eucalyptus 
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spp. diet, thus increasing digestibility of their diet by liberating nitrogen in the form of 
ammonia, which can be used by microflora for protein synthesis (Osawa et al., 1993). 
One study demonstrated the absence of the caecal microbial lining following a striking 
loss of over 30% body weight and subsequent death in a koala receiving systemic 
oxytetracycline for cystitis (Osawa et al., 1993), implicating the loss of these important 
gastrointestinal microflora in the pathogenesis of the wasting syndrome seen with 
systemic oxytetracycline use. Loss of T-PCDE from the caecal wall may render affected 
koalas unable to assimilate their highly indigestible Eucalyptus spp. diet, resulting in 
malnutrition and death (Osawa & Carrick, 1990).  
 
Supplementary feeding with a soya-based product during and following systemic 
oxytetracycline therapy for chlamydiosis has shown promising results. Despite some 
weight loss occurring during treatment, weight was regained following treatment and a 
successful return to a eucalypt-only diet was reported (Osawa & Carrick, 1990). Weekly 
doxycycline injections have also shown promise for keratoconjunctivitis when 
accompanied by supplementary feeding (Blanshard, 1994). However, this approach has 
not gained wide acceptance and alternative antimicrobial therapies have been adopted 
instead. 
 
Current suggested systemic antimicrobial therapy for chlamydiosis typically consists of 
enrofloxacin 10 mg/kg s.i.d. subcutaneously (s.c.), or chloramphenicol 60 mg/kg s.i.d. 
s.c. (Blanshard & Bodley, 2008). Until recently, enrofloxacin was also administered p.o. 
(Blanshard & Bodley, 2008). However, very low plasma concentrations of enrofloxacin 
have been reported following oral administration to koalas (Griffith et al., 2010), thus 
s.c. treatment is now more widely adopted. There are anecdotal reports of success with 
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chloramphenicol 30 mg/kg b.i.d. s.c. (Blanshard, 1994; Blanshard & Bodley, 2008), 
although this protocol is not used widely.  
 
Recent studies have shed some light on the suitability of these therapies for treating 
koalas with chlamydiosis. Four to ten weeks of treatment with enrofloxacin at 10 mg/kg 
s.c. s.i.d. or 20 mg/kg p.o. s.i.d., or with marbofloxacin at 10 mg/kg p.o. s.i.d., led to 
resolution of clinical signs and cessation of mucosal chlamydial shedding by the end of 
the treatment course, as detected by real-time polymerase chain reaction (qPCR) 
(Griffith, 2010). However, rebound shedding of C. pecorum, or C. pecorum and C. 
pneumoniae, occurred following treatment withdrawal in 24 of 29 (83%) koalas. This 
indicates treatment failure in the majority of cases, and raises questions regarding the 
suitability of the fluoroquinolones, enrofloxacin and marbofloxacin, in treating koalas 
with chlamydiosis at these dose rates. By contrast, chloramphenicol treatment trials 
indicated a dosage of 60 mg/kg s.c. s.i.d. stopped chlamydial shedding by the end of the 
treatment course (which lasted up to 45 days, but often shedding ceased earlier) as well 
as a continued absence of chlamydial shedding for two (Markey et al., 2007) or seven 
(Govendir et al., 2012) weeks following treatment withdrawal, as detected by qPCR. 
 
1.7 THE CRYPTOCOCCUS NEOFORMANS SPECIES 
COMPLEX 
The Cryptococcus neoformans species complex consists of C. neoformans var. 
neoformans, C. neoformans var. grubii, and C. gattii. These basidiomycetous fungi 
cause disease in many animal species worldwide, including humans, and clinical 
presentation can vary dramatically between host species (Lin & Heitman, 2006). In 
clinically affected humans and animals, Cryptococcus spp. exists as a yeast; this is the 
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unicellular asexual form, which reproduces by budding. Although Cryptococcus spp. 
can reproduce sexually, this state is not documented to be pathogenic (Casadevall & 
Perfect, 1998).  
 
1.8 CRYPTOCOCCOSIS IN KOALAS 
1.8.1 History and Taxonomy 
Cryptococcosis was first detected in koalas in 1959 (Backhouse & Bolliger, 1960). The 
three cases reported at this time were among the first non-human cases of 
cryptococcosis to be reported in Australia. Sporadic cases were subsequently reported, 
until a comprehensive review of 43 cases was published in 2003 (Krockenberger et al., 
2003). This helped to shed light on the previously poorly described spectrum of clinical 
disease seen in koalas with cryptococcosis. Prior to this review, only 11 cases had been 
published, with the predominant clinical presentations being consistent with respiratory 
and neurological disease. Two of these cases originated from captive koalas in Western 
Australia (Gardiner & Nairn, 1964), and the remainder were from wild and captive 
koalas within their natural range along the eastern Australian seaboard, predominantly 
within and surrounding Sydney (Backhouse & Bolliger, 1960; Backhouse & Bolliger, 
1961; Bolliger & Finckh, 1962; Canfield et al., 1986; Spencer et al., 1993; Malik et al., 
1997; Woods & Blyde, 1997).  
 
Since the first human case of cryptococcosis was reported in 1894 (Viviani & 
Tortorano, 2009), the Cryptococcus neoformans species complex has undergone a 
number of taxonomic reclassifications. By the 1980s, a single species containing two 
varieties and five serotypes had gained acceptance. These were C. neoformans var. 
neoformans, which comprised serotypes A, D, and the hybrid AD, and C. neoformans 
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var gattii, containing serotypes B and C (Kwon-Chung et al., 1982; Casadevall & 
Perfect, 1998). In 1999, serotypes A and D were separated into different varieties: C. 
neoformans var neoformans (serotype D) and C. neoformans var grubii (serotype A) 
(Franzot et al., 1999). A more recent separation based on molecular differences saw 
serotypes B and C reclassified as a distinct species, C. bacillisporus (Boekhout et al., 
2001), which was subsequently renamed C. gattii (Kwon-Chung et al., 2002). Thus, the 
currently used nomenclature, and that used throughout this thesis, is C. neoformans 
(var. neoformans and var. grubii) and C. gattii. There are four molecular biotypes of C. 
gattii, designated VGI to VGIV (Ellis et al., 2000). 
  
1.8.2 Epidemiology 
Although a relatively uncommon disease, cryptococcosis is possibly more common in 
koalas than in any other species (Krockenberger et al., 2003; Malik et al., 2011), with 
clinical disease identified in 2.5% of cases in a post mortem examination series carried 
out at The University of Sydney between 1980 and 2003 (Stalder, 2003). Members of 
the Cryptococcus neoformans species complex are ubiquitous in the environment, with 
C. neoformans commonly isolated from pigeon guano (Emmons, 1955) and soil 
(Emmons, 1951), and the VGI biotype of C. gattii being closely associated with 
Eucalyptus spp. trees, particularly E. camaldulensis and E. tereticornis (Ellis & Pfeiffer, 
1990; Pfeiffer & Ellis, 1992; Chakrabarti et al., 1997; Krockenberger et al., 2002b). 
These two species are the preferred food trees by koalas in some regions (Gordon et al., 
1988; Gordon et al., 1990; White & Kunst, 1990). C. gattii has been identified as the 
causative agent in all of the koala cryptococcosis cases (29 out of 43) that have been 
biotyped, and at least nine of the remaining cases are likely to have been caused by C. 
gattii, based on histopathological or morphological evidence. For the five remaining 
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cases, there was insufficient information for an assessment to be made (Krockenberger 
et al., 2003). VGI is responsible for the vast majority of koala cryptococcosis cases 
(Malik et al., 2011). A small number of clinical cases caused by VGII have been 
detected in captive koalas in Western Australia (Malik et al., 2011), where this biotype 
tends to be more prevalent and may be more virulent than VGI (McGill et al., 2009).  
 
The contact between koalas and Cryptococcus spp. has three known outcomes: nasal 
colonisation only, whereby Cryptococcus spp. may be isolated in the absence of a 
positive serum cryptococcal antigen titre (Connolly et al., 1999); subclinical disease, 
detected as a positive cryptococcal antigen titre in the absence of clinical disease 
(Krockenberger et al., 2002a); and clinical disease, whereby affected animals show 
clinical signs of disease and have relatively high cryptococcal antigen titres 
(Krockenberger et al., 2002a). Although clinical cryptococcosis appears to be a 
relatively uncommon outcome of the complex interaction between the host, pathogen 
and environment, colonisation of the skin and upper respiratory tract by C. gattii occurs 
commonly in koalas, with nasal colonisation being detected in up to 100% of koalas in 
some captive groups (Krockenberger et al., 2002b). Colonisation by C. neoformans also 
occurs, but not as often (Connolly et al., 1999; Krockenberger et al., 2002b). The close 
affiliation between C. gattii VGI and Eucalyptus spp. offers a plausible explanation for 
the increased rates of disease and colonisation caused by this species, compared with C. 
neoformans (Connolly et al., 1999; Krockenberger et al., 2002b). This is supported by 
the finding of increased nasal colonisation and subclinical disease prevalence in 
environments that carry high burdens of C. gattii (Krockenberger et al., 2002a; 
Krockenberger et al., 2002b). Additionally, there is evidence that koalas can amplify 
numbers of C. gattii in their environment (Krockenberger et al., 2002b), which is an 
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intriguing finding that may be related to the prevalence of cryptococcosis in this 
species. 
 
Subclinical disease has the potential to spontaneously resolve, remain subclinical, or 
progress to clinical disease, and all three outcomes have been identified in koalas 
(Krockenberger et al., 2002a). There is no indication that cryptococcosis is zoonotic or 
contagious (Sorrell, 2001), and disease caused by C. gattii usually manifests in hosts 
without overt immunocompromise; by contrast, C. neoformans usually infects 
immunocompromised hosts (Rozenbaum & Gonçalves, 1994; Chen et al., 2000). There 
is strong evidence supporting a respiratory route of infection in humans (Casadevall & 
Perfect, 1998), although primary cutaneous inoculation has also been reported (Hamann 
et al., 1997); both of these routes of infection are suspected in koalas. 
 
1.8.3 Clinical signs and pathological changes associated with 
cryptococcosis 
Clinically, koalas with cryptococcosis tend to present with signs of respiratory tract 
disease (upper or lower) or neurological signs. Nasal discharge is commonly associated 
with disease of the rostral nasal cavity, whereas stertorous breathing, dyspnoea and 
sometimes aerophagia are associated with disease of the caudal nasal cavity and 
nasopharynx. Facial distortion may occasionally be present in cases of rostral nasal 
cavity disease. Pulmonary disease tends to manifest as severe dyspnoea. Some affected 
animals will present deceased with no identifiable cause of death, and affected koalas 
are frequently in poor body condition due to the chronic course of disease 
(Krockenberger et al., 2003). 
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Seizures are a common clinical presentation for koalas with neurological disease 
(Krockenberger et al., 2003), and blindness, nystagmus, rolling, circling, and paresis 
progressing to paralysis have been described (Backhouse & Bolliger, 1960; Backhouse 
& Bolliger, 1961; Bolliger & Finckh, 1962; Spencer et al., 1993). 
 
Histopathology of affected tissues reflects a spectrum of host responses. Some cases 
display minimal host response, others show evidence of acute inflammation 
characterised by neutrophils, and others have more chronic pathological changes 
reflective of pyogranulomatous and granulomatous inflammation (Krockenberger et al., 
2003). 
 
1.8.4 Treatment of cryptococcosis 
There are only a few reports regarding treatment of cryptococcosis in koalas. Early 
recommendations included ketoconazole 10 mg/kg s.id. p.o., itraconazole 20 - 40 mg/kg 
s.id. or b.i.d. p.o., fluconazole up to 100 mg b.i.d. p.o., or fluconazole 3 mg/kg s.i.d. p.o. 
following a loading dose of 6 mg/kg on the first day of treatment (Blanshard, 1994; 
Booth & Blanshard, 1999).  
 
A number of clinical reports of ketoconazole therapy have been made (Blanshard, 
1994). Interpretation of these reports is confounded by the following factors: a koala 
with a positive cryptococcal antigen titre (LCAT) that failed to respond to therapy had 
pneumonia and was receiving concurrent chloramphenicol and gentamicin, so may have 
succumbed regardless of whether ketoconazole treatment was successful; a koala 
receiving ketoconazole for cutaneous nodules with a positive culture of C. gattii and a 
positive LCAT yielded a negative LCAT following ketoconazole therapy (10 mg/kg 
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p.o. s.i.d.), but resolution of the skin disease was attributed to topical silver nitrate; and 
a clinically normal koala with a positive LCAT (1:120) yielded a negative LCAT 
following ten days of ketoconazole treatment at 10 mg/kg p.o. s.i.d. (Blanshard, 1994). 
Although this small set of cases indicates ketoconazole may be effective in reducing a 
positive LCAT titre, more information is required to enable an assessment of clinical 
response to therapy. Additionally, there is anecdotal evidence that positive LCATs can 
resolve spontaneously over time (Krockenberger et al., 2002a), making response to 
treatment of subclinical disease difficult to assess. 
 
Itraconazole therapy has reportedly cured cryptococcal lesions in koalas following 90 
days of therapy, although the dosage and location of the lesions were not reported 
(Booth & Blanshard, 1999). More recently, combination therapy has been 
recommended for cases of cryptococcosis (Blanshard & Bodley, 2008; Malik et al., 
2011), and is based on regimens that were developed for cats (Malik et al., 2001) in an 
attempt to overcome amphotericin B associated nephrotoxicity. The protocol involves 
twice-weekly administration of subcutaneous amphotericin B (0.5 mg/kg diluted in 300 
mL 2.5% dextrose and 0.45% NaCl), in conjunction with an orally administered triazole 
(itraconazole 100 mg/day or fluconazole 50-100 mg b.i.d.), and has been used with 
some success (Krockenberger et al., 2003; Blanshard & Bodley, 2008). This protocol 
has been used in koalas without nephrotoxic side effects being observed, although 
monitoring renal function throughout therapy is recommended (Blanshard & Bodley, 
2008). Treatment duration may range from 2 to 18 months, depending on disease 
severity. Antifungal concentrations in plasma should be monitored and appropriate 
dosage adjustments made in cases that are responding poorly to therapy. Monthly 
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LCATs should be monitored, and treatment should be continued until a negative LCAT 
persists for at least one month (Blanshard & Bodley, 2008). 
 
A recent case study reported a lack of recurrence of a cryptococcal granuloma in the 
nasal sinus, as determined by computed tomography, during combination therapy with 
itraconazole 10 mg/kg s.i.d. p.o. (reduced from 10 mg/kg b.i.d. p.o. based on therapeutic 
monitoring of plasma concentrations) and amphotericin B (initially s.c. as per the above 
protocol, then intralesionally following debulking surgery) (Wynne et al., 2012). 
Although this koala was showing promising results with combination therapy, the koala 
maintained an elevated LCAT so no indication was provided as to whether the disease 
resolved with this therapy. 
 
In another case whereby a koala received fluconazole 100 mg p.o. b.i.d. and 
amphotericin B (0.5 mg/kg in 60 mL Hartmann’s solution) three times weekly, the 
LCAT continued to rise despite nasal swabs becoming negative for C. gattii during 
therapy. This koala was changed from fluconazole to ketoconazole 50 mg p.o. b.i.d., 
and the amphotericin B was continued. At the time of reporting, there was evidence of 
clinical improvement following three months of therapy, although the LCAT was not 
yet negative (Woods & Blyde, 1997). This koala subsequently died in July 1998 
(Krockenberger et al., 2003). 
 
1.9 THERAPEUTIC DRUG STUDIES IN KOALAS 
Prior to 2010, there were no pharmacokinetic data available for any therapeutic drug 
used to treat koalas. For this reason, therapeutic drug dosage regimens have been 
developed by extrapolation from other species, including humans (Blanshard & Bodley, 
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2008). Many of these extrapolated dosages have gained acceptance as they appear to be 
well-tolerated by koalas in most cases (Blanshard & Bodley, 2008). However, this does 
not address the question of whether the dosage is sufficient for treatment of the relevant 
condition. Although the consideration of drug pharmacokinetics in koalas is relatively 
new, the few studies published to date have revealed some interesting and important 
findings that hold implications for therapeutic drug use in this species.  
 
The first koala pharmacokinetic study involved subcutaneous and oral administration of 
the fluoroquinolones, enrofloxacin and marbofloxacin, to koalas with chlamydiosis 
(Griffith et al., 2010). This study demonstrated low bioavailability of oral enrofloxacin 
relative to subcutaneous administration, and absorption rate-limited disposition of the 
oral formulation when compared to the subcutaneous formulation. Bioavailability and 
absorption rate could not be further qualified due to the lack of an intravenous (i.v.) 
treatment group. A subsequent study investigated chloramphenicol pharmacokinetics 
and its effect on chlamydial shedding when administered subcutaneously to koalas with 
chlamydiosis (Govendir et al., 2012). This study concluded that although 
chloramphenicol prevented chlamydial shedding for up to 63 days post treatment-
withdrawal in the majority of koalas, the plasma concentrations attained at 60 mg/kg 
s.i.d. s.c. were below target therapeutic concentrations. These studies had two common 
limitations. Firstly, neither study included an i.v. treatment group, which precluded 
estimation of important pharmacokinetic parameters, namely absolute bioavailability 
(F), volume of distribution (Vd), and systemic clearance (CL). Secondly, the therapeutic 
targets in both cases were deduced from data derived using other antimicrobial-
pathogen combinations, as no data existed regarding the in vitro susceptibility of koala 
isolates of C. pneumoniae or C. pecorum to any antimicrobial agent.  
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The most extensive pharmacokinetic study published to date investigated the 
pharmacokinetic profile of the non-steroidal anti-inflammatory drug, meloxicam 
(Kimble et al., 2013). Not only was meloxicam poorly orally absorbed by koalas in the 
study, it was also rapidly eliminated. This study highlighted the clinical implications of 
the koala’s ability to metabolise and eliminate xenobiotics, and emphasised the need to 
perform pharmacokinetic studies in koalas to enable evaluation of the likely efficacy of 
commonly used drugs. Importantly, this study demonstrated the inherent flaws 
associated with dose extrapolation between physiologically distinct species, namely the 
small carnivores (dogs and cats) from which many koala drug doses have been 
extrapolated, and koalas. 
 
These studies have demonstrated the importance of pharmacokinetic studies in species 
that have unique metabolic needs, such as the koala. Hundreds of koalas are presented 
to individual wildlife hospitals on the east coast of Australia for medical treatment every 
year (Jones, 2008; Griffith et al., 2013), which would equate to thousands being treated 
annually across their natural range. This makes pharmacokinetic studies crucial in 
determining which drugs are likely to have therapeutic benefit in koalas, and which are 
not. Not only are the time and money that go into treating sick koalas important, but the 
animal welfare implications of hospitalising animals to administer drugs without data on 
their likely efficacy must be considered, as well as the dangers of antimicrobial 
resistance development due to the use of subtherapeutic antimicrobial dosages.  
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1.10 PHARMACOKINETICS AND PHARMACODYNAMICS: A 
SUMMARY OF BASIC PRINCIPLES 
The integration of drug pharmacokinetics and pharmacodynamics is important in 
therapeutic drug development and dosage design. Pharmacokinetics pertains to the 
study of the time-course of drug molecules in the body, as described by mathematical 
models. It describes how an animal processes a drug following administration, 
encompassing four key physiological processes: absorption, distribution, metabolism, 
and elimination. Together, these constitute drug disposition (Riviere, 2009a; Riviere, 
2009b). Pharmacodynamics characterises the relationship between the drug 
concentration at target receptors within the body and the resulting physiological effect, 
if one exists. Pharmacokinetic/pharmacodynamic (PK/PD) integration thus describes the 
correlation between the drug concentration in the bloodstream, the drug concentration at 
the therapeutic target site, and the clinical outcome (Martinez et al., 2006a). For 
antimicrobial drugs, this enables specific antimicrobial-pathogen combinations to be 
evaluated and provides a guide for estimating dosages to optimise clinical and microbial 
outcomes (Martinez et al., 2006a).  
 
1.10.1 Protein binding 
PK/PD studies tend to be based on concentrations of free drug (i.e., the portion not 
bound to plasma proteins) in the serum or plasma. Measurement of plasma protein 
binding is an important component of pharmacokinetic studies as it enables the free or 
unbound drug concentration in the bloodstream to be determined. This is the drug 
fraction that is available to exhibit its pharmacologic effects, undergo metabolism, and 
be excreted from the body. The reasons for sampling drug concentrations in serum or 
plasma are numerous. Firstly, following administration, drugs enter the bloodstream in 
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which they are transported throughout the body. Secondly, peripheral blood samples are 
minimally invasive to obtain. Finally, many drugs reach concentrations in the systemic 
circulation that are equivalent to extracellular concentrations in well-perfused tissues, 
meaning serum or plasma concentrations are often indicative of tissue concentrations 
(Riviere, 2009a).  
 
 1.10.2 Absorption, first-pass metabolism, and bioavailability  
Therapeutic drugs can be administered systemically by a number of routes; these 
include, but are by no means limited to, oral administration and parenteral 
administration. Parenteral routes include subcutaneous, intramuscular, intravenous, 
inhalational and transcutaneous administration. For drugs that are administered to elicit 
systemic effects, the drug must move from the site of administration into the systemic 
circulation following extravascular administration. This is the process of absorption 
(Riviere, 2009a). Following oral administration, drug absorption may be affected by the 
dosage form (eg oral solution, suspension, capsule, tablet, or paste); the presence of 
ingesta in the proximal gastrointestinal tract, which may influence gastric-emptying 
time or provide opportunities for drug-chelation to divalent cations or other feed 
constituents; pre-systemic or first-pass metabolism by microorganisms within the 
gastrointestinal tract, or drug metabolism by enzymes within the enterocytes 
themselves; the presence of efflux transporter proteins, such as P-glycoprotein, that 
expel drugs back into the intestinal lumen following absorption; and the 
physicochemical properties of the drug (Baggot, 2006; Riviere, 2009a). Once in 
solution, drugs must be relatively lipid-soluble and in a non-ionised form for successful 
passive absorption across the phospholipid bilayer cell membranes of the 
gastrointestinal mucosa; alternatively, some drugs are absorbed by active transport 
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mechanisms (Schanker, 1962; Kararli, 1989; Kwon, 2001). Drug absorption that occurs 
distal to the oral cavity and proximal to the rectum results in the drug being present in 
the portal circulation. This is true for the majority of drugs, as the primary site of 
gastrointestinal drug absorption is the small intestine. Prior to entry into the systemic 
circulation, absorbed drug in the portal circulation must pass through the liver where 
first-pass metabolism may occur (Baggot, 2006; Riviere, 2009a).  
 
Drugs administered via intramuscular or subcutaneous routes are not subject to first-
pass metabolism, as the capillaries that transport these drugs from the tissues drain 
directly into the systemic circulation. Intramuscular and subcutaneous administration 
routes also evade many of the other barriers to absorption faced by orally administered 
drugs. The main factors influencing absorption from intramuscular or subcutaneous 
injection sites are the degree of vascularity at the injection site, the formulation of the 
injectable preparation, and the physicochemical properties of the drug (Baggot, 2006; 
Riviere, 2009a). 
 
The extent of drug absorption following extravascular administration is reflected in a 
drug’s systemic bioavailability (F), which is the fraction of an administered dose that 
reaches the systemic circulation unchanged (Riviere, 2009a). Bioavailability can range 
from 0.0, whereby none of the drug reaches the systemic circulation, to 1.0, whereby 
100% of the administered drug reaches the systemic circulation. Drugs administered i.v. 
have a bioavailability of 1.0 as the entire dose is deposited directly into the systemic 
circulation, avoiding an absorption phase in the drug disposition profile. Thus, plasma 
disposition of an i.v. dose needs to be known in order to assess the bioavailability of an 
extravascular dose (Birkett, 2002; Riviere, 2009a). Incomplete bioavailability following 
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oral administration is a common finding, and can be attributed to the previously 
mentioned factors that affect oral drug absorption. Following intramuscular or 
subcutaneous administration, incomplete bioavailability may be due to some degree of 
precipitation of the administered formulation at the injection site, or to tissue irritation 
caused by a component or property of the administered formulation (Baggot, 2006). As 
drug disposition following i.v. administration is not confounded by absorption, the i.v. 
route is used to determine the pharmacokinetic parameters of a drug (Baggot, 2006), 
and comparisons can then be made to other routes of administration.  
 
 1.10.3 Drug distribution 
Following absorption into the systemic circulation, the free drug fraction may be 
distributed to the extravascular tissues, including the organs responsible for drug 
metabolism and elimination. Drug distribution is governed by a number of factors, 
including the degree of binding to plasma proteins; the physicochemical properties of 
the drug, which determine its ability to penetrate cellular barriers and its affinity for 
tissues; the degree of tissue perfusion; and the concentration gradient between blood 
and tissue. Many drugs are distributed to tissues through capillary pores, or by diffusion 
down a concentration gradient. Tissue binding may occur, and this may increase the 
distribution of a drug. This does not always correlate with an increase in drug activity, 
as the site of sequestration may not be the site of drug activity (Baggot, 2006; Riviere, 
2009a). 
 
 1.10.4 Metabolism and elimination 
The processes of metabolism and elimination are closely related, and may vary between 
drugs and animal species. The two organs responsible for the vast majority of 
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metabolism and elimination processes are the liver and the kidney. Some agents are 
almost entirely eliminated via renal excretion, whilst others are eliminated by hepatic 
metabolism followed by biliary or renal excretion (Baggot, 2006). Lipophilic drugs 
generally undergo hepatic metabolism into more hydrophilic metabolites prior to 
excretion. Hepatic metabolism is broadly classified into two phases, termed Phase I and 
Phase II metabolism. There are four types of reactions involved in Phase I metabolism: 
oxidation, reduction, hydrolysis, and hydration. These reactions add a functional group 
to the parent molecule. The products of Phase I metabolism are subsequently subject to 
Phase II conjugation reactions to enable deactivation of these metabolites. Phase II 
metabolism usually involves conjugation of the functional group that was added during 
Phase I metabolism, although Phase II metabolism also plays an important role in the 
metabolism of some parent drugs that have no requirement for Phase I metabolism 
(Riviere, 2009a). The most widely studied of the many hepatic metabolic pathways are 
the cytochrome P450-mediated (CYP) reactions. These vary widely between species 
and some of these have been studied in koalas (refer to Section 1.11).  
 
Of those drug metabolites and parent drugs that are secreted into the bile, some are 
excreted in the faeces. Others may undergo a process known as enterohepatic 
recirculation, whereby the drug or its metabolite may be reabsorbed by the small 
intestine, transported back to the liver and either resecreted into the bile, or excreted by 
the kidney after reaching the systemic circulation. In some cases, enterohepatic 
recirculation involves hepatic conjugation and intestinal bacterial deconjugation of a 
drug, prior to its reabsorption in the small intestine (Roberts et al., 2002; Riviere, 
2009a). Enterohepatic recirculation may affect the pharmacokinetic profile of a drug, 
usually by prolonging drug elimination (Roberts et al., 2002).  
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 1.10.5 Systemic clearance  
The disposition of a drug can be described mathematically by its pharmacokinetic 
parameters. The two parameters that are fundamental to the description of drug 
disposition are the systemic CL and the Vd (Baggot, 2006). The systemic CL signifies 
the volume of blood or plasma from which a drug is cleared per unit time (Baggot, 
2006), indicating the ability of the body to irreversibly eliminate a drug following 
administration. Systemic CL is the most important pharmacokinetic parameter as it 
controls overall drug exposure, and is necessary for determination of the dosage 
regimen required for maintenance of a selected steady state plasma concentration 
(Toutain & Bousquet-Mélou, 2004a).  
 
 1.10.6 Volume of distribution 
Vd is a proportionality constant that relates the plasma drug concentration to the total 
amount of drug in the body (Toutain & Bousquet-Mélou, 2004b; Baggot, 2006), and 
can be represented by the following equation: 
 
Vd = total amount of drug in the body at time t 
     drug plasma concentration at time t 
 
This ratio varies depending on the state of drug disposition. To allow for this, there are 
three Vd terms that can be estimated: the volume of the central compartment (Vc), which 
is calculated as the initial volume of distribution following i.v. bolus administration, and 
represents the apparent volume from which drug elimination occurs; the volume of 
distribution during pseudoequilibrium (Varea), which occurs when net drug distribution 
between the plasma and the tissues reaches equilibrium and any decrease in plasma drug 
concentration is solely due to irreversible drug elimination from the body; and the 
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steady-state volume of distribution (Vss), which is used under equilibrium conditions 
where plasma drug CL is null, such as during an i.v. infusion or once steady-state 
plasma concentrations are achieved following multiple drug administration (Toutain & 
Bousquet-Mélou, 2004b). Between drug administration (when Vc is calculated) and the 
attainment of distribution pseudo-equilibrium conditions (when Varea is calculated), Vd 
increases from Vc to Varea as the plasma drug concentration decreases due to distribution 
from the systemic circulation into the tissues. Thus, Vd during the phase of drug 
distribution is a time-dependent variable ranging from Vc to Varea (Toutain & Bousquet-
Mélou, 2004b). If a large proportion of drug is eliminated from the body prior to 
attainment of distribution pseudo-equilibrium, then Varea may be much larger than Vss. 
In most cases, however, Varea is only marginally larger than Vss and will approach Vss in 
cases where CL approaches zero (Toutain & Bousquet-Mélou, 2004b). Of the three Vd 
terms, Vss is the most robust as it is independent of elimination (Baggot, 2006). In 
clinical practice, Vc is rarely used, although it may be useful for prediction of the initial 
maximum concentration of an i.v. bolus administration of a drug. Varea may be used to 
estimate the residual amount of drug in the body during elimination. Vss holds the most 
clinical relevance, as it enables calculation of a loading dose (Toutain & Bousquet-
Mélou, 2004b). Although Vd allows estimation of the extent of drug distribution within 
the body, it does not reveal the pattern of drug distribution or allow prediction of drug 
concentrations in tissues or at the site of infection (Baggot, 2006).  
 
 1.10.7 Terminal half-life 
The plasma terminal half-life (t1/2) is a composite pharmacokinetic parameter that is 
determined by systemic CL and Vd. The terminal t1/2 is the time required for the plasma 
drug concentration to halve during the terminal phase (Toutain & Bousquet-Mélou, 
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2004c; Baggot, 2006). It is calculated using the elimination rate constant (kel), which is 
the negative gradient of the terminal phase of the semi-logarithmic concentration-time 
curve (Riviere, 2009b). In some cases, the rate of drug absorption is slow enough to 
limit the rate of elimination. In these situations, a drug can only be eliminated as quickly 
as it is being absorbed, and the t1/2 is reflective of the absorption rate rather than the 
elimination rate. This is known as absorption rate-limited disposition, or ‘flip-flop’ 
pharmacokinetics  (Figure 1-4) (Toutain & Bousquet-Mélou, 2004c; Yáñez et al., 2011), 
and in this situation the terminal rate constant is an absorption constant, not an 
elimination constant; as such, it is termed ka (Riviere, 2009b).    
 
 
Figure 1-4. Theoretical concentration-time curves for a) a drug that does not display absorption 
rate-limited disposition, and b) a drug that does display absorption rate-limited disposition. In a), 
the similarity in gradient between both curves indicates a consistent rate of drug elimination, 
regardless of administration route. In b), the steeper gradient of the intravenous curve indicates the 
drug is being eliminated more slowly following extravascular administration, which is due to 
delayed absorption following this route of administration. Thus, the curves in b) depict absorption 
rate-limited disposition, or ‘flip-flop’ kinetics. Author’s own image. 
 
Terminal t1/2 is commonly used to compare the rate of drug elimination between 
species, and can vary dramatically for drugs that undergo hepatic metabolism (Baggot, 
2006). Clinically, the terminal t1/2 is used as a basis for selecting dosing intervals. 
Additionally, this parameter enables prediction of drug accumulation following multiple 
dosing and the time to reach steady state conditions (i.e. where the rate of drug input is 
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equal to the rate of drug output) (Toutain & Bousquet-Mélou, 2004c; Baggot, 2006), as 
well as the length of time it will take to eliminate the drug from the body following 
administration of the final dose (Riviere, 2009b).  
 
Species differences in any of the processes of absorption, distribution, metabolism and 
elimination can lead to vast differences in the time course of drug molecules in the body 
(Riviere, 2009a), which can in turn have dramatic effects on drug pharmacodynamics.  
 
 1.10.8 Non-compartmental pharmacokinetic analysis 
Non-compartmental pharmacokinetic analysis, utilising statistical moment theory, is 
frequently used to characterise drug pharmacokinetics, as it has the advantage of 
avoiding the assumptions required for specific compartmental models (Gabrielsson & 
Weiner, 2000). In addition to estimation of the CL, Vd, t1/2, and kel, important outcomes 
of non-compartmental analysis include measurement of the area under the 
concentration-time curve (AUC), which describes the degree of systemic drug exposure; 
the maximal concentration attained (Cmax) and the time the Cmax is reached (tmax), which 
are indicative of the drug absorption rate; and the mean residence time (MRT), which 
indicates the average time drug molecules stay in the body following administration 
(Baggot, 2006; Bulitta & Holford, 2008a). In statistical moment theory, the MRT is 
analogous to the terminal t1/2, and is dependent upon the administration route. The MRT 
is estimated based on the AUC and the area under the first moment curve (AUMC). In 
the same way as the AUC is determined as the area under the curve when plasma 
concentration is plotted against time, the AUMC is determined as the area under the 
curve when the product of plasma concentration and time are plotted against time 
(Baggot, 2006).  
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 1.10.9 Population pharmacokinetic modelling 
Within any population, there is inherent inter-individual variability in drug 
pharmacokinetics following administration of a given drug dose (Drusano et al., 2001; 
Drusano, 2004). In comparison with non-compartmental analysis, population 
pharmacokinetic models are developed using probability distributions and have the 
advantage of being able to statistically account for this often large degree of between 
subject variability (BSV). Including BSV in the population pharmacokinetic model 
enables prediction of the range of drug concentrations and therapeutic responses 
anticipated for an entire patient population. Additionally, population pharmacokinetic 
models can be applied to sparse data sets and allow incorporation of multiple covariates, 
such as renal function, age, and body size into the model. This enables a quantitative 
assessment of the effect these factors may have on drug disposition (Bulitta & Holford, 
2008b; Martín-Jiménez & Riviere, 1998).  
 
 1.10.10  Pharmacokinetic/pharmacodynamic indices 
For anti-infective drugs, pharmacokinetic parameters can be combined with previously 
determined pharmacodynamic parameters, such as the minimum inhibitory 
concentration (MIC) of the target organism. The integration of these parameters enables 
estimation of a dosage that theoretically should reach a predetermined therapeutic target 
(Toutain & Lees, 2004). These therapeutic targets are considered PK/PD indices as they 
incorporate both a pharmacokinetic parameter and a pharmacodynamic parameter 
(Toutain et al., 2002). It was in the 1940s and 1950s that the effect of dosing frequency 
on antimicrobial efficacy was investigated, with variations in the penicillin 
administration schedule noted to have a significant effect on treatment outcome (Jawetz, 
1946; Eagle et al., 1950). Successful therapy with penicillin was found to be dependent 
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upon the aggregate time for which plasma concentrations exceeded the bactericidal 
concentration, with no added benefit seen by further increasing the concentration 
(Eagle, 1948; Eagle et al., 1950; Eagle et al., 1953). This was recognised to differ from 
the pattern of activity observed with other antimicrobials available at the time, for 
which a positive correlation between concentration and efficacy seemed to exist, or that 
seemed to require a substantial host response to enable therapeutic efficacy (Eagle et al., 
1953). Since these early pharmacodynamic studies, three PK/PD indices have been 
recognised, and they tend to vary between different antimicrobial classes. These are the 
AUC0-24/MIC ratio, the Cmax/MIC ratio, and the time for which the plasma concentration 
exceeds the MIC (T > MIC) (Toutain & Lees, 2004; Ambrose et al., 2007).   
 
Population PK/PD modelling differs from PK/PD integration in that it involves 
computer simulations of pharmacokinetic and pharmacodynamic data. These data have 
usually been collected following administration of a single drug dose (Toutain & Lees, 
2004). This provides a basis upon which to optimise dosage regimens based upon 
PK/PD indices.  Estimated population pharmacokinetic parameters can be used in 
stochastic simulations, such as Monte Carlo simulations (MCS). MCS allow the 
relevant pharmacokinetic parameter to be estimated for each simulated subject (eg 
AUC, Cmax), and these can then be integrated with the MIC data for the target organism. 
From this data, the probability of attaining the therapeutic target at various drug dosages 
can be calculated, thus providing an efficient and comprehensible method of enabling 
informed clinical decisions based upon PK/PD datasets (Drusano et al., 2001).  
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 1.10.11 In vitro susceptibility testing 
The MIC values used for PK/PD integration and PK/PD modelling are derived from in 
vitro antimicrobial susceptibility tests, and are specific for the microbe-antimicrobial 
combination tested. The MIC is defined as the minimum antimicrobial concentration 
required to inhibit growth of the microorganism being tested, whereas the minimum 
bactericidal concentration (MBC) is defined as the minimum concentration of 
antimicrobial required to prevent growth of a microorganism following subculture onto 
antimicrobial-free media (Andrews, 2001). In vitro susceptibility testing is usually 
undertaken according to standardised guidelines, to minimise the variability between 
operators and laboratories. Such guidelines are constructed by organisations such as the 
Clinical Laboratory Standards Institute (CLSI), and have been developed for many 
pathogens. However, there are no such guidelines for the in vitro susceptibility testing 
of Chlamydia spp., despite C. trachomatis being estimated to be the most prevalent 
bacterial sexually transmitted disease of humans by the World Health Organisation in 
2005 (World Health Organization, 2011). Further to the lack of standardised guidelines 
for antimicrobial susceptibility testing of Chlamydia spp., there is only one paper 
reporting the antimicrobial susceptibility of C. pecorum isolates (Pudjiatmoko et al., 
1998). These were isolated from ruminants, and did not involve testing of 
chloramphenicol, enrofloxacin or florfenicol. 
` 
1.11 DIETARY AND METABOLIC FACTORS THAT MAY 
INFLUENCE DRUG PHARMACOKINETIC PROFILES IN KOALAS 
The finding of atypical pharmacokinetic profiles for some drugs in the koala is not 
unexpected. Although a number of suggested therapeutic drug dosages for koalas have 
been published without the benefit of pharmacokinetic studies (Blanshard, 1994; Booth 
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& Blanshard, 1999; Blanshard & Bodley, 2008), it has been recognised for over a 
decade that some drugs may be rapidly eliminated by koalas, and that dose 
extrapolation by allometric scaling may be inappropriate in this species (Booth & 
Blanshard, 1999). These insightful speculations were based upon findings of enhanced 
hepatic metabolic activity, as demonstrated by the rapid rate of bromsulphthalein 
clearance in koalas compared with sheep and macropods (Pass & Brown, 1990).  
 
Heightened metabolic function of the koala liver is likely to have developed as an 
adaptation to the Eucalyptus spp. diet on which koalas are almost entirely dependent. 
This specialist diet is high in toxic plant secondary metabolites (PSMs), including 
phenolics, terpenes, and tannins (Cork & Foley, 1997; Pass et al., 1999), and only a 
fraction of the amount of Eucalyptus oil ingested daily by these folivorous marsupials is 
required to induce toxicity in humans after adjusting for body weight (Pass et al., 2001). 
Increased efficiency of certain metabolic pathways has been suggested as one method 
by which specialist folivores, including koalas, detoxify their diet (McLean & Foley, 
1997; Boyle et al., 2000b; Boyle et al., 2001; Pass et al., 2002). There is evidence that 
certain Phase I oxidative reactions, such as those governed by CYPs, are very efficient 
in koalas, and have a high capacity (McLean & Foley, 1997; Boyle et al., 2001); this 
has been supported by in vitro assays using microsomes isolated from koala livers (Pass 
et al., 2001), and is intuitive for potentially toxic dietary components as extensive 
oxidation yields highly polar metabolites that can be excreted readily by the kidneys 
(Boyle et al., 2000b). Although Phase II glucuronidation reactions do occur in koalas, 
they appear less important than Phase I oxidation reactions in metabolising certain toxic 
dietary constituents (McLean & Foley, 1997). This pattern has also been observed in 
two other specialist feeders, the greater glider (Petauroides volans) and the ringtail 
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possum (Pseudocheirus peregrinus), and is in direct contrast with the metabolism of the 
same dietary constituents by a generalist feeder, the brushtail possum (Trichosurus 
vulpecula), which relies more heavily on Phase II glucuronidation for metabolism of 
these compounds (Boyle et al., 1999; Boyle et al., 2000a; Boyle et al., 2000b; Boyle et 
al., 2001). Additionally, the koala CYP responsible for tolbutamide hydroxylation, 
which is a known substrate for CYP2C in humans, shows a high affinity for tolbutamide 
and displays approximately ten-fold higher activity in koalas than in rats (Liapis et al., 
2000). Highly efficient oxidative metabolism is likely responsible for the rapid 
elimination of meloxicam by koalas (Kimble et al., 2013), however, the effect of such 
efficient metabolic pathways on other therapeutic drugs is currently unknown, and 
warrants investigation.    
 
1.12  DRUGS STUDIED IN THIS THESIS 
The focus of this thesis is the characterisation of the pharmacokinetic profiles of three 
commonly used antimicrobials in koalas. Chloramphenicol and enrofloxacin were 
selected for investigation as they are the first-line anti-chlamydial drugs currently used 
in koalas, and as there is evidence that the currently used dosages of these drugs may be 
unsuitable for treatment of chlamydiosis (Griffith, 2010; Griffith et al., 2010; Govendir 
et al., 2012). In order for theoretical pharmacodynamic assessments of chloramphenicol 
and enrofloxacin to be made, in vitro susceptibility testing of these antimicrobials 
against koala isolates of C. pecorum was also performed. This included the 
chloramphenicol derivative, florfenicol, as the commercially available formulation of 
chloramphenicol was withdrawn from the market at the time the susceptibility testing 
was starting. 
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Fluconazole was selected due to its pharmacokinetic profile in other species, which is 
favourable for treating cryptococcosis (Humphrey et al., 1985). This profile consists of 
a long terminal t1/2, large Vd, high bioavailability, and a low degree of protein binding, 
which allows penetration into the cerebrospinal fluid (CSF).   
 
1.12.1 Chloramphenicol  
Chloramphenicol is a broad-spectrum antimicrobial, with bacteriostatic activity against 
many gram negative and gram positive aerobes and anaerobes, as well as Rickettsia spp. 
and Chlamydia spp. (Dowling, 2006). Chloramphenicol use was first associated with 
fatal aplastic anaemia in humans in 1950 (Rich et al., 1950); as such, its systemic use in 
human medicine in Australia is now rare (Shultz et al., 2003), and off-label use in food-
producing animals, including horses, is banned in Australia (Australian Veterinary 
Association, 2005). However, fatal aplastic anaemia has not been documented in 
domestic animals and the most notable adverse effect is dose-dependent bone marrow 
suppression affecting the erythroid precursor cells, which is reversible upon drug 
withdrawal (Papich & Riviere, 2009a). As a highly lipid soluble drug with moderately 
low protein-binding, chloramphenicol reaches effective concentrations in most body 
fluids and tissues, as well as in the CSF and central nervous system (CNS) (Dowling, 
2006). Its high lipophilicity also enables penetration of cellular membranes, thus it has 
been used extensively to treat intracellular infections (Papich & Riviere, 2009a). Most 
studies that have investigated chloramphenicol pharmacokinetics in veterinary species 
have used colorimetry to determine plasma concentrations. This methodology is older 
than the chromatographic separation used in this study, and may make it difficult to 
draw solid conclusions regarding pharmacokinetic comparisons between studies. With 
this limitation in mind, the elimination t1/2 of chloramphenicol varies between species 
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[0.98 h in horses, colorimetry (Sisodia et al., 1975); 1.3 h in pigs, colorimetry (Davis et 
al., 1972); 1.7 h in sheep, HPLC (Dagorn et al., 1990); 2.0 h in goats, colorimetry (Etuk 
et al., 2005); 4.2 h in dogs and 5.1 h in cats, colorimetry (Davis et al., 1972)]. 
Metabolism tends to be via Phase II conjugation with glucuronic acid, with inactive 
metabolites predominantly excreted in the urine (Papich & Riviere, 2009a). As 
chloramphenicol is not metabolised appreciably by Phase I oxidation, an investigation 
of its pharmacokinetic profile in healthy koalas may provide some information 
regarding the glucuronidation capacity of the koala’s liver, as well as further insight into 
the suitability of the currently used chloramphenicol dosage regimen in koalas.   
 
1.12.2 Enrofloxacin 
Enrofloxacin is a fluoroquinolone antimicrobial with a broad spectrum of bactericidal 
aerobic activity, which includes Chlamydia spp. (Walker & Dowling, 2006; Kumar et 
al., 2007). This second generation quinolone is highly lipophilic, allowing it to penetrate 
into cells (Papich & Riviere, 2009b) and making it a good choice for treating 
intracellular bacteria. Following administration, enrofloxacin undergoes N-deethylation 
in the liver to form ciprofloxacin, an active metabolite (Papich & Riviere, 2009b). In 
some species the metabolism of enrofloxacin to ciprofloxacin is extensive, estimated as 
20 to 35% horses (Kaartinen et al., 1997), 40% in dogs (Cester & Toutain, 1997) and 
60% in cattle (Idowu et al., 2010); the two substances have an additive effect against 
some bacteria in vitro (Lautzenhiser et al., 2001), thereby potentially increasing the 
efficacy of enrofloxacin against susceptible bacteria in vivo. The subcutaneous and 
intramuscular bioavailability of fluoroquinolones are generally high, and despite having 
a short terminal t1/2, enrofloxacin is reportedly effective when administered s.i.d. or 
b.i.d. (Paradis et al., 1990; Koch & Peters, 1996). One concerning factor associated with 
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fluoroquinolone use is the emergence of resistance, which is a recognised problem with 
the increasing use of this antimicrobial class in both humans and veterinary species 
(Endtz et al., 1991; Martin Barrasa et al., 2000; Hooper, 2001; Cohn et al., 2003). This, 
coupled with the current evidence that 10 mg/kg s.c. s.i.d. is ineffective at clearing 
Chlamydia spp. from koalas (Griffith, 2010), necessitates a pharmacokinetic evaluation 
of enrofloxacin following i.v. administration in order to establish a potentially 
efficacious dose rate. 
 
1.12.3 Fluconazole 
Fluconazole is a triazole antifungal drug used in both veterinary and human medicine. It 
has a broad spectrum of antifungal activity, which includes the Cryptococcus 
neoformans species complex (Giguère, 2006a). Fluconazole displays a vastly different 
pharmacokinetic profile from the other azole antifungals. It has almost complete oral 
bioavailability in many species (Humphrey et al., 1985; Brammer et al., 1990; Craig et 
al., 1994; Latimer et al., 2001; Davis et al., 2009), and its low molecular weight, large 
Vd, and low protein binding of 10 – 12% in most species (Humphrey et al., 1985) make 
it a good treatment option for CNS cryptococcosis, as it can be administered orally and 
reaches high concentrations in the CSF and most bodily fluids (Foulds et al., 1988; 
Walsh et al., 1989; Vaden et al., 1997; Latimer et al., 2001). The extended terminal t1/2 
[13 h in dogs (Humphrey et al., 1985); 14 - 25 h in cats (Craig et al., 1994; Vaden et al., 
1997); 30 h in humans (Brammer et al., 1990); 41.6 h in horses (Latimer et al., 2001)] 
allows for infrequent administration, which is an important consideration when treating 
wildlife. Fluconazole undergoes minimal metabolism, being predominantly excreted 
unchanged in the urine (Giguère, 2006a). These factors should make it an ideal 
candidate for use in koalas, however, a vast range of dosages are currently used 
 45 
 
(Blanshard & Bodley, 2008; Wynne et al., 2012), and no pharmacokinetic data are 
available for koalas.  
 
1.13 AIMS OF THE THESIS 
Drawing on the limited available information regarding drug absorption and elimination 
in koalas (Griffith et al., 2010; Govendir et al., 2012; Kimble et al., 2013), it is 
hypothesised that those therapeutic drugs that are subjected to hepatic metabolism will 
be rapidly metabolised and eliminated by koalas, and that many commonly used drugs 
will be poorly absorbed when administered orally. Consequently, it is hypothesised that 
the resulting plasma concentrations will be below theoretical therapeutic targets. In 
order to test these hypotheses, the overarching aim of this thesis is to characterise the 
pharmacokinetics of chloramphenicol, enrofloxacin and fluconazole in koalas, and to 
compare these profiles with those previously determined in other, physiologically 
distinct, species. When this study commenced, these three drugs were all first-line 
therapeutic options for koalas. Importantly, they are all known to undergo different 
routes of metabolism and elimination in other species; enrofloxacin and 
chloramphenicol are metabolised by Phase I (N-deethylation) and Phase II 
(glucuronidation) reactions, respectively, whereas fluconazole is almost exclusively 
eliminated by the kidneys. It was hoped that studying drugs that are metabolised and 
eliminated by differing routes would enable a rudimentary assessment of the efficiency 
of these metabolism and elimination pathways in this specialist folivore. 
  
Aim 1: To characterise the pharmacokinetic profiles of the two injectable formulations 
of chloramphenicol available at the time of investigation following subcutaneous and 
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intravenous administration, in order to assess the likely suitability of the currently used 
dosing regimen of 60 mg/kg s.c. s.i.d. 
 
Aim 2: To characterise the pharmacokinetics of enrofloxacin following i.v. 
administration to koalas in order to build upon the already existing subcutaneous and 
oral pharmacokinetic data, and to use this information to assess the likely suitability of 
enrofloxacin as a treatment option for chlamydiosis and other bacterial infections in 
koalas. 
 
Aim 3: To characterise the pharmacokinetics of oral and i.v. fluconazole in koalas, to 
enable assessment of the likely suitability of fluconazole as a stand-alone drug for the 
treatment of koalas with cryptococcosis. 
 
Aim 4: To determine the antimicrobial susceptibility of koala isolates of C. pecorum to 
enrofloxacin, chloramphenicol, and the chloramphenicol-derivative, florfenicol, and to 
integrate these results with pharmacokinetic parameters to enable an assessment of 
current dosing regimens to be made. 
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CHAPTER 2. PHARMACOKINETICS OF 
CHLORAMPHENICOL FOLLOWING ADMINISTRATION 
OF INTRAVENOUS AND SUBCUTANEOUS 
CHLORAMPHENICOL SODIUM SUCCINATE, AND 
SUBCUTANEOUS CHLORAMPHENICOL, TO KOALAS 
(PHASCOLARCTOS CINEREUS) 
 
The following is a re-formatted manuscript, published by John Wiley and Sons Ltd: 
Black, L.A., McLachlan, A.J., Griffith, J.E., Higgins, D.P., Gillett, A., Krockenberger, 
M.B. & Govendir, M. (2012) Pharmacokinetics of chloramphenicol following 
administration of intravenous and subcutaneous chloramphenicol sodium succinate, and 
subcutaneous chloramphenicol, to koalas (Phascolarctos cinereus). Journal of 
Veterinary Pharmacology and Therapeutics, 36, 478-485. 
 
2.1  ABSTRACT 
Clinically normal koalas (n = 19) received a single dose of intravenous chloramphenicol 
sodium succinate (SS) (25 mg/kg; n = 6), subcutaneous chloramphenicol SS (60 mg/kg; 
n = 7) or subcutaneous chloramphenicol base (60 mg/kg; n = 6). Serial plasma samples 
were collected over 24 - 48 h and chloramphenicol concentrations determined using a 
validated HPLC assay. The median (range) apparent clearance (CL/F) and elimination 
half-life (t1/2) of chloramphenicol after intravenous chloramphenicol SS administration 
were 0.52 (0.35 - 0.99) L/h/kg and 1.13 (0.76 – 1.40) h, respectively. Although the area 
under the concentration-time curve was comparable for the two subcutaneous 
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formulations, the absorption rate-limited disposition of chloramphenicol base resulted in 
a lower median Cmax (2.52; range 0.75 – 6.80 µg/mL) and longer median tmax (8.00; 
range 4.00 – 12.00 h) than chloramphenicol SS (Cmax 20.37, range 13.88 – 25.15 
µg/mL; tmax 1.25, range 1.00 – 2.00 h). When these results were compared with 
susceptibility data for human Chlamydia isolates, the expected efficacy of the current 
chloramphenicol dosing regimen used in koalas to treat chlamydiosis remains uncertain, 
and at odds with clinical observations. 
 
2.2 INTRODUCTION 
The koala (Phascolarctos cinereus) is an Australian icon of both ecological and 
economic significance. Currently, koalas are listed as vulnerable in some Australian 
states, with two populations listed as endangered (Department of the Environment, 
Water, Heritage and the Arts, 2009). Chlamydiosis is the most common infectious 
disease in some koala populations (Stalder, 2003; Loader, 2010) and may cause high 
morbidity or even mortality, resulting from one or more of the following: 
keratoconjunctivitis (Cockram & Jackson, 1976), a rhinitis/pneumonia complex 
(Nicolson, 2002) and urogenital inflammation and fibrosis (Brown & Grice, 1986) 
which can cause infertility. Chlamydiosis is caused by the obligate intracellular bacteria 
Chlamydia pecorum and C. pneumoniae, with the former being the more pathogenic of 
the two in koalas (Jackson et al., 1999). 
 
Chloramphenicol is one of the few systemic antimicrobials currently used for treating 
koalas with chlamydiosis due to the syndrome of inappetence, wasting and death that is 
induced by macrolides and tetracyclines (Brown et al., 1984; Osawa & Carrick, 1990). 
Enrofloxacin is also used to treat koala chlamydiosis, but it does not prevent 
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recrudescence of infection after a prolonged course of treatment (Griffith, 2010). 
Chloramphenicol appears to be efficacious, as evidenced by the absence of chlamydial 
shedding during the post-treatment monitoring phase [two weeks in one study (Markey 
et al., 2007) and up to 63 days in another (Govendir et al., 2012)].  
 
As chloramphenicol exhibits a lack of correlation between pharmacokinetic parameters 
and interspecies body size when subjected to allometric scaling (Riviere et al., 1997), it 
is unsuitable for interspecies dose extrapolation. Despite this, and its routine use in 
some wildlife facilities (Blanshard & Bodley, 2008), there is limited pharmacokinetic 
data available regarding chloramphenicol in koalas. Currently, some pharmacokinetic 
data exist for chloramphenicol base administered to diseased koalas only (Govendir et 
al., 2012) and no intravenous (i.v.) data have been reported. The current study aimed to 
determine pharmacokinetic parameters for chloramphenicol following administration of 
two formulations to healthy koalas. The inactive prodrug, chloramphenicol sodium 
succinate (SS), which is hydrolysed to biologically active chloramphenicol following 
administration, was selected as it is the only i.v. formulation available in Australia. 
Subcutaneous (s.c.) pharmacokinetics were compared between chloramphenicol SS and 
the commonly used, veterinary registered chloramphenicol base formulation. The 
results were compared to susceptibility data for human C. trachomatis as a means to 
estimate the suitability of the currently recommended dosing regimen of 60 mg/kg s.c. 
once daily (s.i.d.) (Blanshard & Bodley, 2008) in koalas. 
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2.3  MATERIALS AND METHODS 
2.3.1 Animals 
Clinically normal subadult and adult koalas (n = 19; 7 males, 12 females), ranging in 
age from 15 months to seven years, as determined by tooth wear (Martin, 1981) or 
previous admission data, were recruited opportunistically from those housed 
temporarily at the Australia Zoo Wildlife Hospital (AZWH), Beerwah, Queensland, 
Australia. Koalas had initially been hospitalised for injury or illness, or presented as 
orphaned joeys and provided sanctuary while they matured. All koalas were being 
prepared for release back into the wild and were deemed healthy prior to the study, 
based on results of a full physical examination conducted under general anaesthesia by 
veterinarians at AZWH, and routine haematology and biochemistry analytes within 
reference ranges (Canfield et al., 1989; Blanshard, 1994). Koalas were housed in 
standard veterinary hospital enclosures, and supplied with food ad libitum (various 
Eucalyptus spp.) and water throughout the study. This study was approved by The 
University of Sydney Animal Ethics Committee (protocol number N00/10-
2007/4/4695).  
 
General anaesthesia was induced by mask using 3 – 5% isoflurane in 100% oxygen 
delivered by a precision vaporiser and maintained for 5 - 10 min, to enable placement of 
a 20-gauge i.v. catheter into the cephalic vein for serial blood sampling. Koalas were 
then recovered for one to two hours before drug was administered at t = 0.  
 
Koalas were divided into three treatment groups: i.v. chloramphenicol SS (n = 6), s.c. 
chloramphenicol SS (n = 7) and s.c. chloramphenicol base (n = 6). The i.v. group 
received a 1 min i.v. infusion of chloramphenicol SS (Kemicetine® Succinate Injection, 
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Actavis Italy, Milan, Italy) equivalent to 25 mg/kg chloramphenicol, diluted 1:5 in 
sterile water for injections. The s.c. groups received chloramphenicol SS or 
chloramphenicol base (Chloramphenicol 150, Delvet, Seven Hills, NSW, Australia) at 
60 mg/kg as a single s.c. injection. Serial blood samples (up to 1.5 mL) for 
chloramphenicol concentration determination were collected into lithium heparin tubes 
at the following time points: t = 0, 2, 15, 30, 45 min, 1, 1.5, 2, 4, 6, 8, 12 and 24 h for 
the i.v. group; and t = 0, 15, 30 min, then 1, 1.5, 2, 4, 6, 8, 12, 24, 36 and 48 h for both 
s.c. groups. Blood samples were centrifuged within 1 h of collection and plasma was 
transferred into plain tubes. Samples were stored at -20 
o
C and protected from light until 
analysis.  
  
2.3.2 Analytical method 
Plasma concentrations of chloramphenicol were determined using a reversed-phase 
high-performance liquid chromatography (HPLC) method described previously 
(Govendir et al., 2012), using an SPD-M20A diode array detector (Shimadzu, 
Rydalmere, NSW, Australia) set at 270 nm. Data acquisition and peak integration were 
performed by Shimadzu Class VP software, version 7.4. Retention times for 
chloramphenicol and the internal standard (IS) were 5.62 and 6.41 min, respectively. 
Pooled, drug-free koala plasma exhibited no interfering peaks at the retention times of 
interest. 
 
Triplicate 200 µL samples of medicated koala plasma were analysed. Calibration 
standards (0.1, 0.5, 1, 5, 10, 50, 100, 500 µg/mL) were prepared daily using pooled 
drug-free koala plasma to prepare serial dilutions of an 8,000 µg/mL chloramphenicol 
stock solution (analytical grade chloramphenicol, Sigma-Aldrich, Castle Hill, NSW, 
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Australia) dissolved in analytical grade methanol (Lomb Scientific, Taren Point, NSW, 
Australia). Prior to solid phase extraction (SPE), 50 µL of 50 µg/mL phenacetin 
(Sigma-Aldrich, Castle Hill, NSW, Australia) was added to calibration standards and 
plasma samples as the IS.  
 
Triplicate plasma samples and calibration standards underwent SPE using an Oasis 
HLB 1 cm
3
 column filter (Waters, Milford, Massachusetts, USA) via a vacuum 
manifold, as per manufacturer’s instructions. Eluates were evaporated to dryness at 35 
o
C for 3 h using a vacuum concentrator (SPD 121P, Thermo Electron Corporation, 
Asheville, North Carolina, USA), and reconstituted using 100 µL mobile phase, which 
consisted of acetonitrile (Lomb Scientific, Taren Point, NSW, Australia) and deionised 
water (40:60, v/v). Samples were vortexed for 10 s, and centrifuged for 10 min at 
14,000 x g. The supernatant was injected into the HPLC system in duplicate.   
 
Chloramphenicol recovery was 86 ± 0.08%, determined by comparing replicates of 
three known chloramphenicol concentrations spanning the calibration range spiked into 
blank koala plasma prior to, and following, SPE. 
 
Interpolation of the daily calibration curve with a minimum coefficient of determination 
(R
2
) > 0.999 was used to determine the concentration of chloramphenicol in treated 
koala plasma. A lack-of-fit test was also performed using GenStat 14
th
 edition (VSN 
International, 2011) to verify linearity of the calibration curve, and showed no deviation 
from the linear model (F = 0.42; d.f. = 6, 69; P = 0.87). The lower limit of detection 
(LLD) and lower limit of quantification (LLQ) were calculated at 0.07 µg/mL and 0.20 
µg/mL respectively, using the standard deviation of the y-intercepts of the regression 
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line (International Conference on Harmonisation, 2005). Intra-assay variation was 
assessed by the comparison of six replicates of five calibration standards (1, 5, 10, 50, 
100 µg/mL), assayed on a single day. Inter-assay variation was assessed by comparing 
replicates of three calibration standards (1, 10, 100 µg/mL) on three analysis days. Intra- 
and inter-assay variation were < 8.71% and < 12.25%, respectively.   
 
2.3.3 Plasma protein binding 
The proportion of chloramphenicol binding to plasma proteins was determined by 
ultrafiltration (Dow, 2006). The plasma pH and protein concentration of freshly 
collected, pooled drug-free plasma from eight koalas were determined prior to the 
assay. Analytical grade chloramphenicol was added to 1 mL plasma aliquots to yield 
concentrations of 0.5, 50 and 500 µg/mL. Samples were incubated at 36 
o
C to mimic 
koala core body temperature (Degabriele & Dawson, 1979) for 30 min, then centrifuged 
(4000 x g for 30 min) in a fixed angle rotor centrifuge (Eppendorf 5417C; Eppendorf, 
Hamburg, Germany) using an ultrafiltration tube (Amicon® Ultra-0.5 30 kDa, Merck 
Millipore, Kilsyth, Victoria, Australia). The non-protein bound ultrafiltrate was 
recovered and the chloramphenicol concentration determined. This concentration was 
compared with standards of the same concentrations made in mobile phase. In addition, 
non-specific binding to the ultrafiltration device was determined by repeating the above 
steps using phosphate buffered saline instead of plasma. All samples were prepared and 
analysed in triplicate. Percentage binding to plasma proteins was determined using the 
following equation: 
 
                    unbound drug         
            total drug 
 
(
  
) % protein binding  =   100  – x  100 
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2.3.4 Pharmacokinetic analysis 
The data from each koala were analysed using a standard non-compartmental 
pharmacokinetic approach, for values above the LLQ. The maximal concentration 
(Cmax) and time to reach maximal concentration (tmax) were determined graphically. The 
terminal elimination rate constant (kel) was determined as the slope of the terminal 
portion of the natural log of the concentration-time curve. The terminal elimination rate 
constant was assumed to be the absorption rate constant (ka) for chloramphenicol base 
as this formulation exhibited absorption rate-limited disposition (Yáñez et al., 2011). 
For SC chloramphenicol SS, ka was determined using the method of residuals. The area 
under the concentration-time curve (AUC0-t) and area under the first moment curve 
(AUMC0-t) were calculated to the last measurable concentration using the linear 
trapezoidal method. The elimination half-life (t1/2), apparent clearance (CL/F), apparent 
volume of distribution at steady state (Vss/F), mean residence time (MRT), predicted 
average steady state plasma concentration (Cssaverage), predicted unbound steady state 
plasma concentration (Cssuaverage), bioavailability (F) and terminal segments of the 
AUC0-∞ and AUMC0-∞ (AUCextrapolated and AUMCextrapolated respectively) were calculated 
using the following equations: 
 
t1/2 =   ln 2 / kel 
CL/F =   Dose / AUC0-∞ 
Vss/F =   CL/F  x  MRT 
MRT =   AUMC0-∞ / AUC0-∞ 
Cssaverage =   AUC0-∞ / τ, where τ is the dosing interval (12 or 24 h).   
Cssuaverage  =  Cssaverage   x  fu, where fu is the unbound fraction in plasma (0.416). 
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F =   (AUCsc / AUCiv)  x  (Doseiv / Dosesc), where AUCsc is the individual 
AUC0-∞ term for each koala in the SC chloramphenicol SS treatment group, 
and AUCiv is the mean of the AUC0-∞  data from the IV treatment group. 
AUCextrapolated       =    Clast / kel, where Clast is the last measured plasma concentration. 
AUMCextrapolated    =      [(Clast  x  tlast)  /  kel ]   +   (  Clast  /  kel
2   
), where Clast is the last 
measured plasma concentration, and tlast is the time of the last measured plasma 
concentration. 
Maintenance dose rate    =    target Css(average) x CL/F, where the target Css(average) is 
extrapolated from minimum inhibitory concentration (MIC) data.   
 
AUCextrapolated was only included if it comprised < 20% of the AUC0-∞.  
 
2.3.5 Statistical analysis 
A Kruskal-Wallis analysis of variance, followed by a Mann-Whitney test where 
applicable, was used to compare the terminal rate constant and t1/2 between the three 
treatment groups. A Mann-Whitney test was used to compare Cmax, tmax, AUC0-∞, 
AUMC0-∞ and MRT between the two subcutaneous formulations; parameters for 
chloramphenicol base in healthy koalas with those determined previously in koalas with 
chlamydiosis (Govendir et al., 2012); and to assess for differences in pharmacokinetic 
parameters calculated for subadult versus adult koalas within treatment groups. 
Statistical significance for all tests was accepted at P < 0.05.  
 
2.4  RESULTS 
The median (and range) of calculated pharmacokinetic parameters are presented in 
Table 2-1. Binding of chloramphenicol to plasma proteins was 58.4 ± 4.4% (n = 8), and 
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non-specific binding to the ultrafiltration device was < 5%. The semi-logarithmic 
plasma drug concentration-time curves for each treatment group are presented in Figure 
2-1. The Cmax of biologically active chloramphenicol for all koalas in the IV group was 
recorded at t = 2 min. The i.v. chloramphenicol SS semi-logarithmic plasma drug 
concentration-time curve showed a biphasic decline, and distribution equilibrium was 
reached by t = 15 min. There was no quantifiable chloramphenicol in the plasma of any 
koala in the i.v. group after t = 8 h.  
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Figure 2-1. Semi-logarithmic plasma concentration-time curve (mean ± SD) for i.v. 
chloramphenicol SS (25 mg/kg), s.c. chloramphenicol SS (60 mg/kg) and s.c. chloramphenicol base 
(60 mg/kg). 
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Table 2-1. Pharmacokinetic parameters (median and range) estimated following administration of chloramphenicol sodium succinate and chloramphenicol base. 
i.v.: intravenous administration; s.c.: subcutaneous administration; s.i.d: once daily dosing; b.i.d: twice daily dosing. * denotes predicted concentrations following 
administration of 60 mg/kg s.c. § denotes calculations that have excluded two koalas from s.c. chloramphenicol base group whose AUCextrapolated was > 20% of the 
AUC0-∞. For the statistical analysis, # was compared with ka for s.c. chloramphenicol base, as both were the terminal rate constants.    
 
 
 
 
 
Chloramphenicol 
sodium succinate i.v. 
(25 mg/kg, n = 6) 
Chloramphenicol sodium 
succinate s.c. 
(60 mg/kg, n = 7) 
Chloramphenicol 
Base s.c. 
(60 mg/kg, n = 6) 
Chloramphenicol base s.c.; 
diseased koalas, day 1 
(60mg/kg, n = 9) (Govendir et 
al., 2012) 
Cmax (µg/mL) 
tmax (h) 
kel (h
-1
) 
ka (h
-1
) 
t1/2 (h) 
181.89  (109.78 – 252.41) 
- 
0.62  (0.50 – 0.91) 
- 
1.13  (0.76 – 1.40) 
20.37  (13.88 – 25.15) 
1.25  (1.00 – 2.00) 
0.48  (0.36 – 0.66) 
5.93  (4.55 – 6.49) 
1.45  (1.05 – 1.93) 
2.52  (0.75 – 6.80) 
8.00  (4.00 – 12.00) 
- 
0.06  (0.02 – 0.09) 
13.14  (7.47 – 35.39) 
3.02  (1.32 – 5.03) 
4.00  (1.00 – 8.00) 
0.03  (0.02 – 0.11)# 
- 
- 
Vss/F (L/kg) 
CL/F (L/h/kg)
§ 
AUC0 - t (µg/mL.h)
 
AUMC0 - t (µg/mL.h
2
)
 
AUC0 - ∞ (µg/mL.h)
§ 
MRT (h)
§ 
F 
Cssaverage (µg/mL)*
§
 s.i.d dose 
Cssuaverage  (µg/mL)*
§
 s.i.d dose  
Cssaverage (µg/mL)*
§
 b.i.d dose 
Cssuaverage  (µg/mL)*
§
 b.i.d dose  
0.45  (0.29 – 0.78) 
0.52  (0.35 – 0.99) 
- 
- 
48.41  (25.17 – 72.02) 
0.90  (0.49 – 1.27) 
- 
- 
- 
- 
- 
- 
- 
- 
- 
75.60  (54.71 – 106.82) 
2.66  (2.19 – 4.02) 
0.68  (0.49 – 0.95) 
- 
- 
- 
- 
- 
0.85  (0.40 – 1.76) 
49.81  (27.25 – 143.12) 
645.43  (352.98 – 2078.94) 
70.34  (34.06 – 149.04) 
14.40  (13.95 – 15.53) 
- 
2.93  (1.42 – 6.21) 
1.22  (0.59 – 2.58) 
5.86  (2.84 - 12.42) 
2.44  (1.18 - 5.17) 
- 
- 
48.14  (22.37 – 81.14) 
530.03  (233.05 – 798.97) 
- 
- 
- 
- 
- 
- 
- 
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Some of the pharmacokinetic parameters estimated for chloramphenicol base exhibited 
greater inter-individual variation than those for chloramphenicol SS. The AUCextrapolated 
for all animals in the s.c. chloramphenicol SS treatment group, and for four of the six 
animals in the chloramphenicol base treatment group, comprised < 5.19% of the AUC0-
∞. The remaining two animals had an AUCextrapolated > 20% (23.97% and 45.66%) of the 
AUC0-∞, and were subsequently excluded from any calculations involving the AUC0-∞. 
The final quantifiable chloramphenicol concentrations were detected in plasma drawn at 
t = 8 h (n = 2) and t = 12 h (n = 5) for s.c. chloramphenicol SS, and t = 24 h (n = 1), t = 
36 h (n = 2) and t = 48 h (n = 3) for chloramphenicol base. 
 
There were no statistically significant differences between values calculated for Cmax, 
tmax, kel, AUMC0-t or AUC0-t in this study compared with those determined previously in 
koalas with chlamydiosis (Govendir et al., 2012), and no significant differences were 
found between adult and subadult koalas within the same treatment groups. The 
terminal rate constant was significantly lower and the t1/2 significantly longer for s.c. 
chloramphenicol base compared with the two chloramphenicol SS treatment groups. 
Significant differences were found between the two subcutaneous groups for all other 
parameters, except the AUC. The demeanour, browsing habits and faecal output of each 
animal were unchanged during and following the study, and there were no apparent 
adverse effects resulting from drug administration, i.v. catheter placement, frequent 
handling or hospitalisation.  
 
2.5 DISCUSSION 
This is the first study to report the pharmacokinetic profiles of two different 
formulations of chloramphenicol in clinically normal koalas. The extended sampling 
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time and validated HPLC assay enabled characterisation of the entire single-dose 
pharmacokinetic curves for both chloramphenicol formulations for all but two koalas. 
Although the pharmacokinetics of chloramphenicol following administration of 
chloramphenicol SS documented here are similar to those reported in other species, this 
formulation reaches much higher plasma concentrations and is eliminated more quickly 
than chloramphenicol base, thereby potentially increasing the risk of toxicity and 
requiring more frequent dosing than the base formulation. An important finding was the 
observation of absorption rate-limited disposition of chloramphenicol base, which was 
responsible for the significant differences in the elimination rate between the two 
chloramphenicol formulations. This has important treatment implications, suggesting 
that chloramphenicol base may be the more suitable of the two formulations for 
subcutaneous use in koalas owing to the shape of the concentration-time curve, although 
the currently used dose appears inadequate. 
 
As specialist folivores, koalas possess highly efficient hepatic metabolism to enable 
detoxification of their eucalyptus diet, which contains high concentrations of plant 
secondary metabolites such as phenols and terpenes (Cork & Foley, 1997); these 
compounds are toxic to most mammals. Augmented liver function has been 
demonstrated in koalas by an increased rate of bromsulphthalein clearance, relative to 
sheep and some macropods (Pass & Brown, 1990). Additionally, certain cytochrome 
P450 enzymes (CYPs) involved in xenobiotic metabolism are increased in quantity and 
capacity in koala livers, relative to generalist herbivores (Liapis et al., 2000; Ngo et al., 
2000). Despite this, the elimination of chloramphenicol is similar between koalas and 
various other species. The t1/2 and kel of i.v. chloramphenicol in koalas are similar to 
those established for horses (t1/2, 1 ± 0.1 h; kel, 0.69 ± 0.1 h
-1
) (Pilloud, 1973) while a 
 61 
 
slightly longer t1/2 has been observed in sheep (1.70 ± 0.02 h) (Dagorn et al., 1990) and 
goats (1.97 ± 1.23 h) (Etuk et al., 2005). Although the metabolic pathway of 
chloramphenicol has not been determined in koalas, chloramphenicol is metabolised by 
glucuronidation in other species (Papich & Riviere, 2009a). Hence the similar 
elimination rates observed between koalas, horses, sheep and goats, may indicate a 
similar glucuronidation capacity between these species. In contrast, the non-steroidal 
anti-inflammatory drug meloxicam, which undergoes Phase I metabolism via oxidation, 
is very rapidly eliminated from the plasma following administration to koalas (Kimble 
et al., 2013), possibly due to active biotransformation by CYPs as an adaptation to 
enable detoxification of their highly toxic eucalypt diet (Liapis et al., 2000). Oxidation 
has been postulated as being the most important mechanism for detoxification of dietary 
PSMs in specialist folivores such as koalas (Boyle et al., 1999), whereas Phase II 
conjugation reactions, including glucuronidation, appear to be involved minimally 
(McLean & Foley, 1997). This may have implications for selection of therapeutic drugs 
in koalas, as drugs that are metabolised by conjugation reactions may have a more 
favourable disposition in koalas than those metabolised by oxidation.  
 
The pharmacodynamic surrogate most closely associated with chloramphenicol efficacy 
is the time for which plasma concentration exceeds the MIC of the target pathogen 
(Giguère, 2006b). Thus, the prolonged t1/2 of chloramphenicol observed after s.c. 
administration of the base renders it a more appropriate formulation than 
chloramphenicol SS for targeting chlamydial infections in koalas, based on the shape of 
the concentration-time curve (Figure 2-2). The in vitro susceptibility of koala strains of 
C. pecorum and C. pneumoniae to chloramphenicol have not been established, but 
antibacterial susceptibility patterns appear uniform across chlamydial species 
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(Miyashita et al., 1997; Pudjiatmoko et al., 1998) and hosts (Kumar et al., 2007), 
including isolates of C. pneumoniae from another native Australian marsupial, the 
western barred bandicoot (Perameles bougainville) (Kumar et al., 2007). In the current 
study, theoretical chloramphenicol MICs for C. pecorum and C. pneumoniae were 
assumed, based on those established for C. trachomatis, a widely studied human 
pathogen, and ranged from 1 µg/mL (Johnson & Hobson, 1977; Hobson et al., 1982a; 
How et al., 1985; Bianchi et al., 1988) to 4 µg/mL (Ridgway et al., 1978; Cevenini et 
al., 1987). The predicted Cssuaverage (median 1.22 µg/mL) of chloramphenicol base 
marginally exceeded 1 µg/mL in 50% of koalas in this study, but did not reach the 
higher target of 4 µg/mL in any koalas. However, the predicted Cssuaverage for twice 
daily dosing exceeded 1 µg/mL in all koalas, indicating twice daily dosing may be more 
appropriate than once daily dosing, and warrants pharmacokinetic investigation. 
However, the authors warn that extreme caution should be exercised if pharmacokinetic 
investigations were to proceed following twice daily dosing, as doses of 80 mg/kg SC 
s.i.d. have been associated with fatal gastrointestinal dysbiosis in some koalas (A. 
Gillett 2011, pers. obs.)
1
. For this reason, twice daily dosing at a lower dose may be 
more suitable for future investigations, however extreme caution and vigilance are still 
required due to the risks involved. The discrepancy between the subtherapeutic plasma 
concentrations attained and the observed reduction in chlamydial shedding during, and 
for a short time following, treatment (Markey et al., 2007; Govendir et al., 2012) at the 
current dose rate demonstrates the need for koala isolates of C. pecorum and C. 
pneumoniae to undergo in vitro susceptibility testing to verify therapeutic targets. 
                                                 
1
 Personal observation by one of the authors: Amber Gillett, Wildlife Veterinarian, Australia Zoo Wildlife 
Hospital, Qld, October 2011. 
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Although these tests will not necessarily reflect the situation in vivo, they can be a 
useful guide for dose development.   
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Figure 2-2. Plasma concentration-time curve (mean ± SD) for s.c. chloramphenicol SS (60 mg/kg) 
and s.c. chloramphenicol base (60 mg/kg).  
 
Calculating a theoretical dose of chloramphenicol base to achieve therapeutic targets 
proved difficult due to the marked variation in pharmacokinetic profiles observed 
among koalas. Although this may in part be due to inter-individual variation, erratic 
absorption of this insoluble formulation is a likely cause of the variation between 
koalas. Theoretical doses of SC chloramphenicol base (95
th
 percentile (median; range)) 
for once daily dosing, calculated to exceed MIC targets of 1 µg/mL and 4 µg/mL were 
94 (49; 23 – 102) mg/kg and 375 (197; 93 – 407) mg/kg respectively; and for twice 
daily dosing were 47 (25; 12 – 51) mg/kg and 188 (98; 46 – 203) mg/kg respectively. 
The variability in proposed dose rates is likely due to the physicochemical nature of 
chloramphenicol and may be overcome to some extent by the choice and design of the 
chloramphenicol formulation, such as a formulation compounded into a sustained-
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release vehicle, which may help to stabilise and solubilise this poorly soluble drug 
(Bonacucina et al., 2011). Such a formulation would presumably lead to a more uniform 
absorption profile, thereby making calculation of a standard dose more feasible. 
Alternatively, the chloramphenicol derivative, florfenicol, may have a more uniform 
pharmacokinetic profile between individuals and warrants investigation in this species. 
Florfenicol may also be desirable as the commercially available preparation exhibits 
absorption-rate limited disposition (Dowling, 2006), and it lacks the para-nitro group 
thought to be responsible for the fatal aplastic anaemia in humans that can occur after 
contact with chloramphenicol (Papich & Riviere, 2009a), potentially making it a safer 
option for those in contact with treated animals and their excrement.  
 
Several factors may contribute to reduction in chlamydial shedding in the absence of 
target plasma concentrations. Firstly, intracellular concentrations of chloramphenicol 
are likely to exceed plasma concentrations (English & Withy, 1959; English & 
Seawright, 1961; Watson & McDonald, 1976; Etuk & Onyeyili, 2005). This is due to 
the high lipophilicity of chloramphenicol allowing it to cross the cell membrane readily, 
which can lead to extensive tissue penetration (Ambrose, 1984; Papich & Riviere, 
2009a) and is an important drug characteristic when treating intracellular bacteria such 
as Chlamydiae. Secondly, chloramphenicol persists in various tissues (English & Withy, 
1959; Watson & McDonald, 1976) and reaches high concentrations in the urine 
(Gruhzit et al., 1949; English & Withy, 1959) hours after the plasma concentrations 
have reached undetectable levels, implying that chloramphenicol is quickly 
redistributed into tissues where it persists for prolonged periods, before slowly being 
released back into the systemic circulation and excreted in the urine (Gruhzit et al., 
1949). Finally, chloramphenicol has the ability to block the anti-apoptotic activity (Fan 
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et al., 1998) used by Chlamydiae to protect themselves from apoptosis of the host cell 
(Greene et al., 2004) in which they develop and replicate (Zhong & Brunham, 1998), 
and this may contribute to chlamydial killing by cytotoxic T cells and host cell 
defences.  
 
A limitation of this study was the unknown rate and extent of hydrolysis of 
chloramphenicol SS to active chloramphenicol in koalas. Due to the instability of 
chloramphenicol SS in plasma (Nahata & Powell, 1981) and the remote location of the 
field site, samples were unable to be transported to the laboratory in time to enable 
analysis of the plasma concentration. The bioavailability of chloramphenicol following 
i.v. chloramphenicol SS administration is approximately 0.7 in humans (Glazko et al., 
1977; Burke et al., 1982), 10 - 12 week old calves (Reiche et al., 1980) and adolescent 
pigtail macaques (Koup et al., 1981) as approximately 30% of the succinate ester is 
excreted unhydrolysed in the urine. This limitation may have led to an overestimation of 
chloramphenicol CL and Vd in the current study, which could only be estimated as 
apparent values (CL/F and Vss/F, respectively). Despite this limitation, we can conclude 
that the clinical usefulness of chloramphenicol SS in koalas is limited by its rapid CL. 
Further, the estimated steady state plasma concentrations and subsequent dosing 
calculations are not affected by an overestimation of chloramphenicol SS CL or Vd, so 
this limitation is considered to be of little clinical consequence to this study.  
 
This study demonstrated the pharmacokinetic properties of two chloramphenicol 
formulations in the koala. These results support chloramphenicol base as the more 
suitable treatment option of the two formulations studied, although the adequacy of the 
currently used dose remains questionable, and more appropriate plasma concentrations 
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may be attained following administration of a lower dose twice daily. The marked 
variation in the absorption rate of chloramphenicol base between individuals 
demonstrates the potential value in investigating alternative chloramphenicol 
formulations to achieve a more uniform absorption. Additionally, further work needs to 
be undertaken to determine the in vitro MIC for koala isolates of C. pecorum and C. 
pneumoniae, and to investigate the intracellular concentrations of chloramphenicol in 
koalas.   
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CHAPTER 3. EVALUATION OF ENROFLOXACIN USE IN 
KOALAS (PHASCOLARCTOS CINEREUS) VIA 
POPULATION PHARMACOKINETICS AND MONTE 
CARLO SIMULATION 
 
The following is a re-formatted manuscript, published by John Wiley and Sons Ltd: 
Black, L.A., Landersdorfer, C.B., Bulitta, J.B., Griffith, J.E., Govendir, M. (2014) 
Evaluation of enrofloxacin use in koalas (Phascolarctos cinereus) via population 
pharmacokinetics and Monte Carlo simulation. Journal of Veterinary Pharmacology and 
Therapeutics, 37, 301-311.  
 
 
3.1 ABSTRACT 
Clinically normal koalas (n = 6) received a single dose of intravenous enrofloxacin (10 
mg/kg). Serial plasma samples were collected over 24 h and enrofloxacin 
concentrations were determined via HPLC. Population pharmacokinetic modelling was 
performed in S-ADAPT. The probability of target attainment (PTA) was predicted via 
Monte Carlo simulations (MCS) using relevant target values (30 to 300) based on the 
unbound area under the curve over 24 h divided by the MIC (fAUC0-24/MIC), and 
published subcutaneous data were incorporated (Griffith et al., 2010). A two-
compartment disposition model with allometrically scaled clearances (exponent: 0.75) 
and volumes of distribution (exponent: 1.0) adequately described the disposition of 
enrofloxacin. For 5.4 kg koalas (average weight), point estimates for total clearance 
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(SE%) were 2.58 L/h (15%), central volume of distribution 0.249 L (14%) and 
peripheral volume 2.77 L (20%). MCS using a target fAUC0-24/MIC of 40 predicted 
highest treatable MICs of 0.0625 µg/mL for intravenous dosing, and 0.0313 µg/mL for 
subcutaneous dosing of 10 mg/kg enrofloxacin every 24 h. Thus, the frequently used 
dosage of 10 mg/kg enrofloxacin every 24 h subcutaneously may be appropriate against 
gram-positive bacteria with MICs ≤ 0.03 µg/mL (PTA > 90%), but appears inadequate 
against gram-negative bacteria and Chlamydiae in koalas.  
 
3.2 INTRODUCTION 
The koala (Phascolarctos cinereus) is an iconic Australian marsupial, and the only 
surviving member of the Family Phascolarctidae (Lee & Carrick, 1989). In some 
Australian states the koala is listed as vulnerable, while isolated populations are 
endangered and many populations in New South Wales and Queensland are in decline 
(Natural Resource Management Ministerial Council, 2009; Department of Environment 
and Resource Management, 2012). Wild koalas frequently receive medical treatment in 
wildlife rehabilitation facilities across their natural range along the east coast of 
Australia, predominantly for wounds sustained in motor vehicle accidents, dog attacks, 
or due to disease (Department of Environment and Resource Management, 2011; 
Griffith et al., 2013). 
 
Chlamydia pneumoniae, and the more highly pathogenic Chlamydia pecorum (Jackson 
et al., 1999), are the causative agents of chlamydiosis, which is the most common 
infectious disease in many koala populations (Stalder, 2003; Loader, 2010). 
Chlamydiosis can cause debilitating disease in koalas, resulting in one or more of the 
following: keratoconjunctivitis (Cockram & Jackson, 1976), a rhinitis/pneumonia 
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complex (Brown & Grice, 1984) and urogenital inflammation and fibrosis (Canfield, 
1990; Obendorf & Handasyde, 1990) which can cause infertility. The veterinary 
registered fluoroquinolone, enrofloxacin, is used in some wildlife facilities to treat 
bacterial infections, including chlamydiosis (Blanshard & Bodley, 2008), and is 
anecdotally well tolerated by koalas at the commonly used dose of 10 mg/kg 
subcutaneously (s.c.) every 24 h (q 24 h). In other species, macrolides and tetracyclines 
are often used as first line anti-chlamydial drugs; however, these can induce a syndrome 
of inappetence, emaciation and death in koalas (Brown et al., 1984; Osawa & Carrick, 
1990).  
 
Enrofloxacin has a broad spectrum of aerobic antibacterial activity, including 
Chlamydiae (Walker & Dowling, 2006; Kumar et al., 2007), and displays 
concentration-dependent bacterial killing. Despite fluoroquinolones like ciprofloxacin 
having short half-lives of approximately 1.2 – 3.1 h in mice, they provide good activity 
in murine infection models when dosed every 24 h (Bédos et al., 1998). These 
properties favor fluoroquinolones like enrofloxacin for use in non-domesticated wildlife 
species where long dosing intervals are desirable, and where coverage is required for a 
variety of primary and secondary bacterial infections.  
 
Little is known about the pharmacokinetics of enrofloxacin and its active metabolite, 
ciprofloxacin, in koalas, except that oral absorption is poor relative to subcutaneous 
absorption (Griffith et al., 2010). Additionally, multiple dosing of subcutaneous 
enrofloxacin at 10 mg/kg q 24 h to koalas with chlamydiosis resulted in a median 
unbound area under the plasma concentration-time curve from 0 to 24 h (fAUC0-24) of 
4.54 µg/mL.h (Griffith et al., 2010). With an assumed minimum inhibitory 
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concentration (MIC) of the target organisms of 0.25 µg/mL, this leads to a fAUC0-
24/MIC ratio of 18.2, which is expected to be subtherapeutic against Chlamydiae. Of 
clinical relevance, this dose of 10 mg/kg s.c. q 24 h did not achieve microbiological 
cure when used to treat chlamydiosis, as shown by recurrence of chlamydial shedding 
after treatment withdrawal (Griffith, 2010), indicating a lack of efficacy. Due to the 
limited number of antibacterial agents that are tolerated by the koala, the ever-
increasing problem of antibacterial resistance, and the lack of efficacy of enrofloxacin 
in treating koala chlamydiosis at the current dose of 10 mg/kg s.c. q 24 h (Griffith, 
2010), it is prudent to use species specific pharmacokinetic data to optimise dosage 
regimens of antibacterials.  
 
This study aimed to determine the population pharmacokinetics of enrofloxacin in 
clinically normal koalas after intravenous (i.v.) dosing. Additionally, the plasma 
concentrations of ciprofloxacin as the primary metabolite of enrofloxacin were 
measured. Our second objective was to determine the probability of achieving 
therapeutic targets following administration of a standard dose of 10 mg/kg 
enrofloxacin s.c. q 24 h to koalas, using Monte Carlo simulation (MCS) based on the 
developed population pharmacokinetic model and published minimal inhibitory 
concentrations (MICs) for Chlamydiae, and other bacteria likely to cause infections in 
koalas.  
 
3.3 MATERIALS AND METHODS 
3.3.1 Animals 
Clinically normal koalas of both genders (n = 6; 2 female, 4 male), ranging in age from 
15 months to nine years as determined by tooth wear (Martin, 1981) or previous 
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admission data, were recruited opportunistically from the Koala Hospital of the Koala 
Preservation Society of Australia (KPS), Port Macquarie, NSW and The Australia Zoo 
Wildlife Hospital (AZWH), Beerwah, Qld. Koalas had initially been hospitalised for 
illness or injury, presented as orphaned joeys and provided sanctuary while they 
matured, or had been rescued from dangerous situations (such as near major roads), and 
were being prepared for release back into the wild. Koalas were deemed healthy based 
on the results of a full physical examination conducted under general anaesthesia, and 
routine haematology and biochemistry analytes within reference ranges (Canfield et al., 
1989; Blanshard, 1994). Koalas were housed in standard veterinary hospital enclosures 
and supplied with food ad libitum (various Eucalyptus spp.) and water throughout the 
study. This study was approved by The University of Sydney Animal Ethics Committee 
(protocol number N00/10-2007/4/4695). 
 
General anaesthesia was induced by mask using 3 to 5% isoflurane in 100% oxygen to 
enable placement of a 20-gauge i.v. catheter into the cephalic vein for serial blood 
sampling. Enrofloxacin (Ilium Enrotril, Troy Laboratories, Smithfield, NSW), 
equivalent to 10 mg/kg, was diluted into a total volume of 5 mL using sterile water for 
injection and administered as an i.v. bolus over one minute. Serial blood samples (up to 
1.5 mL) for determination of enrofloxacin concentration were collected into lithium 
heparin tubes (Vacuette®, Greiner Bio-One, Interpath Services Pty. Ltd, Victoria, 
Australia) at 0 (pre-dose), 2, 15, 30, 45 min, and 1, 1.5, 2, 4, 6, 8, 12 and 24 h. Blood 
was protected from light until centrifugation, which was performed within 1 h of 
collection. Plasma was transferred immediately into plain tubes and samples were 
stored at -20 
o
C and protected from light until analysis. 
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3.3.2 Analytical method 
Plasma concentrations of enrofloxacin and ciprofloxacin were determined using a 
modified reversed-phase high-performance liquid chromatography (HPLC) method 
(Griffith et al., 2010), using an SPD-M20A photo-diode array detector (Shimadzu, 
Rydalmere, NSW, Australia) set at 275 nm. Data acquisition and peak integration were 
performed by Shimadzu Class VP software, version 7.4. Retention times for 
ciprofloxacin, enrofloxacin, and the internal standard (IS, difloxacin), were 7.87, 9.82 
and 12.53 min, respectively. Pooled, drug-free koala plasma exhibited no interfering 
peaks. 
 
A volume of 250 µL of each plasma sample was analysed in triplicate. Calibration 
standards (0.05, 0.5, 5, 50, 500 µg/mL enrofloxacin; 0.01, 0.1, 1, 10, 100 µg/mL 
ciprofloxacin) were prepared daily using pooled drug-free koala plasma to make serial 
dilutions from enrofloxacin and ciprofloxacin stock solutions. Analytical grade 
enrofloxacin, ciprofloxacin and difloxacin were obtained from Sigma-Aldrich (Castle 
Hill, NSW, Australia) and dissolved in deionised water. Prior to solid phase extraction 
(SPE), 50 µL of a 50 µg/mL solution of the IS was added to calibration standards and 
plasma samples.  
 
Plasma samples underwent SPE as previously described (Griffith et al., 2010) and 
eluates were evaporated to dryness at 35 
o
C for 3 h using a vacuum concentrator (SPD 
121P, Thermo Electron Corporation, Asheville, North Carolina, USA). The dried 
residue was reconstituted using 100 µL mobile phase, which consisted of acetonitrile 
(Lomb Scientific, Taren Point, NSW, Australia) and deionised water (50:50, v/v), 25 
mM citric acid (Sigma-Aldrich, Castle Hill, NSW, Australia) and 10 mM sodium 
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dodecyl sulfate (Sigma-Aldrich, Castle Hill, NSW, Australia). Samples were 
centrifuged for 10 min at 14,000 g, and a volume of 10 µL supernatant was injected into 
the HPLC system. 
 
Recovery was 91.70 ± 1.06% for enrofloxacin and 80.50 ± 3.89% for ciprofloxacin, as 
determined by comparing three known concentrations spanning the calibration range of 
enrofloxacin or ciprofloxacin spiked into blank koala plasma prior to, and following, 
SPE. Interpolation of the daily calibration curve with a minimum coefficient of 
determination (R
2
) > 0.999 was used to determine the concentration of enrofloxacin and 
ciprofloxacin in treated koala plasma. GenStat (14
th
 edition; VSN International, 2011) 
was used to perform a lack-of-fit test, to evaluate linearity of the calibration curve for 
both drugs; the linear trend was significant for both curves (enrofloxacin: P < 0.001; 
ciprofloxacin: P < 0.001, determined via F-test).  
 
The lower limit of detection (LLD) was 0.16 µg/mL and the lower limit of 
quantification (LLQ) 0.48 µg/mL for enrofloxacin. The LLD was 0.04 µg/mL and the 
LLQ 0.13 µg/mL for ciprofloxacin. These lower limits were determined using the 
standard deviation of the y-intercepts of the regression line (International Conference on 
Harmonisation, 2005). Intra-assay variation was assessed by the comparison of six 
replicates of five calibration standards spanning the assay range. Inter-assay variation 
was assessed by comparing replicates of three calibration standards spanning the range 
of the assay on each analysis day (n = 4). Intra- and inter-assay variation were < 9.35% 
and < 10.2% for enrofloxacin, and < 10.6% and < 19.0% for ciprofloxacin.  
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3.3.3 Non-compartmental analysis 
Non-compartmental analysis was performed to estimate the bioavailability of 
enrofloxacin after s.c. dosing by incorporating previously published s.c. administration 
data (Griffith et al., 2010). Data were analysed using a standard non-compartmental 
pharmacokinetic approach, including only drug concentrations above the LLQ for 
enrofloxacin. The peak concentration (Cmax) was obtained directly from the measured 
concentrations and the terminal half-life (t1/2) was determined by linear regression of the 
log concentration-time plots. The area under the concentration-time curve (AUC0-t) was 
calculated to the last measurable concentration using the linear trapezoidal method. The 
terminal segment of the AUC0-∞ (AUCextrapolated) was calculated as:  
AUCextrapolated = Clast / kel, where Clast is the last measured plasma concentration, and kel 
is the slope during the terminal phase. 
The absolute bioavailability (F) after extravascular administration was calculated as: 
F =     (AUCev / AUCiv)  x  (Doseiv / Doseev),   
where AUCev is the median area under the curve estimated following extravascular 
administration (Griffith et al., 2010), and Doseev is the extravascular dose given to effect 
the AUCev.  
 
3.3.4 Population pharmacokinetic analysis 
Population pharmacokinetic modelling was performed to enable estimation of the 
between subject variability (BSV). BSV is important for performing MCS, which can 
simulate the probability of achieving therapeutic targets following antimicrobial 
administration. A non-linear mixed effects model was developed in S-ADAPT (version 
1.57; Bauer, 2008) with the pre- and post-processing tool S-ADAPT-TRAN (Bulitta et 
al., 2011; Bulitta & Landersdorfer, 2011). The considered models described the one 
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minute infusion by a zero-order input into an infusion site compartment that was linked 
to the central compartment by a first-order mixing process. Models with one, two and 
three disposition compartments were considered. First order elimination and distribution 
were assumed. A log-normal distribution was used to describe BSV for all parameters. 
Models with and without a full variance-covariance matrix for clearance (CL) and 
volume parameters were evaluated. Body weight and plasma creatinine concentrations 
were considered as potential covariates that may affect the pharmacokinetics of 
enrofloxacin.   
 
Visual predictive checks, residual plots and assessment of the S-ADAPT objective 
function were used to evaluate and compare models as described previously 
(Landersdorfer et al., 2012). For the visual predictive checks, enrofloxacin 
concentration-time profiles of 500 koalas were simulated for each of the competing 
models. The median, 50% prediction interval (25
th
 to 75
th
 percentiles) and 80% 
prediction interval (10
th
 to 90
th
 percentiles) were calculated from the simulated profiles 
and overlaid on the observed data. This allows an evaluation of whether the model 
adequately predicts the central tendency and variability in the observed concentrations.  
 
3.3.5 Monte Carlo simulation 
MCS was performed to simulate the disposition of enrofloxacin, taking BSV into 
account. These simulations were used to determine the proportion of koalas likely to 
achieve nominated fAUC0-24/MIC ratios of 30, 40, 75 and 300, based on the estimated 
population pharmacokinetic parameters. These fAUC0-24/MIC targets were chosen based 
on the following: fluoroquinolone fAUC0-24/MIC target values of 30 to 40 were 
associated with bacteriostasis at 24 h in in vitro models and murine infection models, 
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and microbiological cure in patients with infections by gram-positive bacteria (Lacy et 
al., 1999; Ambrose et al., 2001; Andes & Craig, 2002); an fAUC0-24/MIC of 75 was the 
target for microbiological cure in seriously ill patients using ciprofloxacin to treat 
infections caused by gram-negative pathogens (primarily Pseudomonas aeruginosa) 
(Forrest et al., 1993); and fluoroquinolone fAUC0-24/MIC ratios up to approximately 300 
were required to suppress emergence of resistance against various pathogens (Tam et 
al., 2005; Tam et al., 2007). 
 
A range of MICs from 0.03125 to 2 µg/mL were studied via MCS. The median s.c. 
bioavailability determined from the non-compartmental analysis (0.41) was used for 
assessment of s.c. doses. A protein binding value of 55.4% (Griffith et al., 2010) was 
used. Simulations of fAUC0-24 were undertaken for 5000 subjects, using the estimated 
population mean and BSV for CL. For each MIC, the probability of target attainment 
(PTA) was calculated as the fraction of subjects who attained the respective 
pharmacokinetic/pharmacodynamic (PK/PD) target. The PK/PD breakpoint was defined 
as the highest MIC with a PTA of at least 90% (Frei et al., 2008; Landersdorfer et al., 
2009). The PK/PD breakpoints were determined for fAUC0-24/MIC target values 
representing near-maximal bacterial killing and for resistance prevention of gram-
positive and gram-negative bacteria (Forrest et al., 1993; Lacy et al., 1999; Ambrose et 
al., 2001; Tam et al., 2005; Tam et al., 2007).  
 
3.4 RESULTS  
Low ciprofloxacin concentrations (0.13 – 0.25 µg/mL) were found at 2 min in three of 
six koalas following i.v. enrofloxacin administration. Ciprofloxacin concentrations were 
below the LLQ at and after 15 min in these three koalas. There were detectable 
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ciprofloxacin concentrations throughout the study in the plasma of one koala, but these 
remained below the LLQ. The remaining koalas had no detectable ciprofloxacin in their 
plasma. 
 
A two-compartment model with an additional compartment accounting for mixing 
between the infusion site and the central compartment described the present 
enrofloxacin data set well and was the best of the considered models. The area under the 
curve (AUC0-∞) predicted from the population pharmacokinetic parameter estimates 
(Table 3-1) for a 10 mg/kg i.v. dose was 20.9 µg/mL.h for a 5.4 kg koala (the average 
weight of koalas in the study), which matched the median AUC0-∞ from non-
compartmental analysis closely (Table 3-2). The visual predictive check for the final 
model (Figure 3-1) indicated an adequate predictive performance of the population 
pharmacokinetic model; the median predicted concentration profile matched the central 
tendency of the observations reasonably well. Considering the small sample size of six 
koalas, the prediction intervals reasonably reflected the observed BSV (Figure 3-1), 
although the predicted variability was slightly larger than the observed variability at 4, 6 
and 8 h post dose. Plasma creatinine concentrations were not found to be a predictive 
covariate of systemic CL. Gender neither affected body size adjusted CL, nor Vd. As 
our sample size was very small (n = 6), this covariate analysis was only for exploratory 
purposes. Allometric scaling by total body weight with a fixed exponent of 0.75 for CL 
and of 1.0 for the volume of distribution terms decreased the unexplained BSV by 
11.7% for CL, 19.8% for Vc and 4.0% for Vp compared to a model without taking into 
account the effect of body weight.  
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Table 3-1. Population pharmacokinetic parameter estimates for enrofloxacin in koalas 
 
Parameter 
(unit) 
Parameter explanation Population mean 
(%SE) 
Between subject 
variability (%SE) 
CL (L/h) 
a
 Total body clearance 2.58 (15%) 
a
 0.550 (46%) 
Vc (L) 
a
 Central volume of distribution 0.249 (14%) 0.774 (21%) 
Vp (L) 
a
 Peripheral volume of distribution 2.77 (20%) 1.22 (14%) 
CLd (L/h) 
a
 Intercompartmental clearance 2.76 (28%) 1.69 (10%) 
T1/2,mix (min) Half-life of mixing between the 
infusion site and the central 
compartment 
b
 
1.58 (21%) 0.579 (56%) 
CVcp (%) Proportional residual error 1.41  
SDcp (µg/mL) Additive residual error 0.143  
 
a:
  Clearances and volumes were scaled allometrically with an exponent of 0.75 for clearance and of 
1.0 for volume of distribution terms based on a body weight of 5.4 kg (average weight of the 
koalas in the study). 
b:
 The bolus dose entered an injection site compartment that was linked to the central compartment 
with a first-order process. This model structure was necessary to adequately capture the 
concentration time-profiles in plasma after the bolus dose given over 1 min. 
%SE:  Relative standard error representing the precision of the estimated population mean and of the 
estimated between subject variability. 
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Table 3-2. Pharmacokinetic parameters [median (range)] from non-compartmental analysis after 
i.v. and s.c. administration of enrofloxacin. 
 
 Enrofloxacin 
10 mg/kg i.v. (n = 6) 
Enrofloxacin 
10 mg/kg s.c. (n = 10)  
(Griffith et al., 2010)
 
Cmax (µg/mL) 
t1/2 (h) 
72.9  (24.3  -  317) 
1.79  (1.37   -  3.45) 
2.08  (1.34  -  2.96) 
2.31  (1.21  -  3.44) 
AUC0-4 h (µg/mL.h) 
AUC0-∞ (µg/mL.h) 
fAUC0-∞ (µg/mL.h) 
Fs.c. 
15.8 (9.19  -  45.8) 
20.3  (10.6  -  47.1) 
9.05  (4.73  -  21.0) 
- 
4.82  (3.86  -  6.73) 
8.32  (5.17  -  9.43) 
3.73  (2.31  -  4.21) 
0.41 (0.17  - 0.77) 
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Figure 3-1. Visual predictive checks for enrofloxacin plasma concentrations over the whole 
observation period (upper panel) and the first 2 h (lower panel). The graphs show the individual 
observed concentrations, the median of the observed concentrations and the predicted percentiles 
from 500 simulated subjects. Ideally, 50% of the observed concentrations should be inside the 
interquartile range (i.e. between the 25
th
 and 75
th
 percentiles) at each time point, and 80% of the 
observed concentrations should be inside the 80% prediction interval (i.e. between the 10
th
 and 90
th
 
percentiles).  
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MCS predicted low PTAs for MICs at or above 0.25 µg/mL for 10 mg/kg enrofloxacin 
i.v. or s.c. administered q 24 h (Figure 3-2). The PK/PD breakpoints for i.v. and s.c. 
dosing were low (Table 3-3), in particular for the target values fAUC0-24/MIC of 75 and 
300.  
 
 
Table 3-3.  PK/PD breakpoints* for 10 mg/kg enrofloxacin i.v. or s.c. q 12 h and q 24 h. 
 
fAUC0-24/MIC 
target 
Intravenous 
administration  
q 24 h (µg/mL) 
Subcutaneous 
administration  
q 24 h (µg/mL) 
Intravenous 
administration 
q 12 h (µg/mL) 
Subcutaneous 
administration  
q 12 h (µg/mL) 
30 0.125 0.0625 0.25 0.125 
40 0.0625 0.0313 0.125 0.0625 
75 0.0313 0.0156 0.0625 0.0313 
300 0.00781 0.00391 0.0156 0.00781 
*The PK/PD breakpoint was defined as the highest MIC with a PTA of at least 90%.  
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Figure 3-2. Probabilities of target attainment for selected fAUC0-24/MIC targets and MICs following 
administration of enrofloxacin 10 mg/kg a) intravenously q 24 h, b) subcutaneously q 24 h, c) 
intravenously q 12 h, and d) subcutaneously q 12 h. 
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For the proposed chlamydial target fAUC0-24/MIC of 75 and an MIC of 0.03125 µg/mL, 
the PTA was 80% after s.c. dosing and above 95% after i.v. dosing q 24 h. However, for 
an MIC of 0.25 µg/mL, the PTA was only 10% after i.v. dosing and 0% after s.c. dosing 
of 10 mg/kg enrofloxacin against chlamydial infections. When the dosing interval was 
decreased to q 12 h, the PTA was above 95% after i.v. dosing, and 81% after s.c. dosing 
for an MIC of 0.0625 µg/mL. Dosing 10 mg/kg q 12 h only increased the PTA to 50% 
for i.v. dosing and 5% for s.c. dosing for the proposed chlamydial MIC of 0.25 µg/mL.  
 
There were no changes to demeanour, browsing habits or faecal output of any animals 
throughout the study, and there were no apparent adverse effects resulting from the 
general anaesthetic, i.v. enrofloxacin administration, i.v. catheter placement, frequent 
handling or hospitalisation. 
 
3.5 DISCUSSION 
This study provides further insight into the pharmacokinetics of enrofloxacin in koalas. 
The acquisition of i.v. data permitted estimation of previously unavailable 
pharmacokinetic parameters, such as total body CL and s.c. bioavailability. 
Combination of the i.v. data from this study with previously acquired s.c. 
pharmacokinetic data (Griffith et al., 2010), and incorporation of these data into a MCS, 
enabled assessment of whether the commonly used dose of 10 mg/kg s.c. q 24 h is 
likely to achieve PK/PD targets for aerobic bacterial infections, including chlamydiosis, 
in koalas.  
 
A population pharmacokinetic approach was selected for this study as it enables 
analysis of data sets with high inter-individual variability, whilst allowing covariates 
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such as body weight and renal function to be quantitatively incorporated into the 
analysis. The main objective of the model was to predict PTAs for PK/PD targets using 
MCS. Thus, the model that best described the data in order to estimate CL, and 
subsequently AUC0-24, was chosen as the superior model. This model benefitted from 
inclusion of an infusion site compartment to account for mixing (half-life: 1.58 min) 
between the infusion site and the central compartment. This may have been caused by 
the rapid 1-min infusion. The developed population pharmacokinetic model for 
enrofloxacin in the koala provided precise curve fits (Figure 3-3) and yielded a good 
predictive performance (Figure 3-1). All parameters were estimated with adequate 
precision (relative standard errors below 30% for all population typical values). Even 
after accounting for the effect of body size on CL and volume of distribution via an 
allometric body size model, there was considerable random BSV with a coefficient of 
variation of 55.0% for total CL and 77.4% for volume of the central compartment 
(Table 3-1). This highlights the need for using MCS methodology to account for BSV in 
pharmacokinetics for optimising dosage regimens.  
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Figure 3-3. Individual fitted and observed plasma concentrations of enrofloxacin for each koala for the first 10 h (a) and the first 2 h (b). Only concentrations above 
the LLQ are shown.   
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The CL estimated for koalas was within the range of estimates reported for many 
species, and was noticeably lower than in some species (Nielsen & Gyrd-Hansen, 1997; 
Knoll et al., 1999; Bermingham & Papich, 2002; Rao et al., 2002; Gandolf et al., 2005; 
Peyrou et al., 2006; Elmas et al., 2007; Idowu et al., 2010) (Table 3-4). This is an 
important finding in a species, such as the koala, that is able to rapidly metabolise and 
eliminate some chemical compounds (Pass & Brown, 1990; Kimble et al., 2013). This 
enhanced metabolism is thought to be an adaptation to enable detoxification of the 
koala’s Eucalyptus spp. diet, which is high in toxic plant secondary metabolites (Cork & 
Foley, 1997) and has the potential to render some drugs unsuitable for use in this 
species.  
Table 3-4. Comparison of median (range), mean ± SD, or mean ± SE§ values for CL in selected 
species. * mean values. 
#
 population pharmacokinetic values. For this table, population 
pharmacokinetic values were scaled linearly to allow interspecies comparisons. 
 
Species CL (L/h/kg) 
Koala (present study) 0.48
# 
Alpaca (Gandolf et al., 2005) 
Beef steer (Idowu et al., 2010) 
Chicken (Knoll et al., 1999) 
Dairy cow (Idowu et al., 2010) 
Goat (Rao et al., 2002) 
Horse (Peyrou et al., 2006) 
Pig (Nielsen & Gyrd-Hansen, 1997) 
Rabbit (Elmas et al., 2007) 
Sheep (Bermingham & Papich, 2002) 
0.08 (0.04 – 0.12) 
0.70 ± 0.02 
0.62* 
1.45 ± 0.12 
1.33 ± 0.94
§ 
0.38 ± 0.09 
0.37 ± 0.11 
1.7 ± 0.52 
0.20 (0.13 – 0.22) 
 
Prior to renal elimination, many species metabolise enrofloxacin to an active metabolite, 
ciprofloxacin (Kaartinen et al., 1995; Mengozzi et al., 1996; Cester & Toutain, 1997; 
Kaartinen et al., 1997; Seguin et al., 2004). As ciprofloxacin and enrofloxacin both 
 88 
 
contribute activity against susceptible bacteria in vitro (Lautzenhiser et al., 2001), the 
concentration of this active metabolite should be considered when assessing 
enrofloxacin efficacy. Ciprofloxacin peaks were only detected in the chromatograms of 
four koalas (67%) and these were only quantifiable at the first sampling time (2 min). 
Approximately 20 to 35% of administered enrofloxacin is converted to ciprofloxacin in 
horses (Kaartinen et al., 1997), 40% in dogs (Cester & Toutain, 1997) and 60% in cattle 
(Idowu et al., 2010). Low plasma concentrations of ciprofloxacin have been detected in 
pigs (Nielsen & Gyrd-Hansen, 1997), foals (Bermingham et al., 2000) and chickens 
(Knoll et al., 1999) following systemic enrofloxacin administration. The peak 
concentrations of ciprofloxacin were approximately 500-fold lower than those of 
enrofloxacin in koalas, implying metabolism from enrofloxacin to ciprofloxacin is less 
extensive in koalas than in other species. This may indicate a different metabolic 
pathway for enrofloxacin, or rapid metabolism or excretion of ciprofloxacin (Easmon & 
Crane, 1985a; Easmon & Crane, 1985b; Hawkins et al., 1998; Cole et al., 2009). Due to 
the low plasma concentrations of ciprofloxacin detected in koalas, the antimicrobial 
activity of this active metabolite was considered negligible, thus ciprofloxacin was not 
included in the pharmacodynamic assessment of enrofloxacin.  
 
The primary PK/PD index associated with fluoroquinolone efficacy is the fAUC0-
24/MIC ratio (Walker & Dowling, 2006), which varies between pathogens. In the current 
study, target fAUC0-24/MIC ratios of 30, 40, 75 and 300 were investigated, based on 
approximate unbound fractions of published fluoroquinolone targets for gram-positive 
[~30 to 40, (Lacy et al., 1999; Ambrose et al., 2001)], and gram-negative [~75 (Forrest 
et al., 1993)] organisms, as well as the target associated with prevention of antibacterial 
resistance [300 (Tam et al., 2005; Tam et al., 2007)]. Although Chlamydiae are atypical 
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bacteria, they are more closely related to gram-negative than gram-positive bacteria 
(Caldwell et al., 1981), so the gram-negative target of 75 might be more reflective of 
Chlamydiae and was considered here. However, the targets of 30 or 40 may be relevant 
for less seriously ill koalas with an intact immune system. 
 
The in vitro susceptibility of koala isolates of C. pecorum and C. pneumoniae to 
enrofloxacin have not been determined. However, the MIC and minimum bactericidal 
concentration (MBC) of enrofloxacin against C. pneumoniae isolated from another 
Australian marsupial, the western barred bandicoot, were both 0.25 to 0.5 µg/mL 
(Kumar et al., 2007), and the enrofloxacin MIC against Chlamydia psittaci isolated 
from turkeys was 0.25 µg/mL (Butaye et al., 1997). As the in vitro susceptibility of C. 
pecorum to antibacterials is similar across chlamydial species (Kumamoto et al., 1992; 
Pudjiatmoko et al., 1998), 0.25 µg/mL was selected as the target MIC for anti-
chlamydial dosing calculations in this study.  
 
Due to the frequency of dog bite wounds seen in koala hospital admissions (Griffith et 
al., 2013), MIC values for aerobic bacteria known to be part of the normal canine oral 
flora and commonly isolated from dog bite wounds (Bailie et al., 1978) were also 
considered. These included Pasteurella multocida, Staphylococcus epidermidis, 
Streptococcus spp., Bacillus spp. and Enterobacteriaceae. MIC values for canine and 
feline isolates of some of these pathogens range from 0.03 to 0.25 µg/mL (Popova & 
Todorov, 2008; Schink et al., 2013). Additionally, the enrofloxacin susceptibility 
breakpoint for common feline and canine dermal, respiratory and urinary pathogens, 
including canine Enterobacteriaceae and Staphylococcus spp., is ≤ 0.5 µg/mL (Clinical 
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and Laboratory Standards Institute, 2008), hence the required enrofloxacin dose for 
treating chlamydiosis is likely to be similar to that required for some of these pathogens.  
 
MCS was performed to determine the PTA of fAUC0-24/MIC ratios for the above-
mentioned PK/PD targets and MICs. Our MCS did not account for BSV in oral 
bioavailability, since we only had a non-compartmental estimate for the average 
bioavailability. The PK/PD breakpoints for enrofloxacin would have been even lower 
than the already low breakpoints reported in Table 3-3, if BSV for bioavailability was 
included. For gram-positive pathogens with a low MIC of 0.0313 µg/mL, 10 mg/kg 
enrofloxacin s.c. q 24 h appears to be an appropriate dose, with PTAs of 99% and 98% 
at fAUC0-24/MIC targets of 30 and 40. However, 10 mg/kg enrofloxacin s.c. q 24 h 
cannot be recommended for gram-positive infections with MICs of 0.125 µg/mL and 
higher, gram-negative infections with MICs of 0.0313 µg/mL and higher, or for 
preventing emergence of bacterial resistance during therapy, as these situations had 
PTAs below 90%. Increasing the dosage to 10 mg/kg q 12 h had only a limited effect on 
these PTAs, with the PTA for gram-positive infections with MICs of 0.125 µg/mL 
increasing to 91%, and the highest treatable MIC for gram-negative infections 
increasing to 0.0313 µg/mL. It should be noted that administering 10 mg/kg q 12 h 
compared to 10 mg/kg q 24 h may increase the risk of host toxicity due to increased 
drug exposure, and such dose increases should be approached with caution. 
 
The PK/PD breakpoints for i.v. administration of 10 mg/kg enrofloxacin q 24 h indicate 
that gram-negative organisms with low MICs of ≤ 0.0313 µg/mL, and gram-positive 
organisms with slightly higher MICs of 0.0625 to 0.125 µg/mL, may be successfully 
treated. When administered q 12 h, 10 mg/kg enrofloxacin i.v. appears suitable for 
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gram-negative infections with MICs ≤ 0.0625 µg/mL, and for gram-positive infections 
with MICs up to 0.125 to 0.25 µg/mL. However, i.v. dosing greatly increases the risk of 
toxicity due to the attainment of substantially higher Cmax and on average 2.4-fold 
higher AUC0-∞ values (Table 3-2) compared with s.c. dosing. Thus, administering 
enrofloxacin q 12 h i.v. cannot be advocated until safety trials have been performed, and 
may carry a high risk with limited pharmacodynamic benefits. 
 
For the assumed chlamydial MIC of 0.25 µg/mL, the PTA of the proposed s.c. fAUC0-
24/MIC target of 75 was 0% for 10 mg/kg enrofloxacin q 24 h. When administered i.v., 
the PTA for Chlamydiae was 10%, which is well below the breakpoint of 90%; 
increasing the dosage to 10 mg/kg q 12 h still resulted in PTAs substantially below the 
breakpoint. Clearly, doses well in excess of 10 mg/kg q 24 h would be required to reach 
a PTA ≥ 90% for Chlamydiae. Such doses were not calculated in this study due to 
concerns of toxicity. Fluoroquinolones like enrofloxacin have extensive tissue 
penetration due to their physicochemical properties and are potentially toxic at high 
doses. The koala is a monogastric hindgut fermentor with the largest relative caecal 
surface area of any species (Snipes et al., 1993). Hindgut fermentors are particularly 
susceptible to changes in the gastrointestinal microflora induced by antimicrobial 
therapy (Toutain et al., 2010), which is thought to be the reason for the inappetence and 
wasting observed following administration of macrolides and tetracyclines to koalas 
(Brown et al., 1984; Osawa et al., 1993). Thus, in the absence of clinical data 
demonstrating safety of high doses of enrofloxacin in koalas, increasing the dose 
sufficiently to enable attainment of these pharmacodynamic targets appears 
inappropriate.  
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Although chlamydial load decreased markedly during treatment with enrofloxacin in 
clinical and subclinical koalas treated at 10 mg/kg s.c. q 24 h, chlamydial load increased 
after treatment withdrawal, despite apparent resolution of clinical signs (Griffith, 2010). 
Recurrence of chlamydial shedding following antibiotic therapy is concerning, and 
highlights treatment failure, which is supported by this study. Another concern is the 
potential emergence of resistance when subtherapeutic doses are used. This can occur 
rapidly and frequently with fluoroquinolone use (Fink et al., 1994; Papich & Riviere, 
2009b), and is problematic due to the current value of enrofloxacin as a broad spectrum 
antibiotic in veterinary medicine. These factors, in conjunction with the low PTAs 
determined in this study, indicate that reassessment of enrofloxacin as a valid treatment 
option for koalas with chlamydiosis, or other bacterial infections that are likely to have 
MICs above the breakpoints outlined in Table 3-3, is required. Importantly, an 
alternative antibiotic that is not routinely used systemically for other veterinary species 
or humans, chloramphenicol, appears to clear Chlamydiae in koalas following treatment 
(Markey et al., 2007; Govendir et al., 2012), and should be considered for treatment of 
this disease. As for enrofloxacin, the potential toxicity associated with chloramphenicol 
use needs to be considered. 
 
Although stable antibiotic resistance has not been identified in human chlamydial 
infections (Sandoz & Rockey, 2010), fluoroquinolone resistance can develop in vitro 
when Chlamydiae are continuously exposed to subinhibitory concentrations (Morrissey 
et al., 2002). Hence, treatment of koalas with enrofloxacin could potentially lead to the 
development of resistant Chlamydiae, as well as other resistant strains of bacteria from 
sites such as the integument or gastrointestinal system. This is of particular concern for 
a species, such as the koala, in which antibiotic treatment options are already limited.  
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This study provides the first population pharmacokinetic analysis for enrofloxacin in 
koalas. The associated MCS yielded low PK/PD breakpoints and supported previous 
evidence that 10 mg/kg enrofloxacin s.c. q 24 h is inadequate for treating koalas with 
chlamydiosis (Griffith, 2010). Further studies will be required to determine the in vitro 
MICs for enrofloxacin against koala isolates of C. pecorum and C. pneumoniae. When 
such information becomes available for these or other enrofloxacin-susceptible bacteria 
infecting koalas, the data presented in the present MCS plots will enable an informed 
decision as to the appropriate use of enrofloxacin for these infections.  
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CHAPTER 4. PHARMACOKINETICS OF FLUCONAZOLE 
FOLLOWING INTRAVENOUS AND ORAL 
ADMINISTRATION TO KOALAS (PHASCOLARCTOS 
CINEREUS) 
 
The following is a re-formatted manuscript, published by John Wiley and Sons Ltd: 
Black, L.A., Krockenberger, M.B., Kimble, B., Govendir, M. (2013) Pharmacokinetics 
of fluconazole following intravenous and oral administration to koalas (Phascolarctos 
cinereus). Journal of Veterinary Pharmacology and Therapeutics, 37, 90-98. 
 
4.1 ABSTRACT 
Clinically normal koalas (n = 12) received a single dose of 10 mg/kg fluconazole orally 
(p.o.; n = 6) or intravenously (i.v.; n = 6). Serial plasma samples were collected over 24 
h and fluconazole concentrations were determined using a validated HPLC assay. A 
non-compartmental pharmacokinetic analysis was performed.  Following i.v. 
administration, median (range) plasma clearance (CL) and steady state volume of 
distribution (Vss) were 0.31 (0.11 – 0.55) L/h/kg and 0.92 (0.38 – 1.40) L/kg, 
respectively. The elimination half-life (t1/2) was much shorter than in many species (i.v.: 
median 2.25, range 0.98 – 6.51 h; p.o.: 4.69, range 2.47 – 8.01 h) and oral 
bioavailability was low and variable (median 0.53, range 0.20 – 0.97). Absorption rate-
limited disposition was evident. Plasma protein binding was 39.5 ± 3.5%. Although 
fluconazole volume of distribution (Varea) displayed an allometric relationship with 
other mammals, CL and t1/2 did not. Allometrically scaled values were approximately 
seven-fold lower (CL) and six-fold higher (t1/2) than observed values, highlighting flaws 
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associated with this technique in physiologically distinct species. On the basis of 
fAUC/MIC pharmacodynamic targets, fluconazole is predicted to be ineffective against 
Cryptococcus gattii in the koala as a sole therapeutic agent administered at 10 mg/kg 
p.o. every 12 h.   
 
4.2 INTRODUCTION 
Cryptococcosis is a worldwide, life-threatening, systemic fungal disease of both humans 
and animals, and is the second most prevalent infectious disease of koalas (Stalder, 
2003). Cryptococcosis in koalas is caused by Cryptococcus gattii and, unlike disease 
induced by C. neoformans in humans, is not thought to be associated with overt host 
immunocompromise (Krockenberger et al., 2005). Asymptomatic carriage of 
cryptococcal organisms in the nasal mucosa of koalas occurs frequently (Connolly et 
al., 1999; Krockenberger et al., 2002b) and has been attributed to the close affiliation 
between koalas and Eucalyptus spp. trees, which are natural hosts for C. gattii (Ellis & 
Pfeiffer, 1990; Pfeiffer & Ellis, 1992). The interaction between host, pathogen and 
environment is complex, and occasionally results in clinical disease, affecting 
approximately 2.5% of koalas necropsied at The University of Sydney between 1980 
and 2003 (Stalder, 2003). Disease usually affects the respiratory tract, although 
dissemination is common, with CNS involvement detected in 37% of cases in one study 
(Krockenberger et al., 2003).  
 
Fluconazole is an antifungal drug currently administered orally to treat cryptococcosis 
in koalas (Wynne et al., 2012), although pharmacokinetic parameters have not been 
established in this species. Previous studies in koalas have demonstrated low plasma 
concentrations of both the fluoroquinolone antibacterial, enrofloxacin (Griffith et al., 
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2010), and the non-steroidal anti-inflammatory drug, meloxicam (Kimble et al., 2013) 
following oral administration of conventional doses. Therefore, to properly establish the 
utility of fluconazole in the management of cryptococcosis in koalas it is imperative to 
characterise fluconazole pharmacokinetics, including oral bioavailability.  
 
The current published dose rate for fluconazole in koalas for nasopharyngeal 
cryptococcosis is 50 - 100 mg orally (p.o.) twice daily (b.i.d.) (Blanshard & Bodley, 
2008), which equates to approximately 5 - 10 mg/kg. Doses in excess of 15 - 20 mg/kg 
p.o. b.i.d. are sometimes advised by one of the authors (MK), and doses as high as 25 
mg/kg p.o. b.i.d. have been reported (Wynne et al., 2012). Intravenous (i.v.) dosing at 
15 mg/kg once daily (s.i.d.) has also been used (A. Gillett, pers. comm.)
2
. The aim of 
this study was to characterise the pharmacokinetics of fluconazole in clinically normal 
koalas after oral and i.v. dosing, and to assess the suitability of the oral dosing regimen 
of 10 mg/kg b.i.d. This dose was chosen as it approximates both the suggested dose rate 
for koalas (Blanshard & Bodley, 2008), and the canine/feline doses upon which koala 
drug doses are traditionally based. 
 
4.3 MATERIALS AND METHODS 
4.3.1 Animals 
Twelve clinically normal koalas of both genders (8 males, 4 females; average weight 
5.0 ± 2.0 kg), ranging in age from 15 months to 10 years as determined by tooth wear 
(Martin, 1981) or from management records, were recruited for the study. Koalas were 
sourced from Billabong Koala and Wildlife Park (BKWP), Port Macquarie, NSW and 
                                                 
2
 Personal communication: Amber Gillett, Wildlife Veterinarian, Australia Zoo Wildlife Hospital, Qld, 
May 2013. 
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the Australia Zoo Wildlife Hospital (AZWH), Beerwah, Qld. Koalas from BKWP were 
from a display collection; those sourced from AZWH were wild koalas that had 
previously been hospitalised for illness or injury, or had presented as orphaned joeys 
and were being provided sanctuary while they matured. Koalas from AZWH were being 
prepared for release back into the wild. Koalas were deemed healthy based on a full 
physical examination performed under general anaesthesia by veterinarians at AZWH, 
or by recent clinical observations (captive koalas at BKWP) and haematology and 
biochemistry analytes within reference ranges (Canfield et al., 1989; Blanshard, 1994). 
All koalas were free of cryptococcal disease, as determined by a latex cryptococcal 
agglutination test (LCAT; Crypto-LA
®
, Wampole Laboratories, Cranbury, NJ, USA) 
and absence of clinical signs of disease. Koalas were housed in standard veterinary 
hospital enclosures (AZWH) or standard display enclosures (BKWP) and supplied with 
ad libitum food (various Eucalyptus spp.) and water for the duration of the study. The 
study was approved by The University of Sydney Animal Ethics Committee (protocol 
number N00/10-2007/4/4695). 
 
A 20-gauge i.v. catheter was placed into the cephalic vein for serial blood sampling. 
Catheters were placed under manual restraint at BKWP, or under general anaesthesia 
induced by mask using 3 – 5% isoflurane in 100% oxygen at AZWH. Anaesthetised 
koalas were recovered for one to two hours before drug administration commenced at t 
= 0. 
 
Koalas were randomly divided into p.o. (n = 6) and i.v. (n = 6) treatment groups. The 
i.v. group received 10 mg/kg fluconazole (Fluconazole Hexal®, Sandoz Pty Ltd, 
Pyrmont, NSW, Australia) administered as a 30 min i.v. infusion, as per the 
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manufacturer’s instructions, using a syringe pump. The p.o. group received 10 mg/kg 
fluconazole (Bova Compounding Chemist, Caringbah, NSW, Australia) mixed with 
Infasoy paste (Wyeth Australia, Baulkham Hills, NSW, Australia) immediately prior to 
being orally administered using a syringe. Serial blood samples (up to 1.2 mL) for 
fluconazole plasma concentration determination were collected into lithium heparin 
tubes at the following time points: t = 0, 0.5, 1, 2, 4, 6, 8, 12 and 24 h for the p.o. study, 
and t = 0, 0.5, 1, 1.5, 2.5, 4.5, 6.5, 8.5, 12.5 and 24.5 h for the i.v. study. Samples were 
centrifuged within 1 h of collection and plasma was transferred into plain tubes. Plasma 
was stored at -20 
o
C and protected from light until analysis. 
 
4.3.2 Analytical method 
Plasma concentrations of fluconazole were determined using a modified reversed-phase 
high performance liquid chromatography (HPLC) assay (Zhang et al., 2008). The HPLC 
system (Shimadzu, Rydalmere, NSW, Australia) comprised a Shimadzu LC-20AT 
solvent delivery unit, SIL-20AC autosampler, DGU-20A5 degassing unit, CTO-20AC 
column oven maintained at 25
o
C, and an SPD-M20A diode array detector. The 
chromatographic separation was achieved using an Apollo C-18, 5 µm (250 mm x 4.6 
mm ID) column (Grace Davison Discovery Sciences, Rowville, Victoria, Australia) in 
conjunction with an Opti-guard 1 mm C-18 pre-column (Optimize Technologies, 
Oregon City, OR, USA). The isocratic mobile phase consisted of acetonitrile (Lomb 
Scientific, Taren Point, NSW, Australia) and deionised water (30:70, v/v), and was 
delivered at a rate of 1.0 mL/min. Target analyte absorption was monitored at 210 nm.  
Data acquisition and peak integration were performed using Shimadzu Class VP 
software, version 7.4. Retention times for fluconazole and the internal standard (IS), 
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phenacetin, were 5.14 and 11.63 min respectively. Pooled, drug-free koala plasma was 
free of interfering peaks at these retention times. 
 
Triplicate 100 µL plasma samples from treated koalas were analysed. Calibration 
standards (0.033, 0.067, 0.33, 0.67, 3.33, 6.67, 33.3, 66.7 µg/mL) were prepared daily 
using pooled drug-free koala plasma to prepare serial dilutions from a 1,000 µg/mL 
fluconazole stock solution (analytical grade fluconazole, Sigma-Aldrich, Castle Hill, 
NSW, Australia) dissolved in analytical grade methanol (Lomb Scientific, Taren Point, 
NSW, Australia). Prior to solid phase extraction (SPE), 50 µL of 25 µg/mL phenacetin 
(Sigma-Aldrich, Castle Hill, NSW, Australia) and 800 µL of 100 mM phosphate buffer 
(pH 6.0) were added to calibration standards and plasma samples. 
 
Plasma samples and calibration standards underwent SPE using an Oasis HLB 1 cm
3
 
cartridge (Waters, Milford, MA, USA) via a vacuum manifold. SPE columns were 
conditioned with 1 mL methanol followed by 1 mL 100 mM phosphate buffer. Plasma 
supernatant (900 µL) was loaded, and columns were washed with 1 mL 100 mM 
phosphate buffer followed by 1 mL 85% phosphate buffer (100 mM phosphate buffer in 
methanol, 85:15, v/v). Samples were then eluted with 1.5 mL methanol. Eluates were 
evaporated to dryness at 35 
o
C for 3.5 h using a vacuum concentrator (SPD 121P, 
Thermo Electron Corporation, Asheville, NC, USA), and reconstituted with 100 µL 
mobile phase. Samples were centrifuged for 10 min at 14,000 x g, and 15 µL 
supernatant was injected into the HPLC system in duplicate. 
 
 101 
 
Fluconazole recovery was 90 ± 0.03%, determined by comparing replicates of three 
known fluconazole concentrations spanning the calibration range spiked into blank 
koala plasma prior to, and following, SPE. 
 
Interpolation of the daily calibration curve with a minimum coefficient of determination 
(R
2) ≥ 0.999 was used to determine the concentration of fluconazole in treated koala 
plasma. A lack-of-fit test was also performed using GenStat 14
th
 edition (VSN 
International, 2011) to verify linearity of the calibration curve, and showed no deviation 
from the linear model (P < 0.001, determined via an F-test). The lower limit of 
detection (LLD) and lower limit of quantification (LLQ) were calculated as 0.03 µg/mL 
and 0.10 µg/mL respectively, using the standard deviation of the y-intercepts of the 
regression line (International Conference on Harmonisation, 2005). Intra-assay variation 
was assessed by comparing six replicates of five calibration standards spanning the 
assay range on a single day. Inter-assay variation was assessed by comparing replicates 
of three calibration standards spanning the assay range on three analysis days. Intra- and 
inter-assay variation, expressed as % RSD, were < 10.25% and < 13.37%, respectively. 
 
4.3.3 Plasma protein binding 
The fraction of fluconazole bound to plasma proteins was determined by ultrafiltration 
(Dow, 2006). The plasma pH and protein concentration of freshly collected, pooled 
drug-free plasma from six koalas were determined prior to the assay. Analytical grade 
fluconazole was added to 1 mL plasma aliquots to yield concentrations of 0.67, 6.67 and 
66.67 µg/mL. Samples were incubated at 36 
o
C to replicate koala core body temperature 
(Degabriele & Dawson, 1979) for 30 min, and centrifuged in a fixed angle rotor 
centrifuge (Eppendorf 5417C; Eppendorf, Hamburg, Germany) at 4,000 x g for 30 min, 
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using an ultrafiltration device (Amicon® Ultra-0.5 30 kDa, Merck Millipore, Kilsyth, 
Victoria, Australia). The non-protein bound ultrafiltrate (Drugunbound) was recovered and 
the fluconazole concentration determined. This was compared with the initial 
concentration added prior to ultrafiltration (Drugtotal). Samples were prepared and 
analysed in triplicate. Percentage binding to plasma proteins was determined using the 
following equation: 
 
 
4.3.4 Pharmacokinetic analysis 
A standard non-compartmental pharmacokinetic approach was used for data analysis, 
using only values above the LLQ. The maximal concentration (Cmax) and time to reach 
maximal concentration (tmax) were determined from the raw data. The terminal rate 
constant (kel) was determined as the gradient of the terminal portion of the natural log of 
the plasma concentration-time curve. Following oral administration, kel was assumed to 
be the absorption constant (ka) due to absorption rate-limited disposition with this route 
of administration (Yáñez et al., 2011). The area under the concentration-time curve 
(AUC0-t) and area under the first moment curve (AUMC0-t) were calculated to the last 
quantifiable concentration using the linear trapezoidal method. The elimination half-life 
(t1/2), systemic clearance (CL), volume of distribution at steady state (Vss), volume of 
distribution during pseudoequilibrium (Varea), mean residence time (MRT), 
bioavailability (F), terminal segments of the AUC0-∞ and AUMC0-∞ (AUCextrapolated and 
AUMCextrapolated respectively), and unbound AUC0-∞ (fAUC0-∞) were calculated using 
the following equations: 
 
t1/2  =       ln 2 / kel 
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CL  =       dose / AUC0-∞ 
Vss =       CL  x  MRT 
Varea =       CL  /  kel 
MRT =       AUMC0-∞ / AUC0-∞ 
F =     (AUCev / AUCiv)  x  (Doseiv / Doseev), where AUCev is the median AUC0-t 
calculated following extravascular administration, and Doseev is the extravascular dose 
given to effect the AUCev. 
AUCextrapolated      =    Clast / kel, where Clast is the last measured plasma concentration. 
AUMCextrapolated   =   [(Clast  x  tlast)  /  kel ]   +   ( Clast  /  kel
2 
)
 
, where Clast is the last 
measured plasma concentration, and tlast is the time of the last measured plasma 
concentration. 
fAUC0-∞        =    AUC0-∞   x   ( 1  -  % protein binding ) 
             100          
 
Previously derived allometric coefficients and exponents for fluconazole t1/2, CL and Vd 
(Jezequel, 1994) were applied to the body weight of the koalas using the following 
equation: 
y  =  a • (BW)
b
, where y is the pharmacokinetic parameter being scaled (t1/2, CL or Vd); 
BW is the median body weight (kg) of koalas used in this study; and a and b are the 
allometric coefficients and exponents previously determined for fluconazole (Jezequel, 
1994). Vd was assumed to be Varea, as it was derived from t1/2 and CL data for each 
species (Jezequel, 1994). Theoretical values determined allometrically were compared 
with observed values for koalas, as well as observed values for other species, to 
determine the feasibility of allometric scaling of fluconazole in koalas. 
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4.3.5 Antifungal susceptibility testing 
Fluconazole MICs for 10 koala C. gattii isolates were determined in vitro. These 
isolates had been cultured from koalas between 1992 and 2012 and stored at -80 
o
C or 
freeze-dried. Isolates were subcultured twice onto Sabouraud dextrose agar prior to 
susceptibility testing. Susceptibility testing was performed by IMVS Pathology, South 
Australia, using the Sensititre® YeastOne® microbroth dilution test panel. 
 
4.3.6 Statistical analysis 
A Spearman’s rank correlation coefficient was calculated to determine whether 
pharmacokinetic values correlated with age, body weight or plasma creatinine 
concentrations. A Mann-Whitney test was used for comparison of pharmacokinetic 
parameters between treatment groups. For all tests, statistical significance was accepted 
at P < 0.05. 
 
4.4 RESULTS 
The pharmacokinetic parameters estimated for fluconazole are summarised in Table 4-
1. The semi-logarithmic plasma concentration-time curves following p.o. and i.v. 
administration to healthy koalas are presented in Figure 4-1. In conjunction with the 
disparity in terminal t1/2 estimates between the different routes of administration, these 
curves are consistent with absorption-rate limited disposition of orally administered 
fluconazole (‘flip-flop’ kinetics). The i.v. plasma drug concentration-time curve showed 
a biphasic decline, with distribution equilibrium reached within 30 min of cessation of 
the infusion (t = 1 h). The AUCextrapolated across both treatment groups was < 16.87% 
(median 4.61; range 0.72 - 16.87) of the AUC0-∞. The final quantifiable fluconazole 
concentrations in plasma were detected at t = 4.5 h (n = 2), t = 6.5 h (n = 1), t = 12.5 h 
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(n = 2) and t = 24.5 h (n = 1) for the i.v. group, and t = 8 h (n = 1), t = 12 h (n = 3) and t 
= 24 h (n = 2) for the p.o. group. Fluconazole plasma protein binding was 39.5 ± 3.5%, 
and was linear over the range 0.67 – 66.67 µg/mL. 
 
Table 4-1. Pharmacokinetic parameters (median and range) estimated following administration of 
fluconazole i.v. and p.o. to clinically normal koalas. *ka was calculated as the terminal rate 
constant, due to absorption rate-limited disposition. 
 Fluconazole 
10 mg/kg i.v. (n = 6) 
Fluconazole 
10 mg/kg p.o. (n = 6)
 
Cmax (µg/mL) 
tmax (h) 
t1/2 (h) 
kel (h
-1
) 
ka (h
-1
) 
CL (L/h/kg) 
20.63 (10.15 - 35.96) 
- 
2.25 (0.98 – 6.51) 
0.40 (0.11 – 0.71) 
- 
0.31 (0.11 – 0.55) 
2.00 (1.21 – 4.81) 
7.00 (4.00 – 8.00) 
4.69 (2.47 – 8.01) 
- 
0.15 (0.09 – 0.28)* 
- 
Vss (L/kg) 
Varea (L/kg) 
0.92 (0.38 – 1.40) 
1.17 (0.60 – 1.60) 
- 
- 
AUC0-∞ (µg/mL.h) 
fAUC0-∞ (µg/mL.h) 
AUMC0-∞ (µg/mL.h
2
) 
MRT (h) 
F 
34.54 (18.26 – 88.08) 
20.90 (11.05 – 53.31) 
112.33 (19.15 – 987.82) 
3.05 (0.97 – 11.21) 
- 
22.87 (8.48 – 41.83) 
13.84 (5.13 – 25.32) 
250.17 (68.49 – 830.11) 
11.10 (8.07 – 19.84) 
0.53 (0.20 – 0.97) 
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Figure 4-1. Semilogarithmic plasma-concentration time curves (median ± IQR) for fluconazole 
following i.v. and p.o. administration. LLQ = 0.1 µg/mL. 
 
Oral administration resulted in a significantly lower Cmax and a longer MRT (P = 0.005 
and P = 0.043, respectively) than i.v. administration. No statistically significant 
differences were detected between the other pharmacokinetic parameters common to 
both p.o. and i.v. treatment groups. Values for kel, t1/2 and AUMC0-∞ showed a 
correlation with body weight (ρ = -0.83, 0.83 and 0.83 respectively) in the i.v. treatment 
group, although this was not statistically significant (P = 0.05 for all). No other 
parameters in either treatment group displayed a significant correlation with body 
weight, age, or plasma creatinine concentration. The theoretical Varea derived using 
allometric scaling was similar to the median observed value (Table 4-2). CL and t1/2 did 
not show an allometric relationship with the seven species used for comparison (Figure 
4-2), with allometrically scaled values being approximately six-fold higher (t1/2) and 
seven-fold lower (CL) than observed values (Table 4-2). There were no changes to the 
demeanour, browsing habits or faecal output of any koalas during or following the 
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study, and there were no apparent adverse effects resulting from drug administration, 
i.v. catheter placement, frequent handling or hospitalisation. 
 
 
Table 4-2. Comparison of observed and allometrically scaled pharmacokinetic parameters for 
koalas using previously determined coefficients and exponents for fluconazole (Jezequel, 1994). 
Estimates based on the median weight of koalas in this study, 4.48 kg. 
Parameter Observed value Allometrically scaled value 
Varea (L) 5.25 3.21 
CL (L/h) 1.37 0.20 
t1/2 (h) 2.25 12.47 
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Figure 4-2. Allometric plots of log fluconazole Varea (a), CL (b) and t1/2 (c) versus log body weight in 
nine species. Data points for the mouse, rat, guinea pig, rabbit, cat, dog and human taken from a 
previous allometric study (Jezequel, 1994). Data points for the horse taken from Latimer et al 
(2001). 
 
In vitro fluconazole MIC values for C. gattii isolates varied from 1 to 16 µg/mL. Both 
the MIC50 and MIC90 were 4 µg/mL. The median (range) fAUC/MIC ratios calculated 
for twice daily dosing at 10 mg/kg were 6.92 (2.57 – 12.66) for oral administration, and 
10.45 (5.52 – 26.64) for i.v. administration.  
 
4.5 DISCUSSION 
In many species, the low molecular weight, long terminal t1/2, large volume of 
distribution (Vd), almost complete oral bioavailability and low degree of protein binding 
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make fluconazole a sound choice for treating cryptococcosis, allowing good penetration 
into the cerebrospinal fluid (CSF) with the convenience of once daily oral dosing. 
However, this study demonstrated marked differences in t1/2, CL, F and plasma protein 
binding for koalas compared with other mammals. This makes it difficult to predict 
pharmacokinetic parameters for koalas based on allometric scaling, which is an 
important finding for a drug that tends to show an allometric relationship across species 
(Jezequel, 1994). There was also clear evidence for absorption rate-limited disposition 
of orally administered fluconazole, which has not been described in other species. The 
data from this study enabled an assessment of the magnitude of the AUC0-∞ following 
administration of 10 mg/kg fluconazole p.o. and i.v., the parameter that is most closely 
linked to therapeutic outcomes of fluconazole therapy (Klepser et al., 1998). 
 
There was very little difference between estimated values for Vss and Varea, indicating 
only a small fraction of fluconazole is eliminated prior to reaching pseudoequilibrium 
(Toutain & Bousquet-Mélou, 2004b). Values for Vss only marginally exceeded total 
body water volume (Nagy & Martin, 1985; Ellis & Carrick, 1992), implying tissue 
concentrations are likely to approximate plasma concentrations. An allometric 
relationship for fluconazole Varea was observed between the koala and other species 
(mice, rats, guinea pigs, cats, rabbits, dogs, humans and horses) (Jezequel, 1994; 
Latimer et al., 2001); this may be attributed to fluconazole being distributed throughout 
body water in all species studied, and is consistent with fluconazole Varea being 
considered an invariant parameter across species (Jezequel, 1994). However, an 
allometric relationship did not exist between koalas and other species for CL and t1/2. 
Fluconazole is eliminated principally by the kidney, and the prolonged t1/2 observed in 
many species has been attributed to net tubular reabsorption (Davis et al., 2009). The 
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close allometric relationships of CL and t1/2 amongst the above-mentioned species, 
excluding the koala, imply that the extent of tubular reabsorption is fairly consistent 
across these species. Thus, a decreased extent of net tubular reabsorption may be 
responsible for the more rapid CL and shorter t1/2 of fluconazole observed in koalas. 
There are other possible explanations for the anomalous elimination rate in koalas, such 
as active tubular secretion and biotransformation. These may have evolved as adaptive 
mechanisms to enable this folivorous marsupial to detoxify its eucalypt diet (Cork & 
Foley, 1997). It should be noted that the presence of an interspecies allometric 
relationship with a high R
2
 value does not mean that interspecies dose extrapolation 
based on allometry is an appropriate method of dose determination. There can be large 
errors associated with interspecies allometric scaling, even in the presence of a high 
degree of correlation (Mahmood & Balian, 1996; Martinez et al., 2006b; Hunter & 
Isaza, 2008). However, allometry has been introduced here to emphasise the degree of 
error that may be encountered when interspecies dose extrapolation is used in exotic 
species without careful consideration of its limitations and assumptions, which have 
been reviewed elsewhere and can be easily overlooked (Hunter & Isaza, 2008). 
 
Oral bioavailability of fluconazole amongst koalas was variable, and lower than the 
almost complete bioavailability reported for mice, dogs, cats, horses and humans 
(Humphrey et al., 1985; Brammer et al., 1990; Craig et al., 1994; Latimer et al., 2001). 
The tmax in this study was recorded later than the 1 - 4 h recorded for most species 
(Humphrey et al., 1985; Ripa et al., 1993; Craig et al., 1994; Latimer et al., 2001; Davis 
et al., 2009). These observations reflect both a limited rate and extent of oral 
fluconazole absorption in koalas. Similar findings have been reported in koalas for 
another orally administered antimicrobial, enrofloxacin (Griffith et al., 2010), and very 
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low bioavailability of orally administered meloxicam has been reported in koalas 
(Kimble et al., 2013). Possible explanations for the limited extent and rate of oral 
xenobiotic absorption in koalas include extensive first-pass metabolism of oral 
xenobiotics due to enhanced liver function (Pass & Brown, 1990; Liapis et al., 2000; 
Ngo et al., 2000) or metabolism by enzymes within the gastrointestinal wall (George, 
1981; Ilett et al., 1990); binding of xenobiotics by gastrointestinal contents such as 
cellulose, as has been described in horses and sheep (Lees et al., 1988; van Duijkeren et 
al., 1996); or an inability of oral drugs to reach the gastrointestinal wall, due to the 
densely packed, finely masticated material that fills the proximal gastrointestinal tract 
(Blanshard & Bodley, 2008). These are all speculative, and further research is required 
to investigate the reason for the limited oral absorption that is becoming apparent in this 
species.   
 
The in vitro fluconazole MIC for C. gattii is generally much higher than that of many 
antifungals, including amphotericin B and many azoles (Klepser et al., 1998; Burgess & 
Hastings, 2000; Trilles et al., 2004; Torres-Rodríguez et al., 2008; Mendes et al., 2010; 
Espinel-Ingroff et al., 2012). However, it shows good in vivo activity, presumably due 
to its low degree of protein binding, long t1/2, low molecular weight and large Vd. 
Additionally, the in vivo efficacy of fluconazole against CNS mycoses has been 
attributed to its pharmacokinetic properties, namely the high water solubility and low 
protein binding (10 - 12% in most species) (Humphrey et al., 1985) that allow 
penetration into the CSF and most bodily fluids (Foulds et al., 1988; Walsh et al., 1989; 
Vaden et al., 1997; Latimer et al., 2001). Fluconazole protein binding in koalas is 
approximately four times greater than in other documented species (Humphrey et al., 
1985), and may negatively impact antifungal activity when used to treat CNS 
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cryptococcosis by impeding fluconazole’s ability to cross the blood-brain barrier 
(Bailey et al., 1990). Further assessment of CSF penetration and clinical response data 
are required to assess these speculations. 
 
To our knowledge, pharmacodynamic targets for fluconazole against C. gattii have not 
been derived, so targets determined for C. neoformans were used. Fluconazole displays 
concentration-independent fungistasis, and the pharmacodynamic index associated with 
antifungal activity for C. neoformans is the AUC/MIC ratio (Klepser et al., 1998). The 
AUC0-∞ was used for AUC/MIC estimations, as this is equivalent to the AUC at steady 
state during a single dosing interval (Pillai & Venkataramanan, 2012) and this was 
doubled to account for twice daily dosing. The MIC90 of 4 µg/mL and the unbound 
fraction (fAUC0-∞) were used. The fAUC/MIC ratio (median 6.92; range 2.57 – 12.66) 
achieved in this study following administration of fluconazole 10 mg/kg p.o. falls 
markedly short of the C. neoformans fAUC/MIC target of 192 (Burgess & Hastings, 
2000), which is equivalent to maintaining an average plasma concentration of 8 µg/mL 
throughout the dosing interval (Toutain et al., 2007). Another in vitro study found 0.5 x 
MIC as the concentration of maximal C. neoformans suppression (Klepser et al., 1998); 
maintaining an average plasma concentration of 0.5 x MIC corresponds to a much lower 
fAUC/MIC ratio of 12. This target was achieved in only one of six koalas in this study 
following p.o. administration, and in three of six koalas following i.v. administration. A 
fAUC/MIC ratio of 12 sits above the 95th percentile of the p.o. fAUC/MIC distribution 
in this study, indicating fewer than 5% of koalas are likely to reach this target. 
However, this increases to 45% with i.v. administration. As fluconazole displays linear 
pharmacokinetics (Louie et al., 1998a; Louie et al., 1998b), it is unlikely that the dose of 
25 mg/kg p.o. reported previously (Wynne et al., 2012) would reach the fAUC/MIC 
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target of 192 in any koalas, although the lower target of 12 may be attainable in some 
koalas. It should be noted that these targets are not definitive and can only be used as a 
guide to therapy, as antifungal susceptibility results are known to vary widely between 
laboratories and strains of C. gattii (Rex et al., 1993; Rex et al., 2001; Gomez‐Lopez et 
al., 2008). 
 
In treating koalas with cryptococcosis, fluconazole is often administered concurrently 
with amphotericin B in an attempt to improve treatment outcomes. Amphotericin B is 
associated with nephrotoxicity, and reduces renal blood flow and glomerular filtration 
rate of most subjects during treatment (Burgess & Birchall, 1972; Tolins & Raij, 1988). 
If fluconazole is eliminated renally in koalas, concurrent amphotericin B administration 
may result in a slower elimination rate and longer elimination t1/2 than in healthy koalas. 
Thus, a pharmacokinetic study should be undertaken in clinical animals receiving both 
fluconazole and amphotericin B to detect any changes in the fluconazole 
pharmacokinetic profile under treatment conditions.  
 
This study demonstrates important differences in fluconazole pharmacokinetic 
parameters between koalas and many previously studied species, including a shorter t1/2, 
lower bioavailability, a higher degree of protein-binding and absorption rate-limited 
disposition. Importantly, koalas are poorly represented by the allometric relationship 
that has been proposed for fluconazole amongst other species, which highlights the 
errors that can be made when interspecies allometric scaling is employed without 
careful consideration of the technique’s limitations and required assumptions (Hunter & 
Isaza, 2008). The commonly used dose of 10 mg/kg p.o. b.i.d. failed to reach 
pharmacodynamic targets in this study, and it appears that attaining the target 
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fAUC/MIC of 192 using fluconazole as a sole therapeutic agent will be difficult. Due to 
the limited oral bioavailability, i.v. dosing may be advantageous although higher doses 
need to be investigated, and the logistics of long-term i.v dosing would need to be 
considered. In light of the failure to reach pharmacodynamic targets at the dose of 10 
mg/kg p.o. as a sole therapeutic agent, and the clinical bias to use concurrent 
amphotericin B in clinical disease in order to improve therapeutic outcomes, the 
investigation of fluconazole pharmacodynamics when administered in conjunction with 
amphotericin B needs to be undertaken.  
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CHAPTER 5. IN VITRO ACTIVITIES OF 
CHLORAMPHENICOL, FLORFENICOL AND 
ENROFLOXACIN AGAINST CHLAMYDIA PECORUM  
ISOLATED FROM KOALAS (PHASCOLARCTOS 
CINEREUS)  
 
The following is a re-formatted manuscript, currently being reviewed for publication. 
 
 
5.1  ABSTRACT 
Chlamydiosis is a debilitating disease of koalas in Australia and no information exists 
regarding the antimicrobial susceptibility of Chlamydia pecorum or C. pneumoniae 
isolated from koalas. The in vitro susceptibility of koala isolates of Chlamydia pecorum 
to enrofloxacin, chloramphenicol and florfenicol was determined by culturing three 
stored isolates and seven clinical swabs. Susceptibility testing was undertaken using 
cycloheximide-treated Buffalo Green Monkey Kidney cells in 96 well microtitre plates. 
The MICs of enrofloxacin, chloramphenicol and florfenicol for all isolates ranged from 
0.25 – 0.50 µg/mL, 1 - 2 µg/mL, and 1 - 2 µg/mL, respectively. MBC values for five 
isolates were also determined, and were within one two-fold dilution of MICs. The 
MICs and MBCs of these antimicrobials were within ranges previously reported for 
other chlamydial species. When combined with previously published pharmacokinetic 
data, the in vitro susceptibility results support chloramphenicol as a more appropriate 
treatment option than enrofloxacin for koalas with chlamydiosis. The susceptibility 
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results also indicate florfenicol may be an appropriate treatment option for koalas with 
chlamydiosis, and warrants further investigation.  
 
5.2 INTRODUCTION 
Chlamydiosis is a common and debilitating disease of koalas (Phascolarctos cinereus), 
with infection rates of up to 85% detected in some populations (Jackson et al., 1999). 
The aetiological agents are Chlamydia pecorum and C. pneumoniae (Glassick et al., 
1996). C. pecorum is the more pathogenic of the two, being implicated in the majority 
of cases of significant disease (Jackson et al., 1999). By contrast, C. pneumoniae tends 
to be implicated in less severe disease, and sole C. pneumoniae infections are often low-
grade or asymptomatic (Jackson et al., 1999; Griffith, 2010). Clinical disease induced 
by C. pecorum and C. pneumoniae in koalas consists of a spectrum of ocular (Cockram 
and Jackson, 1974), urogenital (McColl et al., 1984) and respiratory disease (Brown and 
Grice, 1984). Whilst the latter has been incompletely described, ocular disease can 
result in severe keratoconjunctivitis (Cockram and Jackson, 1974) and urogenital 
disease can lead to debilitating cystitis, infertility, and ascending pyelonephritis 
(Hemsley and Canfield, 1997; Higgins et al., 2005).  
 
Koalas with chlamydiosis are presented frequently to wildlife hospitals for treatment 
(Griffith et al., 2013). Two antimicrobials are used commonly for systemic treatment: 
chloramphenicol and enrofloxacin. These antimicrobials have been chosen as, at 
conventional dosages (Blanshard and Bodley, 2008), they do not induce the syndrome 
of inappetence, emaciation, and death that has been reported in koalas following 
administration of the first-line anti-chlamydial drugs, the macrolides and tetracyclines 
(Brown et al., 1984; Osawa and Carrick, 1990). Chloramphenicol and enrofloxacin 
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dosages for koalas have been developed by extrapolation from dogs and cats, or by trial 
and error. Recently, pharmacokinetic studies of enrofloxacin and chloramphenicol in 
koalas have been conducted (Griffith et al., 2010; Black et al., 2012; Govendir et al., 
2012; Black et al., 2013;) as a starting point for koala-specific dosage development for 
chlamydiosis. However, a common limitation to these studies was the lack of available 
data regarding the in vitro susceptibility of koala C. pecorum isolates to 
chloramphenicol or enrofloxacin. Although in vitro antimicrobial susceptibilities are not 
always reflective of the susceptibility in vivo, such data are important in the 
development of dosage regimens, as they are used as a basis for establishing target 
antimicrobial plasma concentrations that are theoretically therapeutic. 
 
Although ruminant C. pecorum isolates have undergone susceptibility testing to a range 
of antimicrobials (Pudjiatmoko et al., 1998), the susceptibility of C. pecorum to 
enrofloxacin and chloramphenicol has not been tested. This paucity of information is 
likely due to the expense and technical difficulties associated with antimicrobial 
susceptibility testing of intracellular pathogens, and the lack of standardised guidelines 
for performing antimicrobial susceptibility testing against Chlamydia spp. In order to 
better establish theoretical therapeutic targets for koalas with chlamydiosis, this study 
aimed to determine the minimum inhibitory concentration (MIC) and minimum 
bactericidal concentration (MBC) of enrofloxacin, chloramphenicol, and the 
chloramphenicol derivative, florfenicol, against koala C. pecorum isolates. Florfenicol 
was selected as a potential alternative to chloramphenicol, due to the recent market 
withdrawal of the commercial veterinary chloramphenicol formulation in Australia. 
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5.3 MATERIALS AND METHODS 
5.3.1 Chlamydia pecorum isolates 
Ten C. pecorum isolates from koalas were tested. The koala C. pecorum type strain 
(MC/Mars Bar) (Marsh et al., 2011) was kindly donated by the Institute of Health and 
Biomedical Innovation, Queensland University of Technology. Two archived C. 
pecorum isolates that had been cultured from koalas at Featherdale Wildlife Park in 
Western Sydney, NSW, in 1990 were used. Seven isolates were grown from ocular and 
urogenital swabs (aluminium shafted rayon swabs; Copan, Brescia, Italy) collected from 
wild koalas presenting with ocular or urogenital signs of chlamydiosis to the Currumbin 
Sanctuary Wildlife Hospital, Currumbin, Queensland between November 2012 and 
February 2013. Swabs were stored at -80 
o
C in 2-SP (0.2 M sucrose, 0.02 M phosphate) 
supplemented with 10% foetal bovine serum (FBS), 50 µg/mL gentamicin, 100 µg/mL 
vancomycin, and 25 µg/mL amphotericin B until cultured. A plain swab was also taken 
from each site to confirm presence of C. pecorum and absence of C. pneumoniae by 
real-time PCR (qPCR).   
 
5.3.2 Chlamydia pecorum species identification 
DNA extraction was undertaken using the Bioline Isolate II blood and genomic DNA 
kits (Bioline, Alexandria, NSW, Australia) according to the manufacturer’s instructions. 
C. pecorum and C. pneumoniae were detected using an existing species-specific qPCR 
method (Govendir et al., 2012), revalidated for use with SsoAdvanced
TM
 SYBR® Green 
Supermix (Bio-Rad Laboratories Pty Ltd, Gladesville, NSW, Australia) and run using a 
CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad Laboratories Pty Ltd, 
Gladesville, NSW, Australia).  
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5.3.3 Cell culture and growth of Chlamydial isolates from swabs 
Isolates were grown in Buffalo Green Monkey Kidney (BGMK) cells, which were 
maintained in Dulbecco’s Modified Eagle’s Medium (Hyclone DMEM; Thermo-Fisher 
Scientific, Scoresby, Victoria, Australia) containing 4.5 g/L glucose. Immediately prior 
to use, the medium was supplemented with 9% FBS (In Vitro Technologies, Noble Park 
North, Victoria, Australia), 20 mM HEPES buffer (In Vitro Technologies, Noble Park 
North, Victoria, Australia), and 2 mM L-glutamine (Sigma-Aldrich, Castle Hill, NSW, 
Australia). Flasks were maintained at 37 
o
C in 5% CO2. For the initial inoculation of 
BGMK cells with Chlamydia spp. from clinical swabs, 40 µg/mL gentamicin, 150 
µg/mL vancomycin, and 5 µg/mL amphotericin B were added to the medium. Isolates 
were then passaged four times in antimicrobial-free medium prior to susceptibility 
testing.  
 
5.3.4 In vitro susceptibility testing 
Chloramphenicol, enrofloxacin, florfenicol and ofloxacin (all from Sigma-Aldrich, 
Castle Hill, NSW, Australia) were obtained as powders and solubilised, after accounting 
for purity. 
 
Twenty-four hours prior to inoculation, each well of a 96-well microtitre plate was 
seeded with 100 µL medium containing 3.0 x 10
5
 BGMK cells/mL. The next day, wells 
were inoculated with 100 µL of the test isolate diluted to yield 10
3
 to 10
4
 inclusion-
forming units per mL. Plates were centrifuged at 2000 × g for 1 h, and then incubated at 
37 
o
C in 5% CO2 for 1 h. Following centrifugation, wells were aspirated and overlaid 
with 200 µL medium containing 1 µg/mL cycloheximide (Sigma-Aldrich, Castle Hill, 
NSW, Australia) and serial two-fold dilutions of the test antimicrobial. For MIC 
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determination, plates were incubated for 48 h at 37 
o
C in 5% CO2, prior to fixing and 
staining with a fluorescein-conjugated genus-specific Chlamydia-lipopolysaccharide 
monoclonal antibody (Cellabs, Brookvale, NSW, Australia) according to the 
manufacturer’s instructions. The MIC was defined as one two-fold dilution above the 
transition-point MIC (MICTP), which was defined as the concentration of drug resulting 
in altered size or morphology of at least 90% of inclusions (Suchland et al., 2003). For 
MBC determination, plates were incubated in 5% CO2 for 48 h at 37 
o
C after addition of 
the antimicrobial. The medium was then aspirated and cells were washed twice with 
phosphate buffered saline. Antibiotic free medium containing 1 µg/mL cycloheximide 
was added and plates were frozen at -80 
o
C, thawed, passed onto new monolayers as 
described above and incubated for 48 h at 37 
o
C in 5% CO2. Monolayers were then 
fixed and stained as above. The MBC was defined as the lowest concentration of 
antimicrobial that prevented inclusion formation after a single freeze-thaw passage. All 
tests were run in triplicate. C. trachomatis (ATCC VR-879, serotype H) was donated by 
the Westmead Institute for Clinical Pathology and Medical Research (ICPMR) and used 
as the reference strain. 
 
5.3.5 Mycoplasma testing of cultures 
Each C. pecorum isolate was tested for Mycoplasma spp. contamination at the first 
passage, and again immediately prior to use in susceptibility testing, using a commercial 
Mycoplasma PCR detection kit (Applied Biological Materials Inc., Richmond, BC, 
Canada) according to the manufacturer’s instructions. The maintenance flasks of 
BGMK cells were also tested periodically, including immediately prior to and upon 
completion of susceptibility testing.  
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5.4 RESULTS 
The seven clinical swabs collected from koalas presenting to the Currumbin Sanctuary 
Wildlife Hospital were positive for C. pecorum, but negative for C. pneumoniae. All 
isolates were negative for Mycoplasma spp. on each testing occasion. The BGMK cell 
maintenance flask was consistently Mycoplasma spp. negative on PCR, and remained so 
at the conclusion of susceptibility testing. 
 
For each antimicrobial, the MIC values were within one two-fold dilution across all ten 
isolates. For the five isolates used in MBC determination, results were within one two-
fold dilution of each other (Table 5-1). For each isolate that underwent MBC testing, the 
MBC was within one two-fold dilution of the MIC. Susceptibility results were 
consistent between isolates from different locations (South East Queensland and 
Western Sydney), and between isolates collected 23 years apart (1990 and 2013).  
 
 
Table 5-1. In vitro activity of chloramphenicol, enrofloxacin and florfenicol against ten (MIC data) 
or five (MBC data) koala isolates of Chlamydia pecorum. 
Drug  MIC (µg/mL)  MBC (µg/mL) 
  Range 50% 90%  Range 50% 90% 
Chloramphenicol  1 – 2 1 2  1 – 2 2 2 
Enrofloxacin  0.25 – 0.5 0.5 0.5  0.5 – 1 0.5 1 
Florfenicol  1 – 2 1 2  2 2 2 
 
 
Chloramphenicol and florfenicol displayed comparable in vitro activity against C. 
pecorum; enrofloxacin displayed greater in vitro activity than either chloramphenicol or 
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florfenicol. On all eight testing days, the ofloxacin MIC for the reference strain was 1 
µg/mL; the ofloxacin MBC for the reference strain was consistently 2 µg/mL. 
 
5.5 DISCUSSION 
This study provides novel information regarding the in vitro susceptibilities of 
commonly used antimicrobials against koala isolates of C. pecorum. Such information 
is valuable for the formulation of koala-specific drug dosages, and can also be used in 
conjunction with pharmacokinetic data to determine whether currently used dosage 
regimens are likely to achieve therapeutic targets in vivo.  
 
There are currently no internationally accepted standardised guidelines for the 
antimicrobial susceptibility testing of Chlamydia spp. Despite this, the results of in vitro 
antimicrobial susceptibility testing for different chlamydial species using different cell 
lines are often similar (Bailey et al., 1984; Pudjiatmoko et al., 1998; Suchland et al., 
2003). An exception to this is macrolide susceptibility when tested using different cell 
lines; Chlamydia cultured in BGMK cells yield higher MIC values for macrolides than 
those cultured in various other cell lines (Suchland et al., 2003). This was not the case 
for fluoroquinolones, and the results of this study indicate it is unlikely to be the case 
with chloramphenicol or florfenicol as susceptibilities to these drugs were similar to 
those previously published using other cell lines (Johnson and Hobson, 1977; How et 
al., 1985; Bianchi et al., 1988; Graham et al., 1988). BGMK cells were used in this 
study as they are a hardy cell line that is sensitive to chlamydial infection (Krech et al., 
1989), producing large, easily-visualised inclusion bodies (Hobson et al., 1982b). 
Additionally, as an epithelial cell line, they serve as a good model for the epithelial host 
cells in which Chlamydia spp. grow and replicate in vivo. The reference strain used in 
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this study was tested against ofloxacin on each assay day, and results were consistently 
within the range of previously published MICs and MBCs for this drug when tested 
against C. trachomatis (Bailey et al., 1984; Suchland et al., 2003), reinforcing the 
validity of the method employed in this study. 
 
The MICTP (Suchland et al., 2003) was used to determine MIC values in this study. This 
method has been adopted recently (Chu et al., 2010; Peuchant et al., 2011) to overcome 
the inherent subjectivity in determining an end point for chlamydial MIC determination 
with immunofluorescence staining. Using the MICTP method, visual inspection of serial 
antimicrobial dilutions reveals a noticeable change in inclusion number and morphology 
at the MICTP (Suchland et al., 2003) (Figure 5-1). This provides a method of endpoint 
detection that is likely to be consistent between operators. Using the MICTP to 
determine the MIC has produced MIC values within one dilution of those determined 
using molecular techniques (Peuchant et al., 2011), offering further support for this 
method of MIC determination.  
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Figure 5-1. Sequential photographs of C. pecorum intracellular inclusions (green) in BGMK cells 
(red) following 48 h exposure to serial dilutions of chloramphenicol. a) 0.125 µg/mL 
chloramphenicol; normal Chlamydial inclusions. b) 0.25 µg/mL; normal Chlamydial inclusions. c) 
0.5 µg/mL; few, small Chlamydial inclusions (MICTP). d) 1 µg/mL; no inclusions seen (MIC). The 
isolate was recovered from the left eye of a koala at the Currumbin Sanctuary Wildlife Hospital, 
Qld. Magnification, ×400. 
 
Although chloramphenicol and florfenicol are not considered first line systemic 
antimicrobials for treating chlamydiosis in most species, they were investigated in this 
study alongside enrofloxacin. Chloramphenicol and enrofloxacin are routinely used 
systemically to treat koalas with chlamydiosis, as the macrolides and tetracyclines have 
been associated with a syndrome of inappetence, emaciation and death following 
administration to koalas (Brown et al., 1984; Osawa and Carrick, 1990). Although 
enrofloxacin is metabolised to an active metabolite, ciprofloxacin, in many species 
(Kaartinen et al., 1995; Mengozzi et al., 1996; Cester and Toutain, 1997; Kaartinen et 
al., 1997), the antimicrobial susceptibility of ciprofloxacin was not investigated in this 
study as enrofloxacin metabolism to ciprofloxacin is negligible in koalas (Griffith et al., 
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2010), and we are unaware of anybody using ciprofloxacin to treat chlamydiosis in 
koalas. Florfenicol was investigated in this study as a potential alternative to 
chloramphenicol, as distribution of the commercially available chloramphenicol 
formulation recently ceased in Australia. The in vitro susceptibility of koala C. pecorum 
isolates to florfenicol and chloramphenicol were almost identical. Thus, based on in 
vitro susceptibility testing, florfenicol may be a rational alternative to chloramphenicol 
for treating koalas with chlamydiosis, and further investigation regarding the 
pharmacokinetics, efficacy, and safety of florfenicol in koalas with chlamydiosis is 
warranted. 
 
The C. pecorum susceptibility to enrofloxacin in this study was the same as that of C. 
pneumoniae isolated from western barred bandicoots (MIC 0.25 – 0.5 µg/mL; Kumar et 
al., 2007); C. psittaci isolated from turkeys (MIC 0.25 µg/mL; Butaye et al., 1997); and 
to the susceptibility of ruminant isolates of C. pecorum to other fluoroquinolones 
(ofloxacin MIC 0.25 – 0.5 µg/mL, ciprofloxacin MIC 0.25 – 1.0 µg/mL; Pudjiatmoko et 
al., 1998). Additionally, C. pecorum susceptibility to chloramphenicol in vitro was 
similar to that of C. trachomatis isolated from humans [MIC 0.25 – 1.0 µg/mL (How et 
al., 1985); MIC 1.0 µg/mL (Johnson and Hobson, 1977); MIC 0.5 – 1.0 µg/mL (Bianchi 
et al., 1988)], despite the lack of a standardised testing procedure for chlamydial 
susceptibility testing. This supports the previous observation that chlamydial patterns of 
antimicrobial susceptibility display consistency across chlamydial species (Pudjiatmoko 
et al., 1998). 
 
Up until now, pharmacodynamic targets for treating koalas with chlamydiosis have 
been based on the in vitro susceptibility of other chlamydial species to enrofloxacin and 
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chloramphenicol (Griffith et al., 2010; Black et al., 2012; Black et al., 2013), as C. 
pecorum susceptibility data for these antimicrobials were not available. The MIC values 
used to assess drug pharmacodynamics in these studies (1 – 4 µg/mL for 
chloramphenicol; 0.25 µg/mL for enrofloxacin) are in close alignment with the results 
of the current study, adding weight to the conclusions drawn in previous studies. 
Importantly, when combined with the available pharmacokinetic data (Griffith et al., 
2010; Black et al., 2012; Black et al., 2013) and treatment efficacy data (Markey et al., 
2007; Griffith, 2010; Govendir et al., 2012), the results of the current study offer further 
support for chloramphenicol as a suitable treatment option for chlamydiosis in koalas, 
as well as additional evidence that enrofloxacin is not a suitable treatment option for 
this disease at dosages likely to be safe in koalas. This claim is based on evidence of 
continued chlamydial shedding when enrofloxacin is withdrawn (Griffith, 2010), and a 
0% probability of reaching therapeutic targets at the commonly used dose of 10 mg/kg 
subcutaneously every 24 h, when the lower MIC determined in this study, 0.25 µg/mL, 
is considered (Black et al., 2013). The enrofloxacin dosages calculated to be 
theoretically effective against C. pecorum are well above conventional dose rates, and 
bring with them concerns of toxicity (Black et al., 2013). Thus, until these dosages are 
determined to be safe, alternative treatment options should be explored.  
 
This study provides in vitro susceptibility data for two antimicrobials commonly used to 
treat C. pecorum infections in koalas, as well as an antimicrobial that may hold promise 
for treating this disease in the future. Although in vitro susceptibility results do not 
always correlate with in vivo susceptibility, the data presented herein can be used as a 
guide for the determination of therapeutic targets during dose development. As well as 
highlighting similarities in the in vitro susceptibilities of different species of Chlamydia, 
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this study provides a rational justification for the investigation of florfenicol as a 
potential treatment option for this disease in koalas.    
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CHAPTER 6. GENERAL DISCUSSION AND DIRECTIONS 
FOR FUTURE RESEARCH 
 
Prior to the commencement of this project, pharmacokinetic data for koalas were 
extremely limited, and there were no data available regarding the pharmacokinetics of 
any drug administered i.v. to koalas. The pharmacokinetic profile of a drug established 
following i.v. administration is the gold standard for pharmacokinetic studies as it 
enables estimation of absolute bioavailability (F), volume of distribution (Vd), and 
systemic clearance (CL); the latter is necessary for the determination of dosage 
regimens that will theoretically achieve therapeutic targets. Despite this paucity of 
pharmacokinetic data, many hundreds of koalas each year receive therapeutic drugs at a 
number of wildlife rehabilitation facilities across their natural range (Jones, 2008; 
Griffith et al., 2013), and there is anecdotal evidence that many of these drugs are 
effective at currently used dosages.  
 
The work presented in Chapters 2, 3, and 4 describes the pharmacokinetics of three 
drugs that are commonly administered to koalas: chloramphenicol, enrofloxacin and 
fluconazole. The integration of pharmacokinetic and pharmacodynamic data for 
fluconazole, and for two formulations of chloramphenicol, as well as the use of 
population pharmacokinetic modelling and Monte Carlo simulation (MCS) for 
enrofloxacin, has enabled theoretical PK/PD assessments of whether the currently used 
dosages of these drugs are likely to be reaching therapeutic concentrations in koalas. 
Additionally, this work has raised further questions regarding the pathways involved in 
the metabolism of these drugs in koalas. The three drugs investigated undergo different 
metabolic and elimination pathways from one another in other species. Fluconazole is 
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primarily filtered by the kidneys and excreted unchanged in the urine (Humphrey et al., 
1985; Brammer et al., 1991); the main route of enrofloxacin metabolism in many 
species is N-deethylation to an active metabolite, ciprofloxacin, via Phase I hepatic 
metabolism (Papich & Riviere, 2009b); and chloramphenicol is glucuronidated via 
Phase II hepatic conjugation into chloramphenicol glucuronide (Papich & Riviere, 
2009a). By comparing the pharmacokinetic profiles of these drugs in koalas with those 
from other species, hypotheses can be formed regarding the rate and capacity of these 
metabolic and elimination pathways in koalas. Clinically, this information is invaluable 
for wildlife clinicians when making decisions regarding the choice of drug to administer 
to this species, and may hold similar implications for the treatment of other specialist 
folivores.  
 
Prior to the work presented in this thesis, the limited data available regarding the 
pharmacokinetic profiles of various drugs in koalas led our research group to believe 
that many drugs administered to koalas were poorly absorbed after oral administration, 
and were eliminated at a rate so rapid as to render them inefficacious. This was based on 
preliminary studies of four drugs; enrofloxacin and marbofloxacin (Griffith et al., 
2010), meloxicam (Kimble et al., 2013), and fluconazole (unpublished data). The work 
presented in Chapters 2 and 3 indicates that rapid elimination is certainly not the case 
for all drugs administered to koalas. Based on the CL and kel estimated following i.v. 
chloramphenicol sodium succinate administration in Chapter 2, drugs that are 
metabolised by Phase II glucuronidation may be eliminated in koalas at a rate 
comparable to that seen in other species, if chloramphenicol is metabolised by 
glucuronidation in koalas as it is in other species. This hypothesis is further supported 
by previous evidence suggesting that specialist folivores, such as koalas, tend to rely 
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more heavily on extensive Phase I oxidation of their toxic diet, with Phase II 
conjugation reactions, including glucuronidation, being utilised to a lesser extent 
(McLean & Foley, 1997; Boyle et al., 1999; Lamb et al., 2004). Glucuronidation does 
occur to an appreciable extent in koalas for detoxification of ingested phenols, with 
glucuronides excreted in the urine at a rate approximately 1000-fold that of humans 
(McLean et al., 2003). However, the metabolic pathways involved in hepatic 
conjugation are saturable (Cassidy & Houston, 1984). Thus, it is possible that the net 
glucuronidation capacity available for drug metabolism in koalas is similar to what is 
seen in other, non-specialist species, if there is consistently some degree of saturation of 
the glucuronidation pathways involved in phenol metabolism. Terpenes are detoxified 
by Phase I metabolism in specialist feeders, even though these substrates are often 
glucuronidated by generalist feeders (Boyle et al., 2000b; Pass et al., 2001). The 
tendency of specialist feeders to metabolise these compounds by extensive oxidation, 
rather than conjugation, has been postulated as a method of conserving energy, and 
ensuring adequate conjugation pathways are available for the metabolism of phenols 
(Foley & Moore, 2005). Further work needs to be undertaken regarding the metabolic 
fate of chloramphenicol in koalas. However, if chloramphenicol is found to be 
metabolised primarily by Phase II glucuronidation in koalas, then the finding of 
comparable elimination rates between koalas and other species opens up a range of 
drugs that will potentially have a similar elimination rate in koalas to other species. It 
stands to reason that such drugs would be worthy candidates for pharmacokinetic and 
pharmacodynamic investigation in this species, as they are less likely to be subjected to 
the rapid metabolism experienced by some drugs that undergo Phase I oxidation 
reactions, such as meloxicam (Kimble et al., 2013), and are subsequently likely to be of 
clinical use in this species. Drugs that are utilised in koalas and undergo Phase II 
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glucuronidation in humans include the non-steroidal anti-inflammatory drug, carprofen 
(Ray & Wade, 1982); the opioids, codeine (Yue et al., 1991), morphine (Coffman et al., 
1997) and buprenorphine (Chang & Moody, 2009); the analgesic, paracetamol (a.k.a 
acetaminophen) (Nelson & Morioka, 1963); and the general anaesthetic agent, propofol 
(Sneyd et al., 1994).  
 
The finding of negligible metabolism of enrofloxacin to ciprofloxacin in Chapter 3 
raises questions regarding the metabolic fate of this antimicrobial in koalas. 
Enrofloxacin is metabolised to ciprofloxacin in many species (Kaartinen et al., 1995; 
Mengozzi et al., 1996; Cester & Toutain, 1997; Kaartinen et al., 1997; Seguin et al., 
2004) via N-deethylation (Papich & Riviere, 2009b), which is a Phase I hepatic 
microsomal oxidative reaction (Baggot & Giguère, 2013). However, alternative 
pathways for enrofloxacin metabolism have been found in rats, with both ciprofloxacin 
and a glucuronide metabolite being identified as major metabolites (Heitzman, 1995). 
Glucuronidation of enrofloxacin in koalas, if it occurs extensively, may be a reason for 
the lack of appreciable ciprofloxacin detection following enrofloxacin administration. 
This is purely speculative, and further work is required to identify the pathways 
responsible for enrofloxacin metabolism and elimination in koalas, as well as the nature 
of the metabolites produced. Such work was beyond the scope of this thesis, but would 
add to the growing field of knowledge surrounding koala metabolic processes. 
 
In Chapter 4, fluconazole served as a useful standard for further assessing the 
differences in oral drug absorption (Griffith et al., 2010) and elimination (Kimble et al., 
2013) that have been observed for some therapeutic drugs in koalas, when compared 
with other, non-folivorous species. Fluconazole is well known for having a uniform 
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pharmacokinetic profile across species, with almost complete oral bioavailability 
(Humphrey et al., 1985; Brammer et al., 1990; Craig et al., 1994; Latimer et al., 2001). 
The oral bioavailability documented in Chapter 4 was highly variable, and generally 
lower than that recorded for other species. This is in agreement with both of the studies 
that have investigated oral bioavailability of other drugs in koalas (Griffith et al., 2010; 
Kimble et al., 2013) and offers further evidence that this route of administration may be 
unsuitable for use in koalas. Further to this, Chapter 4 provided clear evidence for 
absorption rate-limited disposition of oral fluconazole in koalas, which has not been 
reported in any other species. It is yet to be determined whether the oral absorption of 
fluconazole was affected by the Infasoy paste with which the fluconazole was 
administered. However, in practice it is unlikely that oral fluconazole will be 
administered to koalas without use of such a vehicle, thus this concept is potentially a 
purely academic one. 
 
Another convenient characteristic of fluconazole’s uniform pharmacokinetic profile is 
that it enables allometric scaling across a wide range of species (Jezequel, 1994); this is 
not the case for many drugs (Riviere et al., 1997) and is presumably due to 
fluconazole’s renal elimination pathway, as glomerular volume and number, effective 
renal plasma flow, and glomerular filtration rate (GFR) are parameters that can be 
scaled across species ranging in size from mice to whales (Edwards, 1975; Holt & 
Rhode, 1976; Singer, 2001). The finding of a poor correlation between koalas and other 
species when fluconazole parameters were scaled using allometry indicates differences 
in the disposition of this drug in koalas, particularly in relation to its elimination. This 
finding highlights the risks of using scaling techniques for species that have 
physiological characteristics that differ from conventionally studied species. The rapid 
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elimination of fluconazole also poses questions about whether this drug undergoes 
metabolism in koalas. It is possible that in koalas, as in many other species, the majority 
of fluconazole (70 – 90%) is excreted unchanged in the urine (Humphrey et al., 1985; 
Brammer et al., 1991), and that the rapid elimination rate seen in koalas is due to more 
efficient renal filtration of this drug. An alternative theory is that fluconazole may be 
subjected to metabolism in koalas. The amount of fluconazole excreted unchanged in 
the urine was not determined as part of the current project due to the difficulties 
associated with prolonged urine collection in koalas. However, should this be pursued 
in future studies, it may offer more information to explain the rapid elimination rate of 
fluconazole in this species by indicating how much fluconazole is renally excreted, and 
how much is eliminated by other mechanisms. Additionally, in vitro assays, such as 
hepatic or extra-hepatic microsome assays, would help to determine whether any 
appreciable metabolism of fluconazole occurs in koalas, and the nature of the 
metabolites produced.  
 
The in vitro C. pecorum susceptibility data presented in Chapter 5 provided 
confirmation of the assumed susceptibilities of this pathogen that had been used for 
pharmacodynamic assessments of chloramphenicol and enrofloxacin in Chapters 2 and 
3. These data helped to bridge the gaps in knowledge that were evident in the initial 
chloramphenicol and enrofloxacin pharmacokinetic studies undertaken in koalas 
(Griffith et al., 2010; Govendir et al., 2012), in which pharmacodynamic targets were 
assumed based on the published in vitro susceptibilities of other species of Chlamydia 
isolated from different host species, including humans. Standardised guidelines for 
antimicrobial susceptibility testing of Chlamydia spp. have not been developed, and the 
interpretation of in vitro antimicrobial susceptibility testing must be undertaken 
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cautiously, as in vitro results cannot be directly transferred to in vivo situations. 
However, the results presented in Chapter 5 helped to shed light on the likely suitability 
of each of these treatment options when combined with data from Chapters 2 and 3, and 
in light of previous data regarding response to treatment with these antimicrobials 
(Markey et al., 2007; Griffith, 2010; Govendir et al., 2012). The results of susceptibility 
testing of C. pecorum indicated that the MIC of chloramphenicol was at the lower end 
of the range used for the pharmacodynamic assessment of chloramphenicol in Chapter 
2, and lower than that previously assumed for the Chlamydia spp.-chloramphenicol 
combination (Govendir et al., 2012). Consequently, the likelihood of reaching 
therapeutic targets against Chlamydia spp. when using chloramphenicol is potentially 
higher than that outlined in these studies. Based on all the available evidence, which 
includes the pharmacokinetic study presented in Chapter 2, the antimicrobial 
susceptibility study presented in Chapter 5, and a previous efficacy study (Markey et al., 
2007), chloramphenicol appears to be a feasible treatment option for koalas with 
chlamydiosis. However, it is still questionable as to whether the current dosage of 60 
mg/kg s.c. s.i.d. should be increased slightly. Importantly, the similarities in patterns of 
in vitro susceptibility between chloramphenicol and florfenicol, presented in Chapter 5 
and determined previously (Graham et al., 1988), offer support for the potential of 
florfenicol in treating koalas with chlamydiosis if its safety can be demonstrated in this 
species, as chloramphenicol is no longer commercially available in Australia.   
 
Due to the vast degree of between subject variability evident in the pharmacokinetic 
profiles of enrofloxacin in Chapter 3, population pharmacokinetic modelling was used 
for pharmacokinetic evaluation instead of the traditional non-compartmental analysis 
that had been used in Chapters 2 and 4. This had the added benefit of enabling MCS to 
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be performed. The use of probability theory enabled an estimation of the percentage of 
koalas likely to attain therapeutic targets when considering various enrofloxacin-
pathogen combinations. This study provided overwhelming theoretical evidence that 
enrofloxacin is unsuitable for treating chlamydiosis in koalas. Prior to the study 
undertaken in Chapter 3, it was known that 10 mg/kg enrofloxacin s.c. s.i.d. was 
unsuccessful in effecting a microbial cure in koalas with chlamydiosis (Griffith, 2010). 
This was further supported by the in vitro susceptibility testing of enrofloxacin against 
koala isolates of C. pecorum presented in Chapter 5, which showed that the in vitro 
susceptibility of C. pecorum to enrofloxacin was the same as what had been assumed 
for the MCS. The doses of enrofloxacin estimated to achieve therapeutic targets against 
C. pecorum using the data from Chapter 3 were too high to warrant publication, as they 
carried concerns regarding sterilisation of the gastrointestinal microflora, and 
subsequent mortality of treated koalas. It is hoped that, as an outcome of this work, 
enrofloxacin will no longer be used to treat chlamydiosis in koalas, and that other 
treatment options will be sought. 
 
As with any research, there were limitations encountered whilst undertaking the work 
presented in Chapters 2, 3 and 4. Some of these are common to the wildlife research 
setting, and include the limitations on the number of animals recruited for each study; 
the concerns associated with holding wild animals in captivity for prolonged periods, 
which precluded a cross-over design for the pharmacokinetic studies; and the remote 
location of the major field site relative to our laboratory.  
 
Although many veterinary pharmacokinetic studies are based on sample sizes of six to 
ten animals, having higher numbers of animals in each group would have helped to 
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maximise the chances of recruiting animals that were truly representative of the 
sampled population. This was overcome to some degree in Chapter 3 with the use of 
population pharmacokinetic modelling, which enabled inter-individual variability to be 
incorporated into the analysis. However, this technique was not available for Chapters 2 
and 4. The number of animals recruited for the pharmacokinetic studies were limited by 
both the number of wild animals available at the field site, and the number condoned on 
ethical grounds. As veterinarians, we are trained under the well-known injunction to 
‘above all, do no harm.’ Thus, recruitment of healthy animals into a pharmacokinetic 
study is always going to be challenging, especially in the case of wild animals where the 
stress of human interaction has to be considered, and wherever possible, minimised.  
 
As all of the koalas recruited into this study were wild animals that were being 
rehabilitated for re-release into the wild, their welfare was a major factor in the study 
design. When these studies were designed, the elimination half-life of these drugs in 
koalas was unknown, with the exception of the chloramphenicol base formulation 
(Govendir et al., 2012). It was anticipated that a washout period of at least one week 
would be required to enable a cross-over study to be performed. A washout period of a 
week, followed by a 24 – 48 h pharmacokinetic study and subsequent monitoring of the 
animals for another 48 h would have increased their time in captivity by a minimum of 
ten days. Not only can this cause undue stress to the animals, but it places extra strain 
on the resources of the wildlife hospital. This limitation could be overcome in the future 
by recruiting captive animals for use in pharmacokinetic investigations (eg. zoo display 
animals), although this requires ethics approval from the zoo’s governing body. Use of 
display animals would also require removal of these animals from display during the 24 
- 48 h sampling period, in order to minimise concerns raised by the general public 
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caused by display animals being used for research as this often generates negative 
publicity. 
 
As outlined in Chapter 2, the distance of the remote field site from the laboratory 
precluded quantification of the inactive prodrug, chloramphenicol SS, in the plasma 
following chloramphenicol SS administration, as this prodrug is only stable for up to 
one week in plasma when stored at -20
o
C (Nahata & Powell, 1981). This prevented 
determination of the true bioavailability of chloramphenicol following i.v. 
chloramphenicol SS administration, as the hydrolysis of chloramphenicol SS to 
biologically active chloramphenicol is known to be incomplete in those species studied 
(Glazko et al., 1977; Reiche et al., 1980; Koup et al., 1981; Burke et al., 1982). Whilst 
this limitation may have resulted in an overestimation of the CL and Vd in Chapter 2, 
this information is purely academic as the clinical use of chloramphenicol SS is limited 
in koalas due to its rapid CL, and the calculations performed regarding use of the 
absorption rate-limited chloramphenicol base formulation were not affected by this 
limitation. 
 
6.1 POSSIBILITIES FOR FUTURE RESEARCH 
6.1.1 Investigation of florfenicol as a treatment option for koalas with 
chlamydiosis 
The work presented in this thesis provided theoretical evidence that the pharmacokinetic 
profile of chloramphenicol in koalas, combined with the in vitro susceptibility of koala 
isolates of C. pecorum to chloramphenicol, render chloramphenicol a suitable treatment 
option for koalas with chlamydiosis, although slightly higher doses may be 
recommended. This was in support of previous evidence that chloramphenicol, when 
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administered at 60 mg/kg s.c. s.i.d., successfully eradicated Chlamydia spp. from 
infected koalas (Markey et al., 2007; Govendir et al., 2012). Unfortunately, 
discontinued distribution of the commercially available chloramphenicol formulation in 
Australia was announced toward the completion of this project. As the work presented 
in this thesis indicated that enrofloxacin is not a suitable alternative to chloramphenicol 
for treating koalas with chlamydiosis (Chapter 3), an alternative treatment option is 
required. Although chloramphenicol can be compounded at some pharmacies, a 
compounded formulation has been tried, and there is anecdotal evidence that it has 
induced ulceration and abscessation at the injection site as well as diarrhoea and 
suspected gastrointestinal dysbiosis (A. Gillett, pers. comm.)
3
. However, the 
chloramphenicol derivative, florfenicol, has a spectrum of activity similar to that of 
chloramphenicol (Graham et al., 1988; Dowling, 2006), as well as a similar in vitro 
ability to inhibit the growth of C. pecorum (Chapter 5). Further work regarding the use 
of florfenicol to treat koalas with chlamydiosis requires initial tolerance studies to 
determine the safety of florfenicol in this species. Should adequate safety be 
demonstrated, follow-up pharmacokinetic studies and PK/PD integration or PK/PD 
modelling would be advantageous to enable dosage assessment and development. This 
could be followed up with efficacy studies to determine the effect of the established 
dosage of florfenicol on C. pecorum and C. pneumoniae in vivo.  
 
                                                 
3
 Personal communication: Amber Gillett, Wildlife Veterinarian, Australia Zoo Wildlife Hospital, Qld, 
November 2013. 
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6.1.2 The use of in vitro models to determine the rate of metabolism of 
commonly used drugs in koalas 
The use of in vitro models, such as microsome assays, to enable assessment of intrinsic 
CL and to identify metabolite production may provide valuable information regarding 
the metabolism of enrofloxacin and fluconazole, as the metabolism and elimination of 
these drugs seems different in koalas from other studied species. In vitro microsome 
assays could also be used to confirm whether chloramphenicol is metabolised by 
glucuronidation in koalas. Such in vitro assays may become an integral component of 
drug dosage development in this species in the future. Drugs that are anticipated to have 
favourable pharmacokinetic profiles in koalas, such as those that are metabolised by 
glucuronidation, could have their metabolic pathway and rate assessed prior to 
pharmacokinetic studies being undertaken, allowing an informed assessment as to the 
suitability of each drug for further development in koalas. This would reduce the 
number of pharmacokinetic studies undertaken using live koalas for drugs that are likely 
to be eliminated too rapidly to be of use in this species, and would enable more efficient 
use of time and resources.  
 
6.1.3 Pharmacodynamic assessment of commonly used therapeutic drugs 
that are metabolised by glucuronidation 
As the net glucuronidation capacity of koalas seems to be similar to that of many other 
species, assessment of the pharmacokinetic profiles of other drugs that are known to 
undergo glucuronidation in veterinary species and humans would be advisable. Many 
such drugs are used for analgesia, thus are widely used in wildlife hospitals where many 
cases are presented with traumatic injuries. Rational dosage development could follow 
pharmacokinetic studies of such drugs in koalas. By selecting drugs that undergo 
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glucuronidation, or at the very least by avoiding drugs that undergo Phase I oxidative 
metabolism by certain CYPs that are known to be highly active in koalas (Liapis et al., 
2000; Ngo et al., 2000), the limited funding available for wildlife research could be 
targeted towards drugs that are likely to have favourable pharmacokinetic profiles in 
koalas.   
 
6.1.4 Assessment of the pharmacokinetics of fluconazole when used in 
conjunction with amphotericin B 
As fluconazole is often administered to koalas in conjunction with amphotericin B, it is 
prudent that further evaluation of this drug as a treatment option for cryptococcosis 
incorporates the concurrent administration of amphotericin B. Amphotericin B reduces 
renal blood flow and glomerular filtration rate (Burgess & Birchall, 1972; Tolins & 
Raij, 1988), which may slow the elimination of fluconazole. The subsequent increase in 
AUC0-∞ may be enough to allow theoretical pharmacodynamic target attainment when 
administering fluconazole at currently used dosages.  
 
6.1.5 Investigation into the poor oral absorption of some drugs in koalas, 
and methods to enhance oral absorption of these drugs 
Based on the limited rate and extent of oral fluconazole absorption in Chapter 4, and 
enrofloxacin and marbofloxacin previously (Griffith et al., 2010), there is scope for an 
investigation into the barriers impeding oral drug absorption in koalas. Whilst these 
barriers may in part be due to physical obstruction caused by the dense, finely 
masticated leaf matter that constantly fills the koala’s stomach, there are other plausible 
explanations that warrant exploration, including drug chelation to divalent cations or 
feed constituents, efficient first pass metabolism, and the presence of efflux transporter 
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proteins (such as P-glycoprotein) that transport drugs back into the intestinal lumen 
following absorption into intestinal epithelial cells. If the factors limiting oral drug 
absorption in this species could be determined, it is possible that methods of disarming 
these barriers could be employed when oral drug administration is important, such as 
during fluconazole therapy for cryptococcosis. The cost of injectable fluconazole, 
combined with the long duration of therapy required for treatment of cryptococcosis, 
renders the oral administration route superior to the intravenous route. However, 
disarming the oral absorption barriers would need to be investigated with caution if such 
barriers have evolved to prevent koalas from succumbing to the toxic constituents of 
their Eucalyptus spp. diet.   
 
6.2 CONCLUSION 
This study investigated the pharmacokinetic profiles of chloramphenicol, enrofloxacin 
and fluconazole in koalas, and used the data generated to make pharmacodynamic 
assessments regarding the suitability of these drugs when used in koalas. Part of this 
work involved determining the in vitro antimicrobial susceptibility of koala isolates of 
C. pecorum to enrofloxacin, chloramphenicol, and the chloramphenicol derivative, 
florfenicol. The results presented in this thesis indicate that chloramphenicol has a 
favourable pharmacokinetic profile in koalas, and is potentially a feasible treatment 
option for chlamydiosis, although slight dosage adjustments may be recommended. 
Unfortunately, discontinued distribution of chloramphenicol base in Australia means 
alternative therapies must be sought, and the results of in vitro susceptibility testing 
indicate florfenicol may be an alternative worthy of investigation. In contrast to 
chloramphenicol, this study showed that enrofloxacin is not a suitable treatment option 
for chlamydiosis in koalas, and its use for this purpose should be discontinued. 
 143 
 
Enrofloxacin may, however, be appropriate for use in various gram positive infections 
of koalas, and its use should be assessed on a case by case basis. Although this study 
found that fluconazole is inconsistently absorbed from the gastrointestinal tract and 
rapidly eliminated from the plasma of koalas, further assessment of its suitability in the 
treatment of cryptococcosis cannot be made until its pharmacokinetics are assessed in 
conjunction with amphotericin B administration. A positive and unexpected outcome of 
this study was the finding that both chloramphenicol and enrofloxacin are eliminated 
from koalas at rates comparable to other species, and are not subjected to the rapid 
metabolism and elimination seen with meloxicam (Kimble et al., 2013) and fluconazole 
(Chapter 4). This provides hope that other drugs may have pharmacokinetic profiles that 
favour their use in koalas, although further work regarding the metabolic pathways 
involved in the metabolism of these drugs in koalas is required to further assess the 
suitability of various drugs and drug classes for use in this species.  
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APPENDIX I 
BUFFER USED FOR HPLC 
 
100 mM Phosphate buffer: 
KH2PO4         6.40 g 
K2HPO4         0.515g 
MilliQ Water         500 mL 
Adjust to pH 6.0 
 
  
 187 
 
APPENDIX II 
CULTURE MEDIA CONSTITUENTS 
 
Seeding Medium: 
High glucose Dulbecco’s Modified Eagle’s Medium4  435 mL 
  200 mM L-glutamine
5
      5 mL 
 1M HEPES buffer
6
       10 mL 
 Foetal bovine serum (not inactivated)
3
    50 mL 
 
Inoculation Medium: 
High glucose Dulbecco’s Modified Eagle’s Medium1  435 mL 
  200 mM L-glutamine
2
      5 mL 
 1M HEPES buffer
3
       10 mL 
 Foetal bovine serum (inactivated; 56 
o
C / 30 min)
3
   50 mL 
 
Maintenance Medium: 
High glucose Dulbecco’s Modified Eagle’s Medium1  435 mL 
  200 mM L-glutamine
2
      5 mL 
 1M HEPES buffer
3
       10 mL 
 Foetal bovine serum (inactivated; 56 
o
C / 30 min)
3
   50 mL 
 Cycloheximide 1 mg/mL
2
       0.5 mL 
 
                                                 
4
 Hyclone: Thermo-Fisher Scientific, Scoresby, Victoria, Australia  
5
 Sigma-Aldrich, Castle Hill, NSW, Australia 
6
 In Vitro Technologies, Noble Park North, Vic, Australia. 
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2-SP (Chlamydial transport medium) 
 
 KH2PO4         0.101 g 
 K2HPO4        0.201 g 
 Sucrose (C12H22O11)       6.846 g
 MilliQ Water        to 100 mL 
 pH adjusted to 7.2 – 7.4 
 Filter sterilised with 0.2 µm filter 
 gentamicin (40 mg/mL)      0.14 mL 
 vancomycin (50 mg/mL)      0.3 mL 
 amphotericin B (500 µg/mL)      6.25 mL 
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APPENDIX III 
PROCEDURE FOR SHELL VIAL CULTURE OF 
CHLAMYDIA PECORUM AND CHLAMYDIA 
TRACHOMATIS USING BUFFALO GREEN MONKEY 
KIDNEY CELLS 
 
Medium: 
- High glucose Dulbecco’s Modified Eagle’s Medium (DMEM) with additives as 
outlined in Appendix II. 
i) Seeding medium 
Used for seeding flasks, shell vials and 96 well plates, and to medium 
change flasks 24 – 48 h prior to passaging.  
ii) Inoculation medium 
Used to medium change shell vial cultures (0.5 mL up to 2 h prior to 
inoculation of specimens) and 96 well plates (100 µL up to 2 h prior to 
inoculation of specimens). 
iii) Maintenance medium 
Medium change inoculated shell vial cultures (1 mL) or 96 well plates 
(200 µL) prior to 48 – 72 h inoculation. 
 
NB: ALWAYS WARM MEDIUM TO 37
o
C PRIOR TO USE SO AS NOT TO 
SHOCK CELLS/BACTERIA 
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Foetal calf serum: 
Heat inactivation 
- Thaw serum rapidly (in a heat block or clean water bath) and mix the contents of 
the bottle thoroughly once thawed. 
- Divide into single-use aliquots. 
- Heat a circulating water bath or heat block to 56oC.  
- When the temperature reaches 56oC, place the thawed tubes in the water 
bath/heat block so each is completely immersed to the level of the serum, 
without immersing the cap. 
- Time the process for 30 min. Agitate the bottles approximately every 5 min 
during the heat inactivation process to prevent gelling of the serum proteins and 
to promote more uniform heating of serum. 
- After 30 min of heat inactivation at 56oC, remove tubes from the water bath and 
rapidly cool them in an ice bath. Prolonged treatment of serum at elevated 
temperatures will cause deterioration of serum components critical for growth of 
cells. 
 
Determining BGMK cell density: 
- Shell vials and 96 well plates require seeding of 3.0 x 105 cells/mL  
- Dilute cells 1:1 in Trypan Blue, and count using a haemocytometer until three 
consistent densities are obtained.  
- Count only living cells (clear) for the cell count, but count dead cells (blue) 
separately for a viability count. 
- Once cell density is determined, aliquot into working dilutions for seeding shell 
vials, 96 well plates and maintenance flasks. 
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Setting up shell vial cultures: 
- Recover BGMK cells from liquid N2, and thaw rapidly. 
- Prepare required volume of suspension, containing 3 x 105 cells/mL, by diluting 
ampoule of cells. 
- Seed 0.5 mL of BGMK cell suspension per shell vial culture, or 100 µL per 96 
well plate. 
- To ensure even settling, shake tubes in the vertical plane before setting rack 
down on a horizontal surface for overnight incubation at 37
o
C in 5% CO2 
incubator.   
- Before use, check each shell vial culture for correct pH and healthy monolayers 
that are 90% confluent 
- Medium change cultures (replace seeding medium with 0.5 mL inoculation 
medium for shell vials, or 100 µL for 96 well plates, up to 2 h prior to 
inoculation of chlamydial specimens.)  
 
Addition of Chlamydia spp. 
- Rapidly thaw frozen vials of Chlamydia or frozen clinical swabs by agitating at 
37
o
C (eg, in a water bath within class II biohazard safety cabinet). For clinical 
swabs stored in CTM, aseptically add sterile glass beads to the vials containing 
the swabs and seal. Vortex for 30 seconds.  
- Inoculate Chlamydia spp. onto confluent monolayers at calculated inoculation 
density (aim for 100 µL diluted to yield 10
3
 – 104 IFU/monolayer) and replace 
lids on vials/plates. Seal with parafilm. 
- Centrifuge shell vials at 2000 x g for 60 min at 36oC  
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- Remove supernatant and add 1 mL maintenance medium to each vial (200 µL to 
wells in 96 well plates) 
- Incubate at 37oC in 5% CO2 for 36 - 72 h in PC2 laboratory incubator. 
 
Harvesting and immunofluorescence staining of shell vial culture coverslips: 
- After incubation for 36 – 72 h at 37oC, decant maintenance medium into liquid 
waste disposal container (1% sodium hypochlorite). 
- Rinse monolayer three times with PBS 
- Drain tubes on paper towel saturated with 70% ethanol. 
- Fix cultures in 1mL methanol  for 10 min at room temperature, then decant and 
drain tubes on paper towel saturated with 70% ethanol. 
- Carefully remove coverslips. Be gentle so as not to damage the cell monolayer 
- Place 10-15 µL fluorescein-conjugated monoclonal antibody onto parafilm, and 
place coverslip onto this (monolayer-down), ensuring entire monolayer is 
covered with stain. 
- Incubate in a humidified chamber as per manufacturer’s instructions (30 min), 
ensuring stain does not dry out. 
- Rinse in distilled water for 10 sec to remove excess antibody. Blot excess water 
and mount with mounting fluid (pH 9.4) when dried 
- Examine through a fluorescence microscope. Scan the entire monolayer using 
minimum total magnification of 100x, and confirm inclusion morphology at 
400x. 
- EB and RB inclusions stain green against a red background 
- Keep stained slides at 4oC for 3 days, or at -20oC for a few months  
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Quantifying Chlamydia spp. isolated from swabs: 
- Change culture medium in shell vials (seeding medium to inoculation medium) 
- Thaw a frozen Chlamydial aliquot and prepare four or five serial 10-fold 
dilutions in CTM (2-SP) 
- Inoculate three confluent shell vial monolayers with 200 µL of each dilution 
- Centrifuge at 2000 x g for 1 h at 36oC 
- Replace inoculation medium with maintenance medium  
- Incubate in 5% CO2 for 48 h at 37
o
C  
- Fix and stain as outlined above 
- Count the inclusions per cover slip at each dilution, and determine the dilution 
necessary to obtain 50 – 100 inclusions per coverslip monolayer. This dilution 
contains 50 to 100 IFU/0.2 mL 
 
  
 194 
 
APPENDIX IV 
SITE OF SAMPLE COLLECTION FOR CHLAMYDIAL 
SWABS USED IN SUSCEPTIBILITY TESTING, AND 
SIGNALMENT OF THE KOALAS SWABBED 
 
Age (years) Gender Date swabbed Site swabbed Geographical 
location 
5 Male 24/11/2012 Bladder wall SE Qld 
9 Male 2/1/2013 Conjunctiva SE Qld 
9 Male 16/1/2013 Cloaca SE Qld 
9 Male 19/1/2013 Conjunctiva SE Qld 
9 Female 21/1/2013 Bladder SE Qld 
9 Female 7/12/2012 Conjunctiva SE Qld 
11.5 Female 18/12/2012 Cloaca SE Qld 
1.5 
6 
Female 
Male 
1990* 
1990* 
Conjunctiva 
Penis 
WS 
WS 
*Denotes isolates cultured in 1990 and subsequently stored at -80 
o
C. SE Qld: South east 
Queensland. WS: Western Sydney.  
 
 
NB: Isolates from the top five koalas were used to determine MICs only. Isolates from the bottom four 
koalas, and the koala C. pecorum type strain (Marsh et al., 2011), were used to determine both MICs and 
MBCs.  
 
